Responder Identification in Clinical Trials by Kehl, Victoria
Responder Identification in Clinical Trials
Dissertation
zur Erlangung des Grades Doktor der Naturwissenschaften (Dr. rer. nat.)
an der Fakultät für Mathematik, Informatik und Statistik 
der Ludwig-Maximilians-Universität München
vorgelegt von
Victoria Kehl
am 28. Juni 2002
Referent: Prof. Dr. K. Ulm
Koreferent: Prof. Dr. L. Fahrmeir
Rigorosum: 21. November 2002
Acknowledgements
This research was done during my work at the Institute for Medical Statistics and
Epidemiology (IMSE) at the Technical University – Munich. It was supported by grant
UL 94/11-1 of the German Research Community (DFG) from December, 1999 until
December, 2000 and by DFG's Special Research Areas (SFB) 386 "Statistical Analysis
of Discrete Structures," project B7: "Prognoses for Cardiac Arrhythmia Patients" since
January 2001.
I would like to thank my advisors Prof. Dr. Ludwig Fahrmeir and Prof. Dr. Kurt Ulm
for their involvement in SFB, which assured perfect research atmosphere with sufficient
funding for computer, software, literature, conferences, and other events that made
contact with other researchers possible on national and international level. I would like
to thank Prof. Dr. Ulm especially for all his support throughout the research period, for
his friendliness and patience, for believing in me, for the countless discussions and
useful suggestions, and for his ever readiness to share knowledge and networking.
Many thanks also to the cardiologists Dr. Petra Barthel and Prof. Dr. Georg Schmidt for
providing the EMIAT data and for clearing the way through the jungle of medical
terminology, as well as for their input on the medical feasibility of the EMIAT models.
Thank you, I consider myself lucky to have worked with such a friendly and
knowledgeable team.
Further, I would like to thank all my colleagues at IMSE for their moral support and for
providing a friendly atmosphere at work, which made the way through the almost daily
ups and downs of my research bearable. 
Last, but not least, I am grateful to my family and friends who, unlike me, never
doubted that this dissertation would become reality.
Thank you all!
 
CONTENTS
1 Introduction  1
1.1 Aims .............................................................................................. 1
1.2 Outline ........................................................................................... 1
2 Responders and non-responders 3
2.1 Motivation ..................................................................................... 3
2.2 Definitions ..................................................................................... 5
3.3 Assumptions .................................................................................. 6
3 Preliminary: Residuals to the Cox-PH model 7
3.1 The Cox-PH model ....................................................................... 7
3.2 Schoenfeld residuals ..................................................................... 11
3.3 Martingale residuals ...................................................................... 12
3.4 Score residuals .............................................................................. 15
3.5 Deviance residuals ........................................................................ 17
3.6 Log-odds and normal deviate residuals ........................................ 20
3.7 Suitable residuals for responder identification ............................. 21
4   The classical approach: Cox-PH model with interactions 28
4.1 Definition ...................................................................................... 28
4.2 Responder identification ............................................................... 29
5 Classification and regression trees (CART) – recursive partitioning 30
5.1 Growing a regression tree ............................................................. 34
5.1.1 Splitting ............................................................................ 34
5.1.2 Stopping criteria ............................................................... 36
5.1.3 Pruning ............................................................................. 36
5.2 Tree Performance ......................................................................... 37
5.3 Responder identification with regression trees ............................ 38
6 PRIM – Patient rule induction method (Bump Hunting) 39
6.1 General structure of the PRIM model .......................................... 40
6.2 Box construction .......................................................................... 42
II
6.3 Responder identification with bump hunting .............................. 46
7 Stabilization of Bump Hunting 48
7.1 Stabilizing with bootstrapping ...................................................... 48
7.2 Algorithm ...................................................................................... 50
7.3 Discussion ..................................................................................... 52
8 Identification of responders and non-responders 53
8.1 Algorithm using Bump Hunting ................................................... 53
8.2 A note on survival curve difference ............................................. 55
8.3 Changes to the responder identification algorithm 
if CART is used ............................................................................ 58
8.4 Covariate considerations .............................................................. 59
9 Simulation study 60
9.1 Methods ........................................................................................ 60
9.2 Results .......................................................................................... 65
9.2.1 Cox-PH with interaction ................................................... 65
9.2.2 Regression trees ................................................................ 69
9.2.3 Bump Hunting .................................................................. 72
9.3 Comparison ................................................................................... 76
9.4 Implementation ............................................................................. 77
10 Applications: EMIAT 78
10.1 Data ............................................................................................... 78
10.2 Previous investigations ................................................................. 78
10.3 Cox-PH with interaction ............................................................... 81
10.4 Responder identification with CART ........................................... 84
10.4.1 The prognostic model ....................................................... 84
10.4.2 The predictive model with continuous factors ................. 85
10.4.3 The predictive model with categorized factor .................. 90
10.5 Responder identification with Bump Hunting ............................. 97
10.6 Comparison and discussion .......................................................... 103
III
Conclusions 109
Summary .................................................................................................. 109
Outlook .................................................................................................... 110
Appendix A: Proofs 112
Appendix B: Simulation study plots 117
Appendix C: Algorithmic Implementation 122
Bibliography 142
1. INTRODUCTION
Some of the main areas of medical research are prevention and cure of pathological
conditions and increase of life quality (and quantity). This is directly linked to the
development of new treatments, which work faster, are more effective and with less side
effects than the old ones. The term treatment here is used in a broad sense to cover the
most common chemical (i.e. medication coming from the pharmaceutical industry), as
well as surgical, mechanical, radial, and psychological treatment. In order to judge the
efficacy of a new treatment objectively, a clinical trial needs to be designed and
evaluated. This is one of the major working fields of biostatistics as well.
Just as any other modern science, biostatistics is a hybrid science. It is mainly based in
the area of statistics, but it reaches over to medicine, mathematics, and computer science
as well. This research represents such a mixture of statistics, optimization, and computer
science in the search for improvements in the clinical trial evaluation process.
1.1 Aims
The subject of this thesis is responder analysis. The term response up to now appears
only in clinical trials, in which surrogate markers are used to describe the effect of the
treatment when that effect is other than to prevent an event.
Example 1: In oncology, the desired effect of a treatment may be reduction of tumor
size, whereas the outcome of interest (called event) may be death. Then a responder is a
patient who experienced tumor reduction or complete remission and a non-responder is
a patient who’s tumor did not change or grew. Notice, that does not necessarily mean
that responders lived longer.
Example 2: If a headache medicine is tested, the event may not be defined to be
death, but recurrence of headache. There is no existing definition of responder in this
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case, but, in general, the goal is to prolong the event-free (headache-free) period.
Notice, side effects and death due to the drug should also be tested before the drug is
approved, but this would not be the main aim of the study.
The European Myocardial Infarction Amiodarone Trial (EMIAT), described in chapter
10 falls in the case described by the second example. Amiodarone is an anti-arrhythmic
drug. In order to approve the drug, an anti-arrhythmic effect as well as prolonging of
life had to be shown, so event was defined to be all cause mortality. Once again, no
definition of responder is available in this case, but the final goal was to show, that
Amiodarone increases the event-free period (prolongs life).
The classical definition of responder is altered in this research in order to fit the more
general clinical trial situation, in which the wished effect of a treatment is increasing the
event-free period of the treated patient (example 2).
1.2 Outline
The term responder is redefined in chapter 2 and distinction between prognostic and
predictive factors is made. The rest of this thesis focuses on methods for identification
of responders. Chapter 3 gives an overview of residuals to the Cox-PH model, which
can be used as a prognostic model. The ability of different residuals to identify
predictive factors is analyzed. The classical approach for responder identification is
presented in chapter 4. Chapter 5 gives an overview of recursive partitioning while
focusing on regression trees. Bump hunting is presented in chapter 6. Both regression
trees and bump hunting can be used for responder identification purposes. An attempt to
stabilize the bump hunting algorithm through bootstrapping is given in chapter 7.
Chapter 8 lists the steps of the proposed responder identification algorithm, as well as
some general suggestions on its use. The results of a simulation study which compares
all discussed versions of the responder identification algorithm are presented in chapter
9. Finally, the last chapter presents the results of the responder analysis performed on
the EMIAT data set.
 2. RESPONDERS AND NON-RESPONDERS
2.1 Motivation
Consider the common clinical trial situation in which the ability of a new treatment to
prevent an event is tested. Patients are randomized into two groups: one receiving the
classical treatment (or placebo) and the other receiving the new treatment. Not rarely,
the outcome of such trials shows no difference in the survival probabilities of the two
treatment groups (see figure 2.1). But still, it could happen that certain subgroups of
patients show improved survival under the new treatment, while others appear to suffer
from it (see figure 2.2). 
Figure 2.1: Kaplan-Meier survival curve estimates for the placebo and Amiodarone
treatment arms of the EMIAT study (details on the study in chapter 10).
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Figure 2.2: Comparison of the Kaplan-Meier survival curve estimates for the
placebo and Amiodarone arms of EMIAT for the subgroups of patients
on and off beta-blocker.
Suppose the survival time of a patient in the new treatment group is greater than the
overall survival time. There can be three reasons for this phenomena:
1. Chance: we cannot predict or account for occurrence by chance in any way or form
in a model.
2. The patient has a prognosis better than the average, due to the specific prognostic
factors that he enjoys.
For example, if younger patients in general have different prognosis than older
ones, independently of their treatment group, then we would say that age is a
prognostic factor.  
We can account for prognostic factors, provided that they have been measured, by
developing a prognostic model on the classical treatment (or placebo) group. Such
model can be the Cox proportional hazards model, a survival regression tree, or
even the more exotic neural network – it simply has to be a model predicting
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survival (or hazard) in the classical treatment arm of the study. Factors found to be
significant in such a model are called prognostic.
Notice, the so defined factors would be prognostic in the real sense of the term only
if they are found on a placebo arm. If the new treatment is tested against a classical
treatment, the factors would be "prognostic" only with respect to the new treatment
and not in general. To avoid confusion, for the rest of this thesis we will call both
factor types prognostic.
3. The new therapy is really working. The purpose of this research is to explore
methods of identifying patients with special reactions to the new treatment (those
could be positive as well as negative), which are different from the whole patient
population and cannot be explained by prognostic factors. In such cases predictive
factors are responsible for the difference in survival. 
"Predictive factors:
 Any factor which predicts how a patient will do with
adjuvant systemic therapy
 Looks for differential effect of treatment
 To understand predictive factors subgroup analyses are
required..."
Silva & Zurrida, 2000 
Note, that a factor can have both prognostic and predictive power, if its prognostic
value is different in the two treatment groups. If only one predictive factor is
involved (or several independent predictive factors), it can be found by adding an
interaction term involving the treatment randomization index and the predictive
factor in question in a model which already accounts for prognostic factors (see
chapter IV). Methods for identifying groups of predictive factors are described in
chapters V and VI.
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2.2 Definitions
We define positive responders to be patients under the new treatment, who benefit
from it. Their benefit is manifested in the fact that their survival time is longer than that
of patients with the same characteristics (predictive factors), randomized in the classical
treatment group.
We define negative responders to be patients under the new treatment who are harmed
by it. Their survival time is shorter than that of a similar, described by predictive
factors, group of patients under the classical treatment.
Consequently, non-responders would be patients who are neither positive nor negative
responders. Their survival time does not differ from similar patients under the classical
treatment. 
We are interested in identifying responders – both positive and negative.
2.3 Assumptions
Responders are identified and characterized by predictive factors. For the successful
identification of predictive factors we need the assumption that all prognostic factors are
already correctly accounted for in a prognostic model. This is a strong, but not
unreasonable assumption. 
If this assumption is not fulfilled, we run the risk of wrong conclusions. For example,
we may conclude a therapy effect where there is none. The patient just has a better
prognosis to begin with, which was not recognized by the prognostic model. The
opposite can also be falsely concluded. We can conclude that a patient is harmed by the
new treatment, when in fact he/she does not react to the new treatment any differently
than the rest of the group. The patient just has a worse prognosis due to a prognostic
factor which was not yet accounted for. 
3. PRELIMINARY: RESIDUALS TO THE COX-PH 
MODEL 
 
 
 
Before describing methods for responder identification, we need a prognostic model. 
One possible method of constructing a prognostic model is the Cox proportional 
hazards model (Cox-PH), which is well known and widely used in the area of survival 
analysis (Cox, 1972). This chapter gives some preliminary knowledge of the Cox-PH 
model and its residuals, as well as the foundation for their possible use for responder 
identification purposes. 
 
3.1 The Cox-PH model 
The Cox-PH model describes a population of n patients with follow-up times ti, final 
status δi, and a set of K covariates xi = (x1i, x2i, ..., xKi) by describing the hazard rate for 
each patient i from 1 to n as: 
ix
i etxt
⋅′⋅= βλλ )(),( 0                                       (3.1) 
The effect of the covariates is assumed to be log-linear and independent of time. 
Proportionality of hazards is also assumed, i.e. the failure rates of any two individuals 
are proportional, which means that their hazard ratio is constant over time. Naturally, 
one can use extensions to the Cox model as prognostic models as well. For simplicity, 
we will restrict this research to the classical Cox-PH model. 
Estimating β: 
As described by Cox & Oakes (1984) and Marubini & Valsecchi (1995), one needs to 
use partial likelihood for estimation of the coefficient vector β, since the baseline hazard 
λ0(t) in the Cox-PH model is not specified parametrically. Suppose a total of J events 
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occur in a sample of N subjects. Let t(j) denote the ordered failure times, j = 1, …, J. Let 
R(t) be the set of subjects at risk at time t and Rj be the set of subjects at risk at time t(j) 
(i.e. Rj = R(t(j))). Let xj be the vector of K covariates for the subject who fails at time t(j) 
and xi be the vector of covariates for the ith subject, i = 1, …, N. Assuming that only one 
individual fails at t(j) ∈ (t, t + ∆t), the probability that it is an individual with covariates 
xj is (Marubini & Valsecchi, 1995): 
∑
∈ jRi
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Then the function describing the entire failure pattern for the set of J deaths is the 
product (Cox & Oakes, 1984): 
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Given the Cox-PH model (3.1), the likelihood function simplifies to: 
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which is a partial likelihood function depending only on the unknown β values (and the 
known x values). The unknown values of β are then estimated by the values , which 
maximize the partial log-likelihood: 
β̂
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where lj is the contribution to the log-likelihood for failure time t(j) (Marubini & 
Valsecchi, 1995). The estimates of β are found by equating to zero the K first partial β̂
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derivatives of LL(β) with respect to βk, k = 1, …, K, and solving the system of K 
equations, each of which has the form: 
                                                 0
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1
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Concentrating just on the derivative contribution to the sum: 
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it can be generalized to: 
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for the entire vector of K covariates for a subject failing at time t(j). 
If more than one deaths occurred at time t(j), the partial log-likelihood can be modified 
to: 
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where sj is the sum of all covariate vectors of the subjects who fail at time t(j) and dj is 
the number of such subjects. This approach was proposed by Peto (1972).    
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Estimating the baseline hazard: 
A simple maximum likelihood estimator of Λ0(t) was proposed by Breslow (1974), 
which is now widely used for baseline hazard estimation. To deal with the censoring 
problem, Breslow assumed that the hazard is constant between two consecutive failure 
times. The baseline hazard was estimated separately in each of the intervals between 
failure times: (t(j-1), t(j)], where j = 1, …, J. Assumed are: t0 = 0 and censoring within the 
interval occurred at the beginning of the interval, t(j-1). Then the estimate of λ0(t) for the 
interval (t(j-1), t(j)], is: 
∑
∈
⋅′
− ⋅−
=
j
i
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x
jj
j
j ett
d
βλ )(
ˆ
)1()(
 
where dj is the number of failures which occurred in the jth time interval. Breslow’s 
estimator of the cumulative baseline hazard at time t is: 
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and the baseline hazard itself is: 
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calculated at each failure time t(j). 
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3.2 Schoenfeld residuals [Schoenfeld, 1982] 
 
For a Cox-PH model involving K covariates for each subject i: xi = (x1i, x2i, ..., xKi) and   
β = (β1, β2, ..., βK), Schoenfeld residuals are defined at each failure time t(j) as the 
difference between the covariates of the subject who fails at time t(j) and their estimated 
values, given the subjects still at risk at time t(j): 
                                                                                                       (3.6) )|(ˆˆ jjjj RxExr −=
There is one Schoenfeld residual for each failure time (assuming that only one 
individual fails at a time) and each residual is a vector of K components (one for each 
covariate), where  is obtained by substituting the maximum likelihood 
estimates  in .  
)|(ˆ jj RxE
)| jj Rxβ̂ (E
∑
∑
∈
′
∈
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j
k
j
k
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x
Rk
x
j
jj e
ex
RxE β
β
)|(  
Note that those residuals belong to time points and cannot be computed for all 
individuals. It can be shown, that under the correct model the values of  are 
asymptotically uncorrelated with their expected value zero. 
jr̂
Each component  corresponds to the kkjr̂
th covariate. A plot of the  values against 
time would show possible departures from the PH assumption related to the k
kjr̂
th covariate 
(Figure 3.1). To discover the presence of patterns over time (hence departure from the 
PH assumption) one would need to smooth the residuals. Figure 3.1 shows no change of 
the residual pattern over time, hence we can conclude that covariate LVEF satisfies the 
PH assumption.  
If more than one subject fails at time t(j), a separate residual is calculated for each 
subject instead of averaging (Therneau & Grambsch, 2000).  
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Figure 3.1: Scatter plot of the Schoenfeld residuals for factor LVEF against follow-
up time for the prognostic model (section 10.4.1) built on the EMIAT 
data. The residuals are smoothed with cubic splines. 
 
 
 
3.3 Martingale residuals [Barlow & Prentice, 1988] 
 
The basis for development of martingale-type residuals is the difference of the counting 
process observed on individual i and the integrated intensity function for this counting 
process: 
)()()()( 0
)(
0
sdesYtNtM sZ
t
iii
i Λ⋅−= ⋅′∫ β                      (3.7) 
where: 
i  = 1, ... , n 
Yi(t)  is a 0-1 process, indicating whether the ith subject is at risk at time t 
β  is a vector of regression coefficients 
Zi(t)  is a p-dimensional vector of covariate processes 
Λ0  is the baseline cumulative hazard function. 
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Ni(t)  is the counting process for subject i; for right censoring, it is 0 prior to 
time of event and 1 thereafter. 
We are in the framework of the Cox-PH model where Λ0 is unspecified and Yi(t) = 1 
until the first event or censoring and zero thereafter. For example, if patient i is censored 
or fails at time t = 5, 



>
≤
=
50
51
)(
tif
tif
tYi  
Subject to standard measurability and intergrability requirements, Mi(·) will be a 
subject-specific martingale [Gill, 1980, 1984]. 
Using standard partial likelihood theory, we can get the maximum likelihood estimate 
of β and consequently an estimate of Λ0 [Breslow, 1974]: 
∫ ∑ ⋅
∑
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t
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We can define the martingale residuals as: 
∫ Λ⋅−= ⋅′
t sZ
iii sdesYtNtM i0 0
)(ˆ )(ˆ)()()(ˆ β                       (3.9). 
Martingale residuals have the following properties: 
1.  asymptotically ,0)ˆ,ˆcov()ˆ( == jii MMME
2.  ∑ ∀= ttM i ,0)(ˆ
Specifically for Cox-PH model, the definition of martingale residuals reduces (see 
Appendix A) to: 
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Z
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⋅′ δδ β                      (3.10) 
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where: 
ti is the observation time for subject i and 
δi is the final status for subject i. 
The residuals can be interpreted at each time t as:  
"... the difference over [0, t] of the observed number of 
events minus the expected number given the model, or as 
excess deaths."                (Therneau et al., 1990)     
Kay (1977) came to this residual from a different perspective and Crowley & Hu, 1977 
developed a similar residual based on the original work of Cox & Snell, 1968. 
Notice that since the status can take only values of 0 or 1 and the hazard is always non-
negative, the martingale residual for the Cox-PH model takes values only in the interval 
(-∞, 1]. The following figures 3.2 & 3.3 give an example of what a plot of the 
martingale residuals could look like and a box plot for demonstration of the skewed 
nature of their distribution. 
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Figure 3.2: Scatter plot of the martingale residuals against follow-up time for a 
model on a data set simulated as in chapter 9.  
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Figure 3.3: Box-and-whisker plot for the martingale residuals from figure 3.2. 
 
3.4 Score residuals [Therneau et al, 1990] 
 
The score residuals are a martingale-transform type of residuals defined for each subject 
on the basis of his/her contribution to the score statistic (3.11). In our case the integral is 
with respect to the martingale residual, which involves β and Λ0. When Λ0 is 
unspecified, as it is the case in the Cox-PH model, it can be estimated using Breslow’s 
estimate. Then, when  β = b, the derivative of the partial likelihood function Lp with 
respect to βj can be written as: 
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where ),( sbZ j is the weighted mean of the covariates over the risk at time s: 
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We define  as the score process and as the score residual of the i),ˆ( ⋅βijL ),ˆ( ∞βijL
th 
subject and the jth variable.  Score residuals measure the leverage exerted by each 
subject on parameter estimates in that they provide an estimate of the changes in the 
coefficients β that would occur when each of the observations are deleted. Therefore, 
one should look for outliers in the residual plots. Several outliers are visible on the score 
residual plots of  figure 3.4. Each outlier corresponds to a patient, who's value for the 
factor being analyzed influence strongly the model coefficient of that factor.  
The score residuals also sum to zero. 
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Figure 3.4: Scatter plots of the score residuals of factors LVEF, NYHA, and AGE 
against follow-up time for the model from section 10.4.1. 
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3.5 Deviance residuals (Therneau et al, 1990) 
 
A major deficiency of the martingale residuals is their skewed distribution. They take 
values in the interval (-∞, 1].  A transformation helps solving this problem:  
Define: deviance: 
D = 2·[ LL(saturated) – LL( )]                       (3.13),  β̂
where the saturated model is one for which β is free, i.e. each observation i has its own 
vector of coefficients β. Any nuisance parameters, such as the baseline hazard  are 
held constant across the two models. Assuming known 
0Λ
0Λ  and letting hi be the 
individual estimates of β for each subject i: 
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      (3.14) 
Using Lagrange multiplier, the maximal value of hi satisfies: 
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Let the Martingale residual with estimated β and known Λ0 be: 
∫ Λ−≡ ⋅′
t Z
ii sdetNtM i0 0
ˆ )()()(~ β                             (3.15) 
Substituting in the deviance definition: 
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Estimation of Λ0 results in the replacement of iM
~  by  in the formula. The deviance 
residual is the signed square root of the deviance D. It is zero if and only if . For 
the Cox-PH model, the deviance simplifies to: 
iM̂
0ˆ =iM
)]ˆln(ˆ[2)ˆsgn( iiiiii MMMd −⋅+⋅−⋅= δδ                    (3.16) 
The ln(·) function inflates martingale residuals close to 1 and the square root contracts 
the large negative values. 
Usually deviance residuals are plotted against the risk score of the model (β·x), but for 
the purpose of outlier screening one can use observation time instead of score or simply 
a box-and-whiskers plot. The martingale residuals used in figures 3.2 & 3.3 were 
transformed to deviance residuals in figures 3.5 & 3.6. Notice that the magnitude of the 
residuals changes, but their relationship to one another stays the same since they are 
monotonic transformations of each other (see figure 3.7 for illustration). The same 
negative outliers can be detected visually on the scatter plots. As expected, after the 
transformation the distribution of the deviance residuals appears more symmetric and 
differences among the positive residuals are enhanced (recall: martingale residuals can 
be at most 1 whereas deviance residuals do not have such restrictions).  
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Figure 3.5: Scatter plot of the deviance residuals against follow-up time 
corresponding to the martingale residuals from figure 3.2. 
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Figure 3.6: Box-and-whiskers plot of the deviance residuals from figure 3.5. 
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3.6 Log-odds and normal deviate residuals (Nardi & 
Schemper, 1999) 
 
Nardi & Schemper (1999) suggested the use of log-odds or normal deviate residuals for 
outlier screening, which seem to have better distributional properties than the Deviance 
residuals. The log-odds and normal deviate residuals are constructed on the basis of the 
estimated survival function for individual i and his/her observed event time ti or 
censored time tic. The prediction of survival is considered "perfect" if . 
Those residuals do not measure directly the difference between observed and predicted 
survival time. Instead, they do this indirectly by comparing the estimated survival 
probability at time t
5.0)(ˆ =ii tS
i (or tic) with the "perfect" value of 0.5. 
Log-odds residuals are defined as the logit transformation of : )(ˆ ii tS
                                             







−
−
=
)(ˆ2
)(ˆlog
)(ˆ1
)(ˆlog
c
ii
c
ii
ii
ii
i
tS
tS
tS
tS
l
                                             (3.17) 
Normal deviate residuals are defined as the probit transformation of : )(ˆ ii tS
                                            
{ }











Φ
Φ
=
−
−
2
)(ˆ
)(ˆ
1
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c
ii
ii
i tS
tS
n ,                                              (3.18) 
where Φ is the normal cumulative distribution function. 
The censored case in both definitions deserves special attention. Since for censored 
individuals the censoring time is always less than the time of event, a uniform 
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distribution of  is assumed on the interval [0, ] (Crowley & Hu, 1977). The 
unknown value of  is then replaced by its mean 
)(ˆ ii TS
(ˆiS
)(ˆ cii tS
)it 2
(ˆ cii tS ) . 
 
3.7 Suitable residuals for responder identification 
 
For the purpose of responder identification we need residuals to the Cox-PH model 
which correspond to data points and are not explicitly connected to single prognostic 
factors contained in the model. Such residuals would be able to identify outlying points 
with poorly predicted individual outcomes by the prognostic model. Those points can be 
used for predictive factor identification and, ultimately, responder identification  
purposes. 
Schoenfeld residuals check the validity of the proportional hazards assumption. A large 
(positive or negative) residual indicates that the event which occurred at time tj is 
unlikely under the current model, given the covariates of the individual who failed 
relative to those still at risk. They belong to time points rather than to individuals and 
are plotted against the prognostic factors. Therefore, they are not suitable for responder 
identification.  
Score residuals look for presence of observations which are influential to a prognostic 
factor's coefficient estimate. They are different for each prognostic factor and, thus, 
cannot be used for predictive factor identification.  
Martingale residuals, on the other hand, are suitable for responder identification. 
Naturally, they were originally constructed with a different implementation in mind, 
namely, to deal with the linearity assumption for prognostic factors, as summarized in 
table 3.1 (Harrell, 2001), but their properties together with their simple and logical 
interpretation make them a natural candidate for responder (outlier) identification.  
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Table 3.1:  Use of martingale residuals (Harrell, 2001). 
 
Purpose Method 
Estimate transformation for a single 
variable 
Force  and compute residuals from 
the null regression 
01̂ =β
Check linearity assumption for a single 
variable 
Compute  and the residuals from the 
linear regression (ordinary Cox model) 
1̂β
Estimate martingale transformations for p 
variables 
Force  and compute 
residuals from the global null model 
0ˆ,,1̂ =pββ K
Estimate transformations for variable i 
adjusted for the rest p-1 variables 
Estimate p – 1 β's, forcing . 
Compute residuals from mixed global/null 
model 
0ˆ =iβ
 
Martingale residuals for the Cox-PH model are defined in 3.10 to be the difference of 
the censoring indicator and the estimated hazard rate at each observation. Recall that 
martingale residuals can only achieve values in the interval (-∞, 1], since δi switches 
only between the values of 0 and 1. For residual interpretation purposes the censoring 
indicator can be thought of as a classification rule, which places patients into either the 
low or the high hazard group. This results in only a few possible scenarios: 
Martingale residuals with values close to zero: 
As by most other residuals, values around zero reflect good fit of the model. In our 
situation this can be achieved if δi = 1 and ≈ 1, which means that the iiΛ̂
th patient with 
an event was predicted to be at high risk, or if δi = 0 and ≈ 0, which means that the iiΛ̂
th 
patient was censored and predicted to be at low risk. Those are candidates for non-
responders. 
0ˆ
0ˆ
0
≈⇒




≈Λ
=
j
j
j
M
δ
                 0ˆ
1ˆ
1
≈⇒




≈Λ
=
j
j
j
M
δ
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Martingale residuals with large positive values: 
Large values of any residuals are a sign of a bad fit of the prognostic model and here – a 
possible sign of existing predictive factors. Values of the martingale residuals close to 1 
can be achieved only if δi = 1 and  ≈  0, i.e. the iiΛ̂
th patient was predicted to be at low 
risk but he/she died. Such patients are candidates for negative responders. 
1ˆ
0ˆ
1
≈⇒




≈Λ
=
j
j
j
M
δ
 
Martingale residuals with large negative values: 
Large negative values are also a sign of a bad fit. Large negative values of the 
martingale residuals (e.g. –1) are achieved if δi = 0 and  > 0 (e.g.  ≈ 1), i.e. the iiΛ̂ iΛ̂
th 
patient was predicted to be at high risk but he/she was censored (i.e. did better than 
expected from the prognostic model). Such patients are candidates for positive 
responders. A large negative martingale residual is also possible for patients who died 
and have extremely large predicted hazard rate (e.g. δi = 1 and Λ  ≈ 2). Notice, that 
even though the patient dies, he would still be candidate for a positive responder, since 
in order to have such a large hazard rate, he must have lived much longer than expected.  
i
ˆ
)1(0ˆ
)1(0ˆ
0
−≈<⇒
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≈>Λ
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                )1(0ˆ)2(1ˆ
1
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≈>Λ
=
j
j
j
M
δ
As mentioned in chapter 3.2, martingale residuals have two major disadvantages. They 
take values only in the interval (-∞, 1] and their distribution is highly asymmetric. 
Furthermore, censored cases always have negative residuals, which skews the 
distribution even further for data sets with large percent censoring. Deviance residuals 
were created especially to deal with the first problem and they have better distributional 
properties (Therneau et al, 1990). However, they do not always manage to transform the 
martingale residuals to a symmetric distribution, especially for data with large 
percentage of censoring. Although the definition of deviance residuals (3.16) looks 
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rather complicated, they can just as well as the martingale residuals be interpreted in the 
traditional form of expected – predicted value (for details, see Appendix A). If we 
regard once again the censoring indicator as the expected value from the data and the 
estimated hazard rate – as the predicted value from the (prognostic) model, with some 
calculations we reach the following conclusions: 
Deviance residuals with values close to zero: 
If the expected and the predicted values are the same, the resulting residual is small in 
absolute value or zero. Just as by martingale residuals, this can be achieved if a  patient 
is predicted (prognostic model) to have low hazard and he/she is censored or if a patient 
is predicted to have high hazard (about equal to one) and he/she experiences an event. 
Such patients are candidates for non-responders. 
0
0ˆ
0
≈⇒




≈Λ
=
j
j
j
d
δ
                 0
1ˆ
1
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
≈Λ
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j
j
j
d
δ
Deviance residuals with large positive values: 
Deviance residuals are transformed martingale residuals and as such, they can have 
positive values only if an event occurred and the predicted hazard rate is less than one. 
Unlike martingale residuals, they do not have an upper limit of one (see figure 3.5). 
Patients with large positive values of the residuals are candidates for negative 
responders: 
)2(0
)5.0(1ˆ
1
≈>⇒




≈<Λ
=
j
j
j
d
δ
 
Deviance residuals with large negative values: 
Deviance residuals can have negative values both for censored cases and for cases with 
events. If a patient is predicted to have large hazard but he/she is censored, the residual 
would be large negative. The patient shows improvement under the new treatment 
(he/she is censored before an event occurred) in comparison to his/her predicted hazard 
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(large positive) as expected from the prognostic model developed on the classical 
treatment group. Just as by martingale residuals, the patient can have an event and still 
show improvement under the new treatment, if his/her predicted hazard is much larger 
than one. Such situation would show that the patient did experience an event, but much 
later than expected. Such patients are candidates for positive responders. 
)2(0
)2(0ˆ
0
−≈<⇒




≈>Λ
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j
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j
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                )2(0)5.4(1ˆ
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≈>Λ
=
j
j
j
d
δ
The general relationship between the size of the predicted hazard and the resulting 
residual (martingale and deviance) is plotted in figure 3.7 for censored and uncensored 
cases. And the relationship between martingale and deviance residuals (defined in 3.16) 
is plotted in figure 3.8. As expected, those residuals are highly correlated (Spearman's 
rho correlation coefficient =.998, p < .001).  
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Figure 3.7: Relationship between the predicted hazard and the martingale and 
deviance residuals for the event and censored (always non-positive) 
cases. The relationship between predicted hazard and martingale 
residual is linear, whereas deviance residuals transform that 
relationship. 
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Figure 3.8: Relationship between the deviance and martingale residuals from figures 
3.5 and 3.2. 
 
The log-odds or normal deviate residuals, which can be used for outlier screening, have 
better distributional properties than the deviance and the martingale residuals. However, 
they are both highly correlated (Spearman's rho correlation coefficient =.998, p < .001) 
with the martingale residuals (see figures 3.9 & 3.10).  
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Figure 3.9: Relationship between the martingale (MART) and log-odds (LOGODDS) 
residuals on a model from the simulation study in chapter 9. 
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Figure 3.10: Relationship between the martingale (MART) and normal-deviate 
(NORMDEV) residuals corresponding to figure 3.9. Notice, that the log-
odds and normal-deviate residuals from figures 3.9 & 3.10 were 
calculated on a different data set than the residuals in figure 3.8, hence 
the different scale of the martingale residuals. 
 
In addition, even though the log-odds and normal deviate residuals quantify the 
departure from perfect prediction of the prognostic model, they cannot be interpreted in 
the classical expected vs. predicted form, which makes them undesirable for responder 
identification. 
The above residual overview leaves us with the following thought. We can either have 
interpretable, hence usable for responder identification residuals, which have 
distributional problems connected to censoring, or we can choose the improved 
residuals, which are perfect for outlier screening and with nice symmetric distributions, 
but which are unusable as responder identifiers since they cannot be interpreted in the  
expected – predicted form (Nardi & Schemper, 1999). This leaves us with the 
martingale and the deviance residuals as suitable for responder identification purposes. 
Since they are highly correlated with each other and since they basically identify the 
same groups of outliers (see figure 3.2 & 3.5), a simulation study is needed in order to 
choose the more appropriate residual for responder identification (see chapter 9).  
4. THE CLASSICAL APPROACH: COX-PH MODEL 
WITH INTERACTIONS 
 
 
 
Up to now, the classical approach for responder identification in clinical trials has been 
the Cox-PH model including interaction terms between the treatment and some or all of 
the covariates (Schemper, 1998). 
 
4.1 Definition 
 
In a clinical trial with two arms, in which a classical and a new treatment are compared, 
one would use the following version of the Cox-PH model on the entire data set: 
44444 844444 76876
predictive
TiziI
prognostic
ix treatztreatzx
ii etzxt
⋅+⋅′+⋅⋅′+⋅′⋅= ββββλλ )(),,( 0  
where:  
i – patient identifier, i = 1, ..., n 
x  – vector of prognostic factors 
βx  – vector of coefficients of the prognostic factors 
z  – vector of predictive factors (z ⊂ x is possible) 
βz  – vector of coefficients of the predictive factors; 
    to avoid double appearance, βz[i] = 0 for zi ⊂ x 
treat  – factor indicating treatment group (0 = classical, 1 = new) 
βT  – coefficient of treatment indicator 
βI  – vector of coefficients of the interaction terms 
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4.2 Responder identification 
 
If a certain predictive factor interaction term shows to be adding information to the 
model, this should be interpreted as follows: 
• If the coefficients in the predictive part of the model are such, that the presence of 
factor zi in the model increases the hazard of patients having that factor and taking 
the new treatment, we can say that zi is a predictive factor and patients having this 
characteristic are negative responders of the new treatment (see figure 2.2).  
• Naturally, if the coefficients in the predictive part of the model lead to reduction of 
the hazard in the presence of factor zi, then zi would be a predictive factor which 
defines the positive responder group. 
The problem with this method is, that in order for it to recognize a combination of 
factors as predictive, this particular combination has to be present in the model as 
interaction. Even assuming that the interaction between the factors is linear, the order of 
the interaction term is unknown. If two predictive factors and factor treatment should 
show interaction, one needs to consider all possible interaction terms of up to third order 
in order to give a chance of a covariate selection procedure to choose the right 
combination. The number of possible interaction terms to be considered grows rapidly 
as the number of factors grows. It is also known, that the power of stepwise variable 
selection procedures decreases as the number of variables (variable combinations) 
increases.    
Considering the limitations of this simple approach, it is clear, that a new more involved 
exhaustive method is needed. A class of such methods is suggested and discussed in 
chapters V through VIII. 
 
5. CLASSIFICATION AND REGRESSION TREES 
(CART) – RECURSIVE PARTITIONING 
 
 
 
We will use the following standard tree terminology: 
Tree   A model based on recursive (usually binary) partitioning 
Node A position in the tree where a new partitioning can be performed. 
The node is the current space for all immediately following 
operations. 
Split  Position in the tree where the current space (node) is partitioned 
into (two) subspaces  
Root tree  A tree consisting of one node and no splits, i.e. the original space. 
End node (leaf) A node on which no more splits can be performed. The objects in 
each leaf are estimated with an appropriate function. 
Branch A node with all its following splits and nodes. A branch is a 
subtree. 
Pruning  Cutting off branches. 
Classification tree A tree model appropriate for data with a categorical response 
variable or, after alteration, for survival response. 
Regression tree A tree model appropriate for data with a continuous response 
variable. 
 
node
 
Tree diagram branch
end node 
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Although the original clinical trial data in our problem is survival data (two response 
variables: survival time and censoring indicator), predictive factor identification does 
not require application of survival trees. A survival model (in our case Cox-PH model) 
was already used on the data for prognostic factor identification. From this point on, we 
will have a single response variable – the residuals to the prognostic model. 
The regression and classification tree method (Breiman et al, 1984) is a method which 
employs recursive partitioning in order to split the response space into a set of 
rectangles. In classification trees, the response is categorical and the objects in one 
rectangle would be predicted to be in one of the response categories (classes). Since 
martingale and deviate residuals are continuous, we will need regression trees, which fit 
a simple (e.g. constant) model in each of the resulting rectangles to predict the response 
of the points in them. 
For illustration purposes, it is convenient to use just two continuous factors and a 
continuous response. Factors LVEF and HRVI were chosen from the treatment arm of 
the EMIAT data set for this example. The response variable here is the martingale 
residual of the prognostic model (see chapter 10.4.1 for details on the prognostic 
model). A binary regression tree was built on the data (figure 5.1b), which splits the 
input space recursively in two parts, as shown in figure 5.1a. The first split is made at 
the value of 8.95415 of factor HRVI, the second – at value 20.5 of LVEF, and so on. 
The result of this recursive binary partitioning is  a set of 6 regions R1, ... R6. The 
regression model predicts the residuals in each region with a constant cm (Hastie, 
Tibshirani, Friedman, 2001): 
∑
=
∈⋅=
6
1
21 }),{()(ˆ
m
mm RxxIcxf , 
where x1 & x2 are the two input factors. The resulting regions are represented in the 3D 
plot of figure 5.1c and the tree model representing this series of splits is shown in figure 
5.1b, where the end nodes of the tree represent the 6 regions. 
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Figure 5.1: A regression tree example built on a two dimensional input space from 
the EMIAT data set, including factors LVEF & HRV_index (HRVI), with 
the martingale residuals of the Cox-PH model from section 10.4.1 as a 
response variable. 
a) The two dimensional input space, divided into six regions as 
defined by the end nodes of the regression tree in b). 
b) The regression tree model 
c) Three dimensional representation of a) including the mean 
response (c) for each region, which represents the mean of the 
martingale residuals for patients in the six regions of a). 
 
Notice that the predictors xi may also be categorical, in which case the set of possible 
splits is predefined and finite (for binary predictors there is only one possible split 
point). Also, in general, we have more than two predictors to choose from. 
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5.1 Growing a regression tree 
 
Consider the following data available for growing a tree, the so called learning sample 
L: a set of p predictors xi = (xi1, xi2, ..., xip) and a response yi, available as pairs (xi, yi) for 
a total of N observations (i = 1, ..., N). The tree algorithm must be able to select splitting 
variables and corresponding split points, starting with L and ending when a stopping 
criteria is reached. The algorithm must also decide at each node if this is an end node or 
if further splitting is needed. Additionally, one may choose to reconsider the tree 
architecture and collapse some unimportant nodes, using pruning. 
 
5.1.1 Splitting 
 
Splitting in regression trees, as introduced by Breiman et al (1984), is done with the 
help of least squares regression. If a tree partitions the space into M regions R1, ..., RM, 
which are modeled with the simplest possible regression model – a constant cm, then the 
response variable can be described by: 
∑
=
∈⋅==
M
m
mm RxIcxfy
1
)()(  
Regression tree models, as described by Breiman et al (1984), use the least mean 
squared error of f(x) in the region as a splitting criterion. Each possible split defined 
with splitting variable xi and split point ti is evaluated by calculating the mean squared 
error of predictor f(xi) of yi:  
∑
=
−
N
i
ii xfyN 1
2))((1  
That means that the best constant  for region Rmĉ m is just the average of yi in Rm: 
)|(ˆ miim Rxyavec ∈=  
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The optimal cutpoint is chosen by minimizing the expected mean squared error. In 
terms of splitting L in two regions at predictor j and point ts, if R1 and R2 are the two 
resulting subspaces at this split, then: 
}|{),(}|{),( 21 sjsjsjsj tXXtXRandtXXtXR >=≤=  
Then one should be looking for splitting variable xj and point ts, which minimize: 


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The minimization over c1 and c2 is solved by the Bayes predictors (see Breiman et al, 
1984, for extensive theory of the splitting process): 
( ) ( )),(|ˆ),(|ˆ 2211 sjiisjii txRxyavecandtxRxyavec ∈=∈=  
Thus, minimization over xj and ts is done by considering all possible xj and ts 
combinations in L, and taking the one which minimizes the sum of the averages of yi in 
the two resulting subspaces. 
Splitting is done iteratively, starting with the original data set (learning sample), finding 
the best split, and then splitting again the resulting subspaces. The process is repeated 
by node number on all nodes which are not end-nodes (see figure 5.2 for node 
numeration scheme).   
 
//
R2 R1
111098
75 64
2 3
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 R3 R4 R5 R6
 
Figure 5.2: Node numbering of trees 
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5.1.2 Stopping criteria 
 
The tree growing algorithm also needs to recognize when a node is final and when 
further splitting is needed. There are two stopping rules, which are used simultaneously. 
The current node is considered end node if: 
1. A minimum, predefined amount of data points in it is reached. 
2. No more splitting can be done, i.e. all data points in the node are described by   
the same vector of predictors (this is possible only if all predictors are 
categorical). 
In addition, goodness of split criteria can be used to decide if a split is significant, or if 
the current node should be final. However, Hastie, Tibshirani, and Friedman (2001) 
note that this strategy is rather "short-sighted" since a "seemingly worthless split might 
lead to a very good split below it." 
 
5.1.3 Pruning 
 
It is preferable to grow a large tree first, knowing that it overfits the data, and then 
reducing it to the right size with the help of cost-complexity pruning for regression 
trees. 
Let Ti be a subtree of the overgrown tree T0; Ti is obtained from T0 by pruning. Let |Ti| 
denote the number of endnodes in Ti and let they be indexed by m = 1, ..., |Ti|, 
corresponding to the regions Rm into which Ti splits the initial space (fig. 5.2). Then the 
cost-complexity criterion (also called error-complexity for regression trees) is defined to 
be (Breiman et al, 1984, Hastie, Tibshirani & Friedman, 2001): 
∑ ∑
= ∈
⋅+−=
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1
2 ||)ˆ()(
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m
i
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The cost-complexity criterion is an AIC type criterion, which penalizes by increasing 
the complexity of big trees. The tuning parameter α ≥ 0 governs the trade off between 
complexity and goodness of fit. The cost-complexity criterion is calculated in Appendix 
A at each possible pruning point for the tree in figure 5.2. Pruning is applied first at the 
weakest link in the tree model, which is followed by the node producing the smallest 
increase (per node) in the error term of the cost-complexity criterion. The result of 
pruning with parameter α would then be a tree Tα ⊆ T0, which minimizes the cost-
complexity criterion. Notice that large α values result in smaller Tα trees and vice versa. 
If α = 0, then Tα = T0. 
Breiman et al (1984) describe the pruning theory in full length, and prove that there is a 
unique solution to the minimization problem. 
 
5.2 Tree Performance 
 
The tree model has lately become popular among medical scientists "... perhaps because 
it mimics the way that a doctor thinks." (Hastie, Tibshirani & Friedman, 2001). The 
main advantage of recursive binary partitioning is that the resulting models are 
interpretable. The whole space is partitioned in disjoint regions and all of them are 
described with a single tree.  
The main disadvantage of tree models is their instability, which is due to the 
hierarchical nature of the model construction method. Bagging, for example, is a 
method developed to cope with this disadvantage (Breiman, 1996). Bagging averages 
among several tree models in order to reduce the variance, but the averaging process 
deprives the model from its main advantage – interpretability.  
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5.3 Responder identification with regression trees 
 
As mentioned earlier, the responder identification idea is based on finding patients in 
the new treatment group, who are badly predicted by the prognostic model. In chapter 3 
we have shown why martingale and deviance residuals are suitable for this purpose. 
Since regression tree models split the input space into regions, which are described by a 
part of the input variables (the predictive factors), and the size of the output variable in 
each region is predicted, we can use regression trees for responder identification. The 
tree would be built on the new treatment arm of the data and the residuals to the 
prognostic model would be used as an output variable. Binary splitting is based on 
maximal difference of the output variable in the regions, so the hope is, that one or more 
of the final regions of the tree model would have much larger or much smaller mean of 
the residuals in them, than the average for the input space ( ≈ 0). 
The responder identification method is described in detail in chapter 8. 
6. PRIM – PATIENT RULE INDUCTION METHOD 
(BUMP HUNTING) 
 
 
 
Bump hunting, presented in this chapter as described by Friedman & Fisher (1999), is a 
Data Mining technique which optimizes a certain target function in order to find regions 
in the input space with special unique properties, different from the rest of the space. 
Unlike prediction models (like CART), which cover the whole input space and attempt 
to capture its general characteristics, bump hunting is designed to identify and describe 
only parts of the space, which gather elements with common special behavior.  
Having a learning sample L = {yi, xi}, i = 1, ..., N, xi = (x1i, x2i, ..., xni) taken from the 
underlying distribution with probability density of y at each x: p(y|x), described by its 
first moment )|()( xyExf = , one can use the minimizer of the mean squared prediction 
error at each input x as a way of describing the underlying distribution with the help of 
the learning sample. 
As previously mentioned, bump hunting is not interested in describing all of f. It merely 
searches for special properties of f, namely, its minima and maxima. This is a typical 
function optimization problem, which is solved by searching for regions of the input 
space (L) in which the average response values (yi) are much larger (or much smaller) 
than the overall response average. Notice, that min f(x) = max [– f(x)], so that the 
maximization algorithm can be transformed into a minimization one with just a simple 
sign change. For the rest of this chapter we will only discuss maximization without loss 
of generality. 
Assuming that Sj is the set of all possible values of variable xj, we can represent the 
entire input space as an n-dimensional product space: 
nSSSS ×××= K21  
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If we are not looking for a single maximal point x, but for a region containing that point, 
the goal of function optimization would be to find a subregion B of S, such that: 
SBxB
fxfavef >>=
∈
)( . 
The size, also called support, of region B is then the integrated probability density:  
∫
∈
=
Bx
B dxxp )(β . 
Usually there is a trade-off between Bf  and Bβ  – larger function average is associated 
with smaller support in the region. Since we do not know the underlying distribution, 
but just have a learning sample, we will use the estimates of Bf  and Bβ : 
∑
∑
∈
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where yi are the output values and function I is an indicator which (in the sum) counts 
the number of observations in region B. 
Optimization theory offers many different strategies for function optimization. Bump 
hunting is a type of greedy algorithm equipped with patience, which stresses 
interpretability of the resulting regions. 
 
6.1 General structure of the PRIM model 
 
In general, bump hunting focuses on solutions which can be described in terms of 
important characteristics of the data. In particular, that means that the sought region B 
(also called bump) can be described by simple statements involving the input variables. 
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The final bump can be composed of several sub-regions (called boxes) Bk, k = 1, ... , K, 
where B is the union of all sub-regions: 
k
K
k
BB
1=
= U . 
Each sub-region Bk is constructed of simple logical rules (called borders) involving 
different input variables. These borders are obtained by combining a certain number of 
basic rules that concern only one variable at a time. This makes the resulting region 
interpretable: 
nkkkk sssB ×××= K21 , 
where sjk is a subset of all possible values of xj, Sj:{ . Thus, the sub-regions Bnjjk Ss 1}⊆ k 
are defined by the intersection of the subsets of all possible values of each single 
variable: 
)(
1
jkj
n
j
k sxBx ∈=∈
=
I . 
If input variable xj is continuous, subset sjk will be an interval; if variable xj is 
categorical, sjk is a finite set of values from Sj. 
Now we know that bumps are unions of boxes and boxes are intersections of borders. 
Next we need to know how to construct these elements. The construction of bumps 
happens stepwise. The calculation of the first box B1 is done with the entire data set. 
Then the elements contained in B1 are removed from the construction data set and the 
second box is constructed using the reduced data set. The kth box is found using all data 
not included in any of the previous boxes. In this manner, since the successive box 
definitions depend on the previously constructed boxes, box-definitions grow more and 
more complicated, but all building blocks stay simple logical rules. This process of 
removing the constructed boxes, and thus, indirectly including them in the definition of 
all following boxes is called covering. 
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Theoretically, the entire input space can be covered with boxes, however this is not 
done, since, as mentioned earlier, bump hunting is designed for the identification of 
extreme regions of the target variable, rather than for an optimal approximation or a 
good prediction of the output over the entire input space. 
 
6.2 Box construction 
During the box construction process, just as in regression trees, bump hunting (PRIM) 
looks for rectangular regions (boxes), but not by minimizing the sum of the averages of 
the (two) new regions into which the current space is split. Bump hunting "peels off" a 
certain percentage of the data while optimizing the response average of the elements left 
in the box (see figure 6.1 for illustration of the box construction process with two input 
variables). At each peeling step, a variable and a peel-off value is chosen, which 
together define a border (the lines in figure 6.1) so that the data points left in the region 
have the largest mean of the output variable: 
Btx
y
jj ,
max , 
where B is the box resulting from a peeling at variable xj and peeling point tj. The top-
down-peeling process stops when a minimum number of elements in the box is 
reached. 
Since peeling is a greedy process, the average of the response variable in the box can 
often be improved by "pasting" back some of the data to the box (the checked regions in 
figure 6.1). The bottom-up-pasting process stops when the average in the box can no 
longer be improved. In general, when pasting is possible, the new box does have a 
larger mean of the response variable, but that rarely has a dramatic effect (Friedman & 
Fisher, 1999) 
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a) b)
B1
X2 X2
X1 X1 
c) d)
B2 
B1B1X2 
X2
X1 X1 
e) t7 t8 
B1
B2B2  
t2 
t1 
Legend 
 
 borders 
 
final result of 
peeling 
added region 
by pasting 
BOX 
DEFINITIONS:
 
Box 1 (B1) 
t3 ≤ X1 < t4 
t1 ≤ X2 < t2 
Box 2 (B2) 
X1, X2 ∉B1 
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Figure 6.1: Example of bump hunting model growth in a two dimensional input space 
(X1 & X2 are the input factors): 
a) the entire input space 
b) construction of the first box through peeling 
c) improving the first box by pasting 
d) construction of the second box through peeling in the input space, 
excluding the first box; improving the second box by two step 
pasting 
e) the input space and the bump, consisting of two boxes; all borders 
are shown with factor and cut-value 
 
After covering, all resulting boxes together describe the maximal region – the resulting 
bump. Notice, that since each box is removed from the space before the construction of 
the next one, the following boxes are not always rectangular and, therefore, cannot 
always be expressed by a tree model.  
Two parameters need to be specified in the box construction algorithm: peeling 
quantile α and minimal support β0. The peeling quantile determines the percentage of 
data points excluded (peeled away) from the current box at each peeling step. Friedman 
and Fisher suggest values of α between 0.05 and 0.1, which results in the removal of 5% 
to 10% of the data at each step. The minimal support is a threshold parameter, which 
determines the minimal size of the final box. The choice of the minimal box support 
involves statistical and domain of application dependent considerations. The 
development of a box mean (i.e. mean of the target variable for data points in the box) 
with respect to support β can be observed with the help of the box construction 
trajectory. The trajectory allows one to visually choose an optimal β0. Figure 6.2 shows 
an example of a trajectory, constructed with α = 0.1 where the mean of the response 
variable is maximized. One can observe how the mean grows from the mean of the 
whole data set (0) to about 0.75. The points on the trajectory represent the consecutively 
chosen borders. The trade off between support and mean in the growing box is clearly 
visible. Notice, maximization is done only in the direction of mean response. 
Multivariate optimization is not performed 
If the input factors are categorical, that limits the peeling procedure in the following 
manner: 
• Binary variables allow of only one peeling point, which splits the data into two 
parts. 
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• Variables with more than two categories are treated the same way as in CART. The 
peeling points are defined in such manner, that any category can be peeled off. 
Unlike continuous variables, where only the largest or the smallest values can be 
peeled off, in a categorical variable with, say, three categories: A, B, and C, 
category B can be peeled off (categories are not ordered). 
• Continuous variables are often categorized. In this case, to preserve the order among 
the categories, we suggest artificially entering the categorized input variable as 
"continuous" in the bump hunting algorithm. 
The general bump hunting algorithm delivers rather unstable models (just as CART 
does). If data permits, one can use cross validation at each box in order to stabilize the 
resulting model. If the initial space is small and does not allow cross validation, another 
stabilizing improvement of bump hunting can be used (see chapter 7). 
Global Mean
Border 1 
  ...           Border 3
Border 2
 
Figure 6.2:  Trajectory – visualization of the box-building process (α = 0.1). 
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A comparison between a tree and a bump model can only be made in a very lose sense, 
although both models partition the input space in regions, since trees describe the entire 
space and bumps – just extreme parts of it. A general advantage of bump hunting over 
CART is its patience. Due to the binary splitting in CART, the input space is quickly 
fragmented into large regions. Bump hunting peels off a certain adjustable proportion of 
data points at each step and can perform many more steps (on continuous factors) before 
running out of data.    
For further detail on the bump hunting procedure, please refer to Friedman & Fisher 
(1999). 
 
6.3 Responder identification with bump hunting 
 
Although not created originally for responder identification, bump hunting seems to be 
tailor made for that purpose. Consider the function plotted in figure 6.3 to be the 
residual of a prognostic model of an imaginary (for visualization purposes two 
dimensional) input data set. The positive and negative bumps are clearly visible. The 
negative bump consists of two boxes; the positive one of three boxes. Bump hunting is 
designed precisely to identify the regions in the (two dimensional) input space, shown 
as the projection, where minima and maxima of the output function occur (the darker 
and lighter shaded areas). Applied to the residuals of the prognostic model, this 
procedure would identify patients with specific properties, who are not well predicted 
by the prognostic model. Those groups of patients, described by values of the input 
variables, would be candidates for positive and negative responders.  
For details on the responder identification method, please refer to chapter 8. 
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Figure 6.3: Visualization of bump hunting for responder identification (the surface 
was created using function "peeks" in MATLAB 5). The horizontal 
coordinates represent a two dimensional input space, the vertical 
coordinate – the response variable. The two dimensional projection 
includes the response average on color scale, corresponding to each 
subdivision of the plane. 
 
 
7. STABILIZATION OF BUMP HUNTING 
 
 
 
As mentioned earlier, bump models are rather unstable, due to their hierarchical nature. 
There are two general ways of assuring that a model is "good": validation and 
stabilization. Harrell, Lee, & Mark (1996) summarize the procedure for performing 
external validation and the types of internal validation: data splitting, cross-validation, 
and bootstrapping. The external and the first two internal validation methods require 
abundance of (appropriate) data, which one rarely has. Bootstrapping uses the entire 
data set in the model building process and then calculates come goodness-of-fit statistic 
on a large number of bootstrap samples taken from the original data.  
There is no known goodness-of-fit statistic for the bump model. One can use the mean 
squared error as a type of homogeneity statistic, showing the difference between the 
mean of the output variable and the actual output values in the bump, but this does not 
capture the goodness-of-fit of the entire model. The choice of input variables and cut 
points is just as important. Therefore, bootstrapping as a validation procedure is not 
directly applicable for bump models. The validation choices left are external validation 
or internal validation involving data splitting. Both are not always possible. 
If there is no direct way to validate a bump model, one should at least reduce the 
variability of the bump hunting model resulting from small changes in the data – the so 
called stabilizing.   
 
7.1 Stabilizing with bootstrapping 
 
Bootstrapping can be used as a stabilization procedure during the model building 
process (see Tibshirani & Knight, 1999, and Dannegger, 2000). One can use bootstrap 
samples of the original data in order to estimate the model coefficients or to choose 
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stronger predictors. Bootstrapping, in all of its shapes and forms improves or qualifies 
the predictive capacity of the model. 
We apply bootstrapping in the method for identification of responders at each predictor 
selection step of the bump hunting process. 
Referring back to chapter 6.2, figure 6.2, the borders involving different predictor 
variables are chosen one-by-one in the box-building procedure. Border 1 is represented 
in fig. 6.2 with its mean and support, i.e. using the restriction involving the predictor in 
Border 1, we obtain a box having a single border representing a set of patients from the 
treatment group. In order to choose the second border, the first one needs to be fixed. 
This hierarchical dependency leads to large variation in the bump hunting model after 
small alterations of the data set. We stabilize the bump hunting model  in two ways: 
1. Categorization of all continuous predictors needs to be done in order to reduce 
peel-off point variation. This limits somewhat the power of bump hunting, since 
it restricts the peeling process, but it is a necessary preliminary step for the 
bootstrapped bump hunting. We suggest using at least three categories, which 
can be either already known from previous studies cut points or the 
corresponding percentiles. Notice, however, that many of the predictors coming 
from the area of medicine can only be split into two logical parts (i.e. tumor size 
= increasing/decreasing), whereas others allow for more categories (i.e. age = 
child/adult/elderly). As suggested in chapter 6, such categorized continuous 
variables should be entered as "continuous" in the bump hunting procedure. See 
chapter 8.4 for a note on a more sophisticated procedure for cut point 
identification. 
2. In order to stabilize the border selection method, we choose each border (i.e. 
predictor-restriction combination) after considering all borders chosen from n 
bootstrap samples. We fix a border and proceed to the next one only if it was 
chosen in the majority of the bootstrap samples. 
The process in 2. is repeated according to the following algorithm: 
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7.2 Algorithm 
 
1. Set the p-value of the log-rank statistic to 1 ( p(LR) = 1) and let T be the set of all 
patients in the new treatment arm. 
2. Take n bootstrap samples of T and, using the original bump hunting algorithm, 
create a trajectory for each one of them, including the original sample. 
3. Consider all n + 1 first borders and the associated predictors and choose the one 
which appears most often. If there is a tie, choose the less restrictive border, i.e. 
one which results in a box with bigger support when applied to the original data 
set. 
Note: Predictor and border are not equivalent terms. One predictor may appear with different 
restrictions in different bootstrap samples. We are only interested in the border 
frequency as a combination of predictor and constraint. 
4. Restrict T using the border from step 3. Calculate the mean response and the 
support of the resulting box. 
5. Apply the rules restricting T to the classical treatment (or placebo) group and 
create a set P of patients under the same restrictions as in T. 
6. Calculate the log-rank statistic for the difference in survival between patients in 
P and in T. If p(LR) improves1 from its previous value, return to step 2. If not, 
stop. 
Notice, that any stopping criteria which considers only one step at a time is easily 
implemented, but in general nearsighted. An alternative is to look several steps ahead 
before a stopping decision is made, since a seemingly "bad" border can lead to a "good" 
one and result in a better model (see section 10.5 for an example). We choose not to do 
this in the simulation study of chapter 9 in order to fully automate the software 
implementation and reduce computation time. 
                                                          
1 The definition of "improves" can be different for different types of data. If initially there is no difference 
in survival between the new and the classical treatment groups, the p-value improves when it decreases. 
For cases where there is initial difference, please refer to chapter 8.2 
 
 
 
     51 
 
As an example to the general algorithm above, the result of a single border selection 
step (steps 2 & 3) could be as summarized in table 7.1. 
 
Table 7.1: Hypothetical example of border selection with bootstrapping. AGE = 1 if 
patient age ≤ 30 years; AGE = 2 if patient age ∈ (30, 65] years; AGE = 
3 if patient age > 65 years. SMOKER = 0 if patient is non-smoker; 
SMOKER = 1 if patient is smoker. 
 
Restrictions: AGE = 1 AGE = 2 AGE = 3 SMOKER = 0 SMOKER = 1 
Original data 1 0 0 0 0 
100 bootstrap 
samples 
10 0 85 0 5 
 
Table 7.1 should be interpreted as follows: 
1. The first row shows all possible restrictions in the two input variables, i.e. all 
possible borders. Notice that the effect of restriction AGE = 1 is that all points 
with this characteristic would be chosen to be peeled off, i.e. AGE ≠ 1 are left in 
the box. 
2.  The second row shows which border was chosen when ordinary bump hunting 
was applied to the original data. 
3. The third row shows how many times each border was chosen by ordinary bump 
hunting in the 100 bootstrap samples of the original data. 
4. Notice, that the ordinary bump hunting procedure would choose border AGE = 1 
at this border selection step, whereas the stabilized procedure would choose 
border AGE = 3.  
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7.3 Discussion 
 
The above algorithm can be modified to include pasting as well. In this case, we would 
use the minimal support (calculated in the original data set) as stopping criteria of the 
peeling process instead of the p-value of the log rank statistic. Pasting borders would 
also be chosen through bootstrapping. Here we can use both the p-value of the log rank 
statistic and the indicator for increase (decrease) of the box mean as stopping parameter.  
Please refer to chapter 9 for implementation and comparison of performance between 
ordinary and stabilized bump hunting. 
 
 
8. IDENTIFICATION OF RESPONDERS 
 
 
 
Assuming that we have a good prognostic (Cox-PH) model, we can use bump hunting 
or regression trees for responder identification. One can use both martingale and 
deviance residuals of the prognostic model in order to identify predictive factors. 
Without loss of generality, we will concentrate on martingale residuals for the rest of 
this chapter. A systematic comparison of the performance of martingale and deviance 
residuals in responder identification is shown in chapter 9. 
 
8.1 Algorithm using bump hunting 
 
Consider the following strategy for positive and negative responder identification using 
a predictive model based on bump hunting (original or improved algorithm): 
1. Develop a good prognostic Cox-PH model on the classical treatment arm of the 
data. 
2. Apply the prognostic model together with its estimated coefficients and baseline 
hazard to the new treatment group.  
3. Calculate the martingale residuals of the prognostic model in the new treatment 
group. Patients who are not well predicted (outliers in the residuals) would be 
candidates for responders. 
4. Develop a bump hunting model on the new treatment group, using martingale 
residuals of the prognostic model as response.  
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Figure 8.1.  Flow diagram of the responder identification algorithm. 
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5. Identify the groups of patients in the classical treatment group, who correspond to 
the extreme groups (bumps) in the new treatment arm, i.e. divide the classical 
treatment space in the same way as the new treatment space and consider the regions 
which were identified as extreme (bumps) in the new treatment space. Compare the 
survival curves of each classical-new treatment pair of extreme regions (log rank 
test). If there is a significant difference in survival, the group with extreme 
positive residuals would identify negative responders and the extreme negative 
residuals – positive responders. Also, the factors involved in the description of the 
regions will be predictive. For illustration, please refer to figure 6.3. 
The responder identification algorithm is shown schematically in the flow-chart of 
figure 8.1. The algorithm is tested in a simulation study (chapter 9). An application on 
the EMIAT data set can be found in chapter 10. 
 
8.2 A note on survival curve differences  
 
The responder identification method was developed with a situation in mind, in which 
overall the new treatment does not show to be better or worse than the classical 
treatment (i.e. the survival curves in both treatment arms do not differ significantly). 
The method needs slight alteration if initial difference in survival is at hand. Please refer 
to figure 8.2 for the following discussion. 
In chapter 2 we have defined positive and negative responders starting out with two 
treatment arms which do not differ in survival as in case A (figure 8.2). Then a 
subgroup of positive responders is one, for which the new treatment increases 
significantly the survival rate of patients taking it, as in case B (figure 8.2). The 
negative responders on the other hand are such patients in the new treatment group, 
who's survival time is significantly shorter than that of an equivalent group of patients 
taking the classical (old) treatment, as in case C (figure 8.2).  
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Figure 8.2: Possible overall survival curves in a clinical trial with two arms: 
A) No difference between the survival curves of the two arms 
B) The new treatment is overall better than the old one 
C) The new treatment is overall worse than the old one 
 
Let us consider now a clinical trial, in which the new treatment is better than the old 
one, when the entire patient populations are compared (case B). Then the entire new 
treatment group would be considered positive responders. In this case, it would be 
interesting to know if a certain subgroup of patients under the new treatment are 
actually harmed by it (as in case C). They would be considered negative responders. 
There might be a subgroup of patients taking the new treatment, who do just as well as 
their counterparts taking the classical treatment (case A). In this case, those patients 
would not be considered to be negative responders, since they are not harmed by the 
new treatment, although they do not profit from it either. 
Unfortunately, there are also trials in which the new treatment patients show worse 
survival rates than the classical treatment patients  (case C). In such disastrous trials one 
would be interested to know if a certain group of patients taking the new treatment 
actually do survive longer than a similar group taking the old treatment (as in case B). 
This would be a group of positive responders among the entire population of negative 
responders. Just as in the previously described situation, case A would be of no interest. 
In the last two trial scenarios, the algorithm for responder identification needs slight 
alteration. Ordinarily, one would use the change in p-value of the log-rank statistic as a 
stopping criteria in the bump hunting procedure (chapter 7.2, point 6 and chapter 8.1, 
point 5). In the peeling process of bump hunting, one would reduce the new treatment 
patient arm step by step. If there is a significant difference (case B or C) for the entire 
population, reducing the group would lead to less and less significant p-values before it 
eventually reduces the new treatment group to this one special subgroup, for which the 
p-values become significant again to show difference in survival between the new and 
the old treatment subgroups in the opposite direction from the initial situation (as in 
case C or B). In those cases, the p-value of the log-rank statistic cannot be used as an 
automatic stopping criteria and the growth of the bump hunting model needs to be 
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controlled manually. Alternatively, the algorithm can be changed to "intelligently" 
evaluate the p-values by looking some steps ahead in the algorithm. 
 
8.3 Changes to the responder identification 
algorithm if CART is used 
 
It is also possible to use a regression tree instead of a bump model. In this case, one 
would construct a regression tree model in step 4 of the algorithm in 8.1 and change the 
algorithm from that point on as follows:  
Steps 1 through 3 as in the algorithm in section 8.1. 
4. Develop a regression tree model on the new treatment group, using the martingale 
residuals of the prognostic model as response. 
Note:  A tree model describes the whole input space. We are interested only in extreme 
regions, i.e. end nodes with patients who have large positive or large negative residuals 
(e.g. R1 & R3 and R4 & R6 in figure 5.1). Notice that it is quite possible to have tree 
models which do not identify extreme regions or just deliver a negative or just a positive 
one. This depends on the tree complexity and on the data at hand. If an extreme region, 
positive or negative, is identified, the factors involved in defining it will be candidates 
for predictors. 
5. Order all end nodes by size of the mean response in them. 
6. Split the classical treatment group into subgroups as defined by the end nodes of the 
regression tree model. 
7. Start with the largest in absolute value (by mean of response) negative end node in 
the new treatment arm. Compare the survival curves of the new and classical 
treatment patients identified with that node. Calculate the p-value of the log-rank 
statistic. 
8. Add the patients contained in the next largest negative end node (from the list in 5.) 
to the previously considered group of new treatment patients. Calculate p(LR) for 
the identified groups in the new and classical treatment arms. 
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9. Repeat step 8 while p(LR) decreases or until there are no more negative end nodes. 
10. The last combination of end nodes defines the set of positive responders. The 
factors involved in defining it are predictive. 
11. Repeat steps 7 through 9 for the non-negative end nodes from the list in 5., starting 
with the largest (by mean of response). 
12. The last combination of non-negative end nodes defines negative responders. The 
factors involved in defining it are predictive. 
Notice again, that the algorithm can be improved, if it looks at p-values several steps 
ahead before it stops the growth of the responder groups.  
This strategy is tested in the simulation study of chapter 9 and applied on the EMIAT 
data set in chapter 10. 
 
 
8.4 Covariate considerations 
 
Obviously, continuous predictors give a large choice of borders (split-points in CART). 
Limiting this choice by categorizing continuous variables stabilizes the resulting model 
(see chapter 7.1). However, even though we recommend and perform categorization 
before bump hunting, one needs to carefully consider the dangers of such a procedure 
(see Altman et al, 1994). 
The most simple and most often applied categorization procedure is splitting at the 
median when dichotomizing or at the appropriate percentile for more than two 
categories. This results in equally sized categories, but the cut points are generally not 
"optimal." For some well established prognostic factors one could take the cutpoints 
which were used in previous studies. This is also dangerous, especially in cases, in 
which the new study differs in some major point from the old one (which is usually the 
case). Altman et al (1994) have suggested the minimal p-value approach instead – a 
more sophisticated categorization technique, which exists in different variations since 
1994.  
9. SIMULATION STUDY 
 
 
 
The responder identification method proposed in chapter 8 requires justification. If there 
is a data set, in which the positive and negative responder groups are known, one can 
apply the different versions of the algorithm discussed up to now and compare their 
ability to recognize those groups. Unfortunately, this is not possible in a real life data 
set, since the actual groups to be identified are not known. On the other hand, one can 
simulate survival data, in which the positive and negative responders are known. The 
full analysis and comparison of the responder identification algorithm requires a 
carefully planned simulation study. 
 
9.1 Methods 
 
A survival type data set was simulated to resemble a two arm randomized clinical trial 
with a total of 1000 patients, in which no difference in survival is observed between the 
two treatment groups (some structure of the EMIAT data set was mimicked). A total of 
seven factors were created: five binomial, one categorical with three levels, and one 
continuous in order to test the power of the different procedures in dealing with 
different types of variables. The factors were simulated in the following way: 
Binary factors X1, X4, X5, X6, and TREAT: 
Each factor is a vector of length 1000, each component of which is chosen at random 
from a binomial distribution with probability p = .5. TREAT = 0 denotes placebo 
patients, TREAT = 1 denotes new treatment patients. 
Categorical factor X2: 
Factor X2 is a vector of length 1000, the components of which were chosen at random 
from the set {0, 1, 2} with corresponding probabilities {.33, .33, .34}. 
 
 
 
     61 
 
Continuous factor X3: 
Factor X3 is a vector of length 1000 with components chosen at random from a normal 
distribution with mean five and variance two. 
Follow-up time for the data set was simulated in a way, which assures that the following 
Cox-PH model with prognostic and predictive parts would fit the data set: 
4444444444 84444444444 7644444 844444 76
predictiveprognostic
TREATXXcTREATXXXcXXXXetXt ⋅⋅⋅+⋅⋅⋅⋅+⋅+⋅⋅+⋅⋅= 52265433110 maxmin321)()|(
βββλλ
(9.1) 
where: 
 X is the matrix of factors in the model 
cmin and cmax are coefficients in the predictive part 
X22 = 
 1 if X2 = 2 
0 else 
β1, β2, and β3 are coefficients in the prognostic part 
The following pairs of values for cmin and cmax were chosen for further investigation: (-2, 
2), (-1, 1), and (-.5, .25). Note, that larger absolute values of the coefficients simulate 
stronger influence of the predictive part of the model on the hazard. In addition, since 
cmin is always negative, this term of the model decreases the hazard, i.e. patients with X4 
=1 & X5 = 1 & X6 = 1 would have lower hazard under treatment than under placebo – 
this is the simulated positive responder group. Conversely, since cmax is always positive, 
that term would increase the hazard, i.e., patients with X2 = 2 & X5 = 1 would have 
higher hazard under treatment than under placebo – this is the negative responder group. 
The values for the prognostic coefficients β1 = ln3, β2 = -(ln3)/5, and β3 = (ln3)/10       
(≈ 1.0986, -.2197, and .1099 respectively) simulate an interaction between categorical 
factor X1 and continuous factor X3 as depicted in the relative hazard plot of figure 9.1. 
The interaction can be interpreted the following way: in absence of factor X1 (X1 = 0), 
increase of factor X3 (from 0 to 10) increases the relative hazard (from 1 to 3); in 
presence of factor X1 (X1 = 1), increase of factor X3 (from 0 to 10) decreases the 
relative hazard (from 3 to 1). 
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Follow-up time for this model was simulated to be Weibull distributed with shape 
parameter equal to two and scale parameter equal to the relative hazard, i.e. TIME was 
created to be a vector of length 1000, each component of which was chosen at random 
from the unique to each patient Weibull distribution, depending on his/her relative 
hazard (= λ(t|x)/λ0(t)).  
Censoring was simulated in the usual way by first defining a temporary vector TEMP of 
length 1000, containing random values of the uniform distribution on the interval [0, τ]. 
Vector DEATH indicating event was then defined to be: 
DEATHi = 
 1 if ti ≤ TEMPi 
0 else 
This procedure for  assigning censoring allows for regulation of the percent censored 
cases in the data through parameter τ and assures, that censoring is assigned 
independently of time. Three different values of τ were considered: (11, 2.15, .65), 
which result in three different percentages censoring in the data: ≈ (10, 30, 70)% 
respectively. 
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Figure 9.1:  Interaction between X1 & X3 
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The above described survival data set was simulated a in groups with different model 
coefficients and censoring rates as shown in table 9.1.  
Table 9.1:  Simulation groups 
Simulation 
group # 
cmin cmax τ 
1 -2 2 11
2 -1 1 11
3 -.5 .25 11
4 -2 2 2.15
5 -1 1 2.15
6 -.5 .25 2.15
7 -2 2 .65
8 -1 1 .65
9 -.5 .25 .65
 
The survival curves of the placebo (TREAT = 0) and treatment (TREAT = 1) groups 
were compared in each simulation group. The difference was not significant at the .05 
level as it was expected by the simulation study design. Scatter plots of martingale 
residuals vs. follow-up time as well as deviance residuals vs. follow-up time are given 
in appendix B for the placebo and treatment groups of one data set in each of the nine 
simulation groups. One can observe how the different percentage of censoring and 
values of the predictive coefficients influence the residuals. 
The actual positive responder group in all simulations contained data points with 
TREAT = 1 and all of the following constraints: 
X4 = 1 & X5 = 1 & X6 = 1 
The actual negative responder group contained data points with TREAT = 1 and both 
constraints: 
X2 = 2 & X5 = 1 
The simulated responder groups differ in survival between the treatment and placebo 
groups (as expected). For example, a data set from simulation group 2 would have p-
values of the log-rank statistic, which are significant at the .001 level (please refer to 
figure 9.2 for Kaplan-Meier survival curves in the responder and non-responder groups 
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of TREAT = 0 and TREAT = 1). Figure 9.3 shows the martingale and the deviance 
residuals for both responder groups plotted against follow-up time in the placebo and 
treatment groups. 
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Figure 9.2: Kaplan-Meier survival curve estimates in the actual positive and 
negative responder groups for a data set in simulation group 2. 
 
 
 
     65 
 
A Responder
B Non-responders
Placebo
Treatment
-20.00
-15.00
-10.00
-5.00
0.00
m
ar
t
AAAAA
A
AAAAAAAAA
A
AAAA AAAA
A
BBBBBBBBBBBBBBBBBBBB
BBB
B
B
BBBB
BBB
BB
BBB
B
B
BBB
0.00 1.00 2.00
time
-20.00
-15.00
-10.00
-5.00
0.00
m
ar
t
AAAAAAAA
AAA
A
A
AAAA
A
A
A
A
A
A
A
AAA
A
A
A
A
A
A
AA
A
BBBBBBBBBBBBBB
B
BBBBB
B
BB
B
B
B
B
B
B
B
B B
 
 
 
 
 
 
 
 de
 
 
 
-6.00
-4.00
-2.00
0.00
2.00
de
vi
A
A
AAAA
A
A
AAAAAA
A
A
A
A
A
A
AA
A
AA
AAAAA
A
B
BBB
BBBB
B
B
BB
B
B
BBBB
BB
B
B
B
BB
B
B
B
B
B
BB
B
B
BB
BB
B
BBBB
B
B
BB
B
B
BB
BBB
0.00 1.00 2.00
time
-6.00
-4.00
-2.00
0.00
2.00
vi
AA
A
A
A
A
A
A
AAA
A
A
A
AAA
A
A
A
A
A
A
A
AAA
A
A
A
A
AA
AA
A
BBB
BB
BBBBBBBB
B
B
BB
B
B
B
BB
B
BB
B
B
B
B
B
B
B
B
B
BB
BB
BBBB
B
BB
B
B
B
B
B
B
B
B
B
B
B
B
B
B â  + responder 
ã − responder 
Figure 9.3:  Scatter plots of the deviance and martingale residuals in the placebo and 
treatment groups against follow-up time for the positive and negative 
responder groups of figure 9.2. 
 
9.2 Results 
 
9.2.1 Cox-PH with interaction 
 
The simulation study was designed in such a way, that a certain Cox-PH model with 
treatment interaction terms (model 9.1) should fit the data. We fit model 9.1 to all 
simulated data sets in order to check the simulation method. The mean of the Cox 
model coefficients over 100 data sets in each simulation group are shown in table 9.2. 
Notice, those coefficients are very close to the simulated ones, as they should be, so we 
can conclude that the data simulation was done correctly. The Wald statistic for factor 
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input to the model was significant in general at the .01 level, except for models 
constructed on data sets from simulation group 9. Apparently, the Cox-PH model 
cannot distinguish the simulated effect of the factors on hazard from noise when that 
effect is not strong (cmax and cmin are small in absolute value) and there is high 
percentage of censoring in the data. 
Table 9.2:  Mean coefficients of model 9.1 over 100 simulations 
Simulation 
group # β1 β2 β3 cmin cmax 
1 1.1116 -.2234 .1116 -1.9925 2.0039 
2 1.1205 -.2254 .1142 -.9981 .9942 
3 1.1120 -.2233 .1105 -.5019 .2628 
4 1.1238 -.2276 .1104 -1.9971 2.0226 
5 1.0935 -.2193 .1100 -1.0000 1.0030 
6 1.1433 -.2268 .1138 -.5048 .2629 
7 1.0857 -.2156 .1074 -2.1266 2.0410 
8 1.0970 -.2205 .1143 -1.0623 .9543 
9 1.0607 -.2143 .1008 -.4950 .2402 
 
Three representative simulation groups were chosen in an attempt to evaluate the power 
of the most frequently used variable selection process, forward stepwise selection, to 
identify the simulated Cox-PH model with interactions (model 9.1) as "best." Forward 
selection with likelihood ratio test as model improvement criteria was used with 
inclusion p(Wald) = .01 and exclusion p(Wald) = .05. Table 9.3 gives a summary of this 
investigation. Simulation groups 1, 5, and 9 were chosen as representative. Simulation 
group 1 has strong simulated treatment effect (easy to detect) and only 10% censoring. 
Simulation group 5 has medium strength simulated treatment effect and 30% censoring. 
Simulation group 9 has 70% censoring and slight treatment effect (difficult to detect). A 
total of 10 data sets were simulated in each group. The null model (no factors) and the 
correct model likelihood ratios were computed on each data set. Forward stepwise 
selection was applied on each data set four times: once including all factors X1 through 
X6 and TREAT and all their possible two-way interactions (a total of 7 + 21 = 28 
factors to choose from), once including all single factors and all their up to third order 
interactions (28 + 35 = 63 factors), all single factors and all their up to fourth order 
interactions (63 + 35 = 98 factors), and finally, all single factors and their up to fifth 
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order interactions (98 + 21 = 119 factors). The largest interaction term in the correct 
model is of fourth order. Interactions of up to fifth order were considered in order to 
check if forward selection including interaction terms of higher than needed order 
would choose more complicated terms than necessary. This should give a hint on the 
behavior of the automated selection procedure in a "real life" data set, for which the 
correct model is unknown. 
Table 9.3: Table of likelihood ratios for the null model, the models found with 
forward selection when different highest order interactions were present, 
and the correct model. 
 
Simulation 
group 
Run Null (df=0) 2d order 
interaction 
(df) 
3d order 
interaction 
(df) 
4th order 
interaction 
(df) 
5th order 
interaction 
(df) 
Correct 
(df=6) 
1 11239 11076 (11) 10976 (8) 10942 (6) 10942 (6) 10942 
2 11110 10941 (9) 10860 (5) 10844 (4) 10844 (4) 10820 
3 11121 10986 (10) 10884 (9) 10860 (5) 10860 (5) 10814 
4 11161 10946 (9) 10893 (6) 10868 (4) 10857 (6) 10822 
5 11094 10966 (9) 10787 (11) 10803 (5) 10803 (5) 10764 
6 11093 10929 (10) 10861 (5) 10819 (5) 10804 (8) 10784 
7 11132 10914 (13) 10801 (12) 10736 (10) 10736 (10) 10761 
8 11103 10919 (11) 10857 (5) 10819 (5) 10819 (5) 10803 
9 11109 10998 (6) 10878 (7) 10828 (7) 10828 (7) 10805 
1 
10 11189 11015 (11) 10912 (12) 10894 (8) 10894 (8) 10903 
1 8651 8608 (3) 8593 (5) 8581 (5) 8581 (5) 8555 
2 8705 8677 (3) 8633 (6) 8636 (5) 8636 (5) 8632 
3 8441 8422 (2) 8394 (5) 8395 (3) 8382 (5) 8366 
4 8525 8491 (5) 8476 (3) 8472 (3) 8472 (3) 8447 
5 8407 8381 (3) 8321 (9) 8329 (7) 8329 (7) 8324 
6 8412 8387 (3) 8365 (5) 8363 (4) 8363 (4) 8343 
7 8444 8410 (3) 8401 (3) 8384 (4) 8384 (4) 8368 
8 8584 8529 (4) 8522 (3) 8503 (3) 8503 (3) 8472 
9 8428 8397 (3) 8342 (4) 8335 (4) 8335 (4) 8316 
5 
10 8586 8547 (3) 8495 (3) 8486 (3) 8486 (3) 8453 
1 2740  2722 (3) 2722 (3) 2722 (3) 2724 
2 2474     2455 
3 2614     2600 
4 2643  2627 (2) 2627 (2) 2627 (2) 2631 
5 2845 2829 (3) 2829 (3) 2829 (3) 2829 (3) 2823 
6 2956     2945 
7 2509     2489 
8 2738 2729 (1) 2729 (1) 2729 (1) 2729 (1) 2724 
9 2751     2745 
9 
10 2291     2279 
 
bold = models with better LR than the corresponding correct model 
             = identical models (valid for the row) 
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In defense of the forward stepwise selection procedure, one should note, that in most 
cases (21 out of 24 constructed models) it did not add a fifth order interaction term, but 
delivered the model chosen from the procedure including up to fourth order interactions 
(see table 9.3). Unfortunately, it also chose the correct model only once out of 30 times. 
Consider first simulation group 9, the most realistic one. When the correct model 9.1 
was applied on the 10 data sets, it always reduced the likelihood ratio from the null 
model, but not always significantly (3 out of 10 were significant at the .01 level). In 
addition, the factor coefficients were also not significant (at the .01 level). In 6 out of 10 
cases the forward selection procedure did not find any significant factors. In the 4 data 
sets, in which significant factors were found, they were other than the simulated ones 
(i.e. noise).  
The overall impression is that the Cox-PH model with interactions is not a sensitive 
enough method for responder identification purposes when the effect of factors and 
factor combinations on treatment is weak and there is large percentage of censoring in 
the data. 
In simulation groups 1 and 5 (see table 9.3), the likelihood ratio of the correct model 
was better than that of the forward selected models for 18 out of 20 data sets (notice, in 
the cases where LR(forward) < LR(correct) the forward selected model contained the 
correct model and some additional factors). The coefficients of the correct model were 
always significant at the .01 level and most often at the .001 level. The Cox-PH model 
with interactions performs well on data sets with small to moderate percent censoring 
and strong to moderate treatment effect. The problem with applying this responder 
identification procedure in praxis is that the correct model is unknown and the forward 
selection procedure has low power (it chose the correct model only once out of 20 
times!). 
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9.2.2 Regression trees 
 
The regression tree version of the responder identification method described in chapter 
8 was applied on the following simulated data. In each of the nine simulation groups 
from table 9.1, 200 data sets were constructed as described in section 9.1. Martingale 
residuals were calculated on half of the data sets in each group. Deviance residuals were 
calculated on the other half. 
Goal: Using the known positive and negative responder groups in each data set: 
1) to evaluate the prognostic power of the responder identification procedure with 
regression trees (described in chapter 8), i.e. to compare the identified through the 
method groups of responders to the correct groups 
2) to compare the power of identification of the method when martingale and deviance 
residuals are used as response variables in the regression tree model. 
Step 1 of the responder identification algorithm can be skipped in the simulation study. 
The prognostic model here is known. It was simulated to contain factors X1, X3, and 
their linear interaction. This Cox-PH model was applied on the placebo part (TREAT = 
0) of each data set, where the three model coefficients and the baseline hazard were 
estimated. As shown in 9.2.1, the estimated coefficients would be very close to the 
simulated ones. Using the so estimated model coefficients and baseline hazard, 
martingale (or deviance) residuals were calculated on the treatment  (TREAT = 1) 
groups. The treatment groups of each simulated data set were used to construct 
regression tree models. All factors were included in the model selection procedure. 
Factor X3 was used dichotomized at the mean and the residuals were used as response 
variable. All regression tree models were pruned to size 5 (five end nodes), which 
showed to be sufficiently large to include all known predictive factors. A typical 
resulting tree is shown in figure 9.4. Generally, the correct predictive factors were 
chosen, but not always in an optimal arrangement, which is crucial for the responder 
identification power of the model. The pruned tree models were "applied" on the 
placebo groups and the data was divided into subgroups, corresponding to the end 
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nodes. Each pruned tree couple was analyzed separately. All end nodes were arranged 
by size of the mean response in the treatment arm.  
 
 
 
 
 
 
 
 
 
 
2 0, 1
10
10 
1 0 
node 9 
c = 0.1964
node 8
c = -30.31
node 6
c = 0.3437
node 4 
c = -0.0111
node 2 
c = 0.1884
node 7
X2
node 5
X4
node 3
X5 
node 1
X6 
 
Figure 9.4: A sample regression tree built on a simulated data set, pruned to 5 end 
nodes (c = mean response). 
 
Starting with the largest negative node, as described in the algorithm of section 8.3, we 
calculated the  log-rank statistic for difference in survival of the placebo and treatment 
patients in the node. Then we made a joint group of patients, containing the two most 
negative nodes and calculated the log-rank statistic for this group. We kept adding 
negative end nodes to the group according to their size until there were no more 
negative end nodes or until the p-value of the log-rank statistic stopped improving. The 
group of chosen negative end nodes defined positive responders. 
The same procedure was repeated for the positive end-nodes, starting with the largest 
one. The result was a set of negative responders in each simulation. 
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The so defined responder groups were then compared to the correct groups. Table 9.4 
shows the average number of times the entire responder sets were chosen correctly over 
the 100 data sets in each simulation group and each residual type. Since this did not 
happen very often, the mean percentage of correctly identified patients was also 
calculated (see table 9.4). 
 
Table 9.4:  Mean percent (%) correctly identified responders and number of times 
(#) the correct responder groups were chosen from 100 simulations for 
each simulation group, when regression tree is used as predictive model. 
 MART = martingale residuals; DEVI = deviance residuals. 
 
MIN end nodes 
(+ responders) 
MAX end nodes 
(− responders) 
MART DEVI MART DEVI 
sim. 
group # 
# % # % # % # % 
1 98 98 100 100 0 32.53 65 72.67
2 73 73 94 94 23 47.71 71 73.31
3 22 37.57 52 63.80 10 41.88 10 33.74
4 94 94 94 94 0 33.99 81 81.68
5 76 77.15 76 76 41 59.24 70 75.39
6 28 45.02 33 50.79 6 35.59 6 30.40
7 66 66 59 59 60 68.95 52 70.84
8 51 53.08 53 56.64 53 61.73 32 55.89
9 21 38.37 10 24 4 22.74 1 16.08
 
The results were better for data with low percentage censoring (sim. groups 1, 2, & 3 ≈ 
10%) than for data with high percentage censoring (7, 8, & 9 ≈ 70%), except for 
simulations with large coefficients in the positive nodes (1 & 4) with martingale 
residuals. This might be explained by the fact that MART ∈ (-∞, 1], whereas  DEVI ∈ 
(-∞, ∞). Large cmax delivers large positive residuals, so that with 90 and 70 % of the data 
being in the interval (0, 1], a lot of martingale residuals would be very close to 1. CART 
is based on splitting the data space into regions with most different mean of the 
response variable (here MART) and it obviously has a problem with simulation groups 
1 & 4. Deviance residuals, on the other hand, "stretch" the positive side of the 
martingale residuals distribution, so that CART shows to perform much better on them 
in groups 1 & 4. 
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Deviance residuals in general were about the same or better than martingale residuals 
for the purpose of positive responder identification (i.e. negative nodes). The same was 
true for negative responders (positive nodes), except for data sets with large percentage 
of censoring. Overall, the responder identification algorithm using regression trees 
showed acceptable power of identification for data, in which the groups to be identified 
were with much larger (or much smaller) hazard than the entire data set (sim. groups 1, 
4, & 7 with large predictive coefficients). The results were miserable for the data in sim. 
groups 3, 6, & 9, where the predictive coefficients were very small. This leads us to the 
conclusion, that regression trees are not sensitive enough method to be applied in 
responder identification. Nevertheless, if we had to make a recommendation which 
residuals to use as a response factor in CART, we would prefer deviance residuals, as 
they have acceptable performance at least for the case when censoring is not too large 
and the responder coefficients are strong (sim. groups 1, 2, 4, & 5). For data with large 
percentage censoring it is preferable to use martingale residuals.  
 
9.2.3 Bump Hunting 
 
Similar to section 9.2.2, the responder identification method from section 8.1 with 
original and stabilized bump hunting was applied on each of the 200 data sets of the 
nine simulation groups defined in table 9.1 (100 with martingale and 100 with deviance 
residuals as response in bump hunting).  
Goal: 
1) to evaluate the prognostic power of the responder identification algorithm (chapter 
8) with bump hunting 
2) to compare the power of identification of the method when martingale and deviance 
residuals are used as response variable in bump hunting, as well as when the original 
and the stabilized bump hunting procedure is used. 
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We began the responder identification process with the algorithm of section 8.1 as 
described in section 9.2.2. This time bump hunting (original and stabilized) was used 
instead of regression trees. It turned out, that in the simulated data the p-value of the 
log-rank statistic never grew insignificant in the stabilized and original bump hunting. 
We developed the bump hunting models using minimal support of .05 as stopping 
criteria (as suggested by Friedman & Fisher, 1999). Since we knew the correct 
responder and non-responder groups, we considered just one box per bump and just the 
first three selected borders. The developed model was considered correct if the first 
three borders of the maximal box were any permutation of the following: 
X2 ≠ 0, X2 ≠ 1, X5 ≠ 0 
and the minimal box – any permutation of the following borders: 
X4 ≠ 0, X5 ≠ 0, X6 ≠ 0. 
Table 9.5 summarizes an example of border selection with bootstrapping (100 bootstrap 
samples + original data) when the correct model was chosen. Figure 9.5 gives the 
support vs. mean of residuals and support vs. p(LR) for the maximal and the minimal 
box construction process of this particular example. 
 
Table 9.5: Example of border selection when the correct border was chosen and 
stabilized bump hunting was used as predictive model (100 bootstrap 
samples + original data). 
 
 X1≠0 X1≠1 X2≠0 X2≠1 X2≠2 X3≠0 X3≠1 X4≠0 X4≠1 X5≠0 X5≠1 X6≠0 X6≠1 
max1 0 0 12 63 0 0 0 0 0 26 0 0 0
max2 0 0 101 0 0 0 0 0 0 0 0 0 0
max3 0 0 0 0 0 0 0 0 0 101 0 0 0
max4 0 0 0 0 0 0 0 0 32 0 0 0 69
max5 12 17 0 0 0 4 30 5 33 0 0 0 0
min1 0 0 0 0 0 0 0 43 0 10 0 48 0
min2 0 0 0 0 0 0 0 62 0 39 0 0 0
min3 0 0 0 0 23 0 0 0 0 78 0 0 0
min4 1 6 0 0 91 3 0 0 0 0 0 0 0
min5 7 12 46 3 0 31 2 0 0 0 0 0 0
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Notice, that the correct three borders in the maximal box were the only ones chosen as 
first borders (max 1). Once border X2 ≠ 1 is chosen, the other two correct borders were 
chosen in all bootstrap samples and the original data set (max 2 & max 3). For details 
on stabilized bump hunting, please refer to chapter 7. We know that the effect of the 
other two borders in the maximal box is by chance, since it was not programmed in the 
simulation. This also proves to be the case, as those borders change even in the 
stabilized procedure when a completely new data set is simulated (not shown in table 
9.5). A weaker, but similar effect can be seen for the minimal box. 
 
Figure 9.5: Plots of mean response (res.mean.min & res.mean.max)  vs. support 
(res.supp.min & res.supp.max)  and p-value of the log-rank statistic 
(res.lr.min & res.lr.max)  vs. support for the box built in table 9.5. 
 
Naturally, the correct bumps are usually not known. One does not even know how many 
boxes each bump has. Fortunately, "real life" data sets are not as clean and ordered as 
our simulated data, so that the bump growth process can actually be governed by the 
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log-rank statistic, as described in chapters 7 & 8. A statistician's educated guess is still 
needed sometimes for altering the algorithm, as shown in chapter 10.5, where the 
stabilized bump hunting procedure was applied on the EMIAT data set in a responder 
identification process. An additional step lead to an improvement of the p-value of the 
log-rank statistic, which had grown in the previous step (see table 10.6). 
Table 9.6 summarizes the results from all simulation runs. Each entry in the table 
represents the number of times the correct minimal or maximal bump was chosen from 
a total of 100 runs. 
 
Table 9.6: Number of times the correct minimal and maximal bump was chosen 
from 100 runs with original or stabilized bump hunting as predictive 
model and martingale or deviance residuals as response. 
 
MART DEVI 
MIN MAX MIN MAX 
sim. 
group # 
original stabilized original stabilized original stabilized original stabilized
1 71 97 95 99 42 72 100 100
2 65 88 98 100 33 52 100 100
3 47 84 94 99 26 46 100 100
4 72 99 98 99 39 78 100 100
5 67 92 97 99 35 59 99 100
6 52 79 97 100 22 36 100 100
7 75 97 96 99 43 78 100 100
8 67 89 94 99 31 48 100 100
9 56 83 94 98 26 35 99 100
 
 
The results seem to be independent of percent censoring: simulation groups (1, 4, 7), (2, 
5, 8), and (3, 6, 9) have similar outcomes across the different methods. Size of the cmin 
and cmax coefficients show effect: larger in absolute value coefficients result in better 
performance of the different methods – please refer to table 9.7, which summarizes the 
results by coefficient size, averaged over all censoring cases. Martingale residuals show 
to be better suited for positive responder identification (minimal bump) than deviance 
residuals. For negative responder identification (maximal bump) deviance residuals 
perform just as well or slightly better than martingale residuals. In all cases where 
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improvement was possible, the stabilized bump hunting algorithm showed much better 
results than the original algorithm. 
Table 9.7: Averages from table 9.6 over simulation groups with equal percent 
censoring. 
 
MART DEVI 
MIN MAX MIN MAX 
sim. 
group # 
original stabilized original stabilized original stabilized original stabilized
1, 4, 7 72.67 97.67 96.33 99 41.33 76 100 100
2, 5, 8 66.33 89.67 96.67 99.33 33 53 99.67 100
3, 6, 9 51.67 82 95 99 24.67 39 99.67 100
 
Conclusions:  
Deviance residuals perform excellent in negative responder identification and 
unsatisfactory in positive responder identification. Their use is not recommended when 
both responder groups are needed. The stabilized bump hunting procedure with 
martingale residuals as response variable delivers excellent results both in positive and 
negative responder identification, especially if the effect is strong. 
 
9.3 Comparison 
 
Table 9.8 gives a summary of the results of the responder identification algorithm when 
the best of regression trees and the best of bump hunting is employed (see tables 9.4 & 
9.6).  
Recall, comparison between a tree and a bump model can only be made in a very lose 
sense, since tree models describe the entire space and bump models – just extreme parts 
of it. In other words, the nature of bump models is much more adequate for responder 
identification. 
Indeed, in 16 out of the 18 cases, bump hunting was more powerful than regression tree 
(as predictive model in the responder identification algorithm). In the two other cases 
the results of both models were comparable; regression tree performed slightly better 
than bump hunting. We can then conclude, that the best version of the responder 
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identification method employing regression trees is not nearly as good as the one with 
stabilized bump hunting. It is, therefore, recommendable that the responder 
identification method, suggested in chapter 8, be used with martingale residuals as 
a response variable in the stabilized bump hunting (described in chapter 7).  
 
Table 9.8:  Number of correctly identified models from 100 runs in the nine 
simulation groups using the best of the responder identification 
algorithms employing regression trees and bump hunting. 
 
MIN MAX 
sim. group # TREE 
+ DEVI 
stable BUMP 
+ MART 
TREE 
+ DEVI
stable BUMP 
+ MART 
1 100 97 65 99 
2 94 88 71 100 
3 52 84 10 99 
4 94 99 81 99 
5 76 92 70 99 
6 33 79 6 100 
7 59 97 52 99 
8 53 89 32 99 
9 10 83 1 98 
 
 
9.4 Implementation 
 
This simulation study was performed with the help of the readily available statistical 
packages SPSS and S-PLUS and the programming languages S and C. The Cox model 
with interactions and the Kaplan-Meier curves were generated using the survival 
analysis tools in SPSS 10.0. The simulation of all data sets, as well as the bump hunting 
analysis were done with especially written for the purpose S programs, which run with 
S-PLUS 4.5. Construction of the bump models was done in S-PLUS for Unix, using the 
algorithms of Becker (1999) called .boxes, .express.boxes, and .border.ranking, which 
use C subroutines.  The part of the simulation study involving regression tree models 
was done in S-PLUS for Windows. S routines using the S-PLUS tools for regression 
tree construction were written for that purpose. The code of all self-implemented S 
routines are given in Appendix C. 
10.  APPLICATIONS: EMIAT 
 
 
 
                                                          
10.1 Data 
 
The European Myocardial Infarction Amiodarone Trial (EMIAT) is a randomized 
double blind placebo controlled trial, designed to compare the drug Amiodarone to 
placebo with respect to all cause mortality. It includes a total of 1486 survivors of acute 
myocardial infarction who have left ventricular ejection fraction (LVEF) of 40% or less, 
randomized into two groups of 743 patients each. There were 103 deaths in the 
Amiodarone arm and 102 deaths in the placebo arm of the study. A total of 1169 
patients had Holter recordings available with sinus rhythm and at least one ventricular 
premature beat (VPB), which are necessary for calculation of the new parameters Onset 
and Slope – the two components of heart rate turbulence (HRT)1. The Amiodarone 
group had 577 patients, 87 of which died during the two years of follow-up (85% 
censoring). 592 patients were in the placebo group, 82 of which died (86% censoring). 
Figure 2.1 shows the Kaplan-Meier survival function estimates in the two study arms. 
Visually, as well as statistically, no difference between the two curves can be found 
(p(LR) = .5815). Baseline patient characteristics can be found in table 10.1. Continuous 
factors were categorized as shown in the table, using cut points, chosen by the EMIAT 
investigators and the research group of Prof. G. Schmidt at the Technical University in 
Munich. 
 
10.2 Previous investigations 
 
Janse et al (1998) did subgroup analysis of the EMIAT data in order to find patients, 
who may benefit from treatment with Amiodarone, i.e. they were looking for positive 
responders. The strategy performed in this substudy of EMIAT was to choose four 
1 Updated information on parameter HRT can be found at www.h-r-t.com 
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important, readily available baseline characteristics and consider all groups resulting 
from their combinations. The factors chosen were: 
Left ventricular ejection fraction, dichotomized at 30% 
Arrhythmia signs on Holter recordings (Yes/No) 
Beta-blocker treatment (Yes/No) 
Heart rate (Low/High)* 
In both arms of the study: 
Amiodarone treatment (Yes/No (placebo)) 
* The lowest and the highest 25% of the heart rate measurements were used; cut 
points were determined separately for each subgroup, defined by a combination 
of the rest of the factors. A total of 80 subgroups were analyzed. 
All possible subgroups were considered. In each group, the event rates in the placebo 
and the Amiodarone arms were compared. The log-rank statistic was computed.  
The largest reduction of event rate on Amiodarone vs. placebo (i.e. positive responders) 
was found for the group: 
ARRHYTHM = Yes 
Beta-blocker = Yes 
Heart rate = High ( ≥ 75 beats/min) 
p(LR) = 0.15 (not significant at the 0.05 level)  
The largest increase of event rate on Amiodarone vs. placebo (negative responders) was 
found for the group: 
LVEF ≥ 30% 
Beta-blocker = No 
Heart rate = Low ( ≤ 66 beats/min) 
p(LR) = 0.0314 (significant at the 0.05 level)  
Notice, that only interactions of up to third order were considered. No adjustment for 
prognostic factors was done. For details, see Janse et al, 1998. 
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Table 10.1:  Baseline characteristics of EMIAT. 
Placebo (n = 592) Treatment (n = 577)  
Variable 
 
Code Name 
 
Dichotomization Mean (SD) Number (%) Mean (SD) Number (%)
Sex SEX 1 = male  506 (86%)  487 (84%) 
More than one 
infarct INFARCT 1 = Yes  157 (27%)  188 (33%) 
New York Heart 
Association 
Classification 
NYHA 
1 
2 
3 
  
251 (42%) 
44 (7%) 
  
264 (46%) 
46 (8%) 
Diabetes DIABETES 1 = Yes  95 (16%)  98 (17%) 
Thrombolyse THROMBOL 1 = Yes  355 (60%)  321 (56%) 
Digoxin DIGOXIN 1 = Yes  73 (12%)  86 (15%) 
β - blocker  BETABLO 1 = Yes  262 (44%)  255 (44%) 
Calcium-
antagonist CALCANT 1 = Yes  81 (14%)  71 (12%) 
ACE - inhibitors ACEINHI 1 = Yes  348 (59%)  354 (61%) 
Arrythmia on 
Holter ARRHYTHM 1 = Yes  208 (35%)  212 (38%) 
Left-ventricular 
ejection fraction LVEF 1 if LVEF ≤ 30 29.92 (7.52) 278 (47%) 30.20 (6.99) 275 (48%) 
Age AGE 1 if AGE > 65 60.62 (9.33) 240 (41%) 60.21 (9.67) 220 (38%) 
Mean heart rate 
frequency FREQ 1 if FREQ > 75 73.37 (11.76) 250 (42%) 73.10 (12.02) 251 (44%) 
Heart rate 
variability index HRVI 1 if HRVI ≤ 20 26.08 (10.38) 185 (31%) 26.34 (10.41) 175 (30%) 
Onset ONSET 1 if ONSET > 1 0.99 (0.023) 158 (27%) 0.99 (0.026) 148 (26%) 
Slope SLOPE 1 if SLOPE ≤ 2.5 6.60 (8.08) 172 (29%) 6.43 (8.39) 189 (33%) 
Heart Rate 
Turbulence HRT 
0 if ONSET = 0  
   & SLOPE = 0 
1 if ONSET = 1  
   or SLOPE = 1 
2 if ONSET = 1  
   & SLOPE = 1 
  
 
174 (29%) 
 
78 (13%) 
  
 
181 (31%) 
 
78 (14%) 
 
Malik et al (2000) performed subgroup analysis of the EMIAT data set with final aim to 
test the hypothesis that EMIAT patients with depressed heart rate variability (HRV) 
benefit from the Amiodarone treatment (i.e. are positive responders). They did this by 
developing a Cox-PH model on the entire data set, including Amiodarone treatment as a 
factor, which accounts for the following prognostic factors: 
Age, dichotomized at 60 years 
LVEF, dichotomized at 30% 
History of MI (Yes/No) 
Heart rate, dichotomized at 75 beats/min 
Arrhythmia on Holter (Yes/No) 
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Beta-blocker treatment (Yes/No) 
HRV index, dichotomized at 20 units 
The authors applied this model on various subgroups of the data and concluded, that in 
groups of patients with depressed HRV, the Amiodarone treatment factor increases its 
significance. Table 10.2 gives a very brief summary of their findings. For further 
details, please refer to the original publication. 
Table 10.2: Summary of the results of Malik et al (2000). 
 
Group p-value of Amiodarone treatment  after accounting for prognostic factors 
Total population .9068 
Depressed HRV .3221 
Depressed HRV & Low LVEF .3785 
Depressed HRV & No history of MI .0417* 
Depressed HRV & High heart rate .2404 
Depressed HRV & Arrhythmia .1458 
Depressed HRV & on Beta-blocker .4909 
  * significant at the 0.05 level        
 
 
10.3 Cox-PH with interaction 
 
The following results were obtained after applying the method described in chapter 4 on 
the EMIAT data set. Continuous factors were not dichotomized. 
Using forward selection on the entire data set, the model summarized in table 10.3 was 
found as "best." 
The search for interactions delivered just one possible predictive factor, heart rate 
(HR_V0), which was not significant at the .05 level but, nevertheless, increased the 
significance of factor treatment from .78 (in a model including prognostic factors only) 
to .08. The interaction model is summarized in table 10.4. 
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Table 10.3: Summary of the "best" Cox-PH model without interactions on the entire 
EMIAT data set. 
 
Variables β p(Wald) Exp(β) 95% CI for Exp(β) 
    Lower Upper 
LVEF -.032 .002 .968 .949 .988 
AGE .030 .003 1.031 1.010 1.051 
INFARCT .737 .000 2.090 1.534 2.849 
DIABETES -.454 .009 .635 .452 .893 
HR_V0 .016 .003 1.017 1.006 1.028 
HRT .001  
HRT(1) .439 .022 1.551 1.064 2.261 
HRT(2) .842 .000 2.320 1.506 3.575 
score statistic = 148.49 
p(score) < .001 
 
 
Table 10.4: Summary of the "best" Cox-PH model with interactions on the entire 
EMIAT data set. 
 
Variables β p(Wald) Exp(β) 95% CI for Exp(β) 
    Lower Upper 
LVEF -.032 .001 .967 .948 .987 
AGE .031 .002 1.031 1.011 1.052 
INFARCT .734 .000 2.084 1.528 2.841 
DIABETES -.464 .008 .629 .447 .884 
HR_V0 .025 .001 1.025 1.011 1.040 
HRT .001   
HRT(1) .434 .024 1.544 1.059 2.252 
HRT(2) .842 .000 2.321 1.506 3.578 
TREATMEN 1.420 .083 4.137 .830 20.626 
HR_V0*TREATMEN -.017 .087 .983 .964 1.002 
score statistic = 150.60 
p(score) < .001 
 
Analyzing the part of the linear predictor corresponding to the interaction term in the 
last model, i.e. the linear predictor for factors HR_V0, TREATMEN, and their 
interaction, it is easy to see that, in general, increase in HR_V0 results in increase of the 
hazard. A treatment with Amiodarone decreases this effect (please refer to figure 10.1). 
The lines cross at about HR_V0 = 83, so that patients with heart rate greater than 83 
should be positive responders and ones with heart rate less than 83 – negative 
responders. However, looking at the survival curves of the two groups in both treatment 
arms, we find the difference to be not significant at the .05 level (p(LR) = .3058 for 
HR_V0 ≤ 83 and p(LR) = .6045 for HR_V0 > 83). 
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Figure 10.1: Interaction of factors HR_V0 and treatment (TREAT = 0 denotes 
placebo, TREAT = 1 denotes Amiodarone). 
 
 
On the other hand, figure 2.2 in chapter 2.1 shows different effects of treatment with 
beta-blocker on mortality in the two arms of EMIAT. One should expect to see 
interaction between beta-blocker and Amiodarone treatment, but it does not appear in 
the predictive part of the Cox model. Considering the fact that the EMIAT data set has 
even higher percentage censoring than data from group 9 of the simulation study 
(chapter 9), and knowing how badly the Cox-PH model with treatment interaction 
performed on such data (see section 9.2.2), one should not expect great results on the 
EMIAT data. Cox-PH model with interactions is simply not a sufficiently good way of 
doing responder analysis, even though it is more systematic than the work of Janse et al 
and Malik et al. 
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10.4 Responder identification with CART 
 
10.4.1 The prognostic model 
 
As described in chapter 8, one needs to develop a "good" prognostic model in the first 
step of the responder identification algorithm. We developed a Cox-PH model on the 
placebo group of EMIAT, using stepwise selection methods and validated it internally. 
The "good" prognostic model we found contains the continuous factors left-ventricular 
ejection fraction (LVEF) and heart rate at initial visit (HR_V0), and the categorical 
factors previous infarction (INFARCT) and Heart Rate Turbulence (HRT). The model 
was internally validated using 100 bootstrap samples of the placebo group. When 
applied to the samples, the Cox model had mean score statistic of 78.68 (SE = 20.64), 
which is in the same order as the one from the original sample, even slightly better. A 
summary of the chosen prognostic model is given in table 10.5. 
Table 10.5:  Summary of the "best" Cox model on the placebo group of EMIAT. 
 
 
Variable   β p(Wald) Exp(B) 95.0% CI for Exp(B) 
Lower    Upper 
LVEF -0.035 .013 0.966 0.939     0.993 
HR_V0 0.024 .001 1.024 1.009     1.039 
INFARCT 0.603 .008 1.827 1.171     2.850 
HRT .000   
HRT(1) 0.599 .030 1.820 1.059     3.128 
HRT(2) 1.181 .000 3.257 1.818     5.835 
score statistic = 69.83             
                              p(score) = 1.14×10 -13 
 
Further, the hazard function and martingale residuals in the Amiodarone group were 
calculated using the baseline hazard function and the factor coefficients as estimated in 
the placebo group Cox model. 
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10.4.2 The predictive model with continuous factors 
 
The use of continuous vs. categorized factors in regression trees was discussed in 
section 8.4. The simulation study in chapter 9 considered the only continuous factor 
(X3) dichotomized at the mean. It is well known, that categorization of continuous 
factors limits the recursive partitioning process and decreases the goodness of fit of the 
resulting model, however, it also increases the predictive power of the model, which is 
often the more desirable quality of both. In the following two sections, we will build 
regression tree models with both types of factors, which we will then compare. 
Regression tree analysis was performed on the Amiodarone arm of EMIAT, where all 
available factors (see table 10.1) were used as predictors. Since EMIAT has very large 
percent censored cases, we used martingale residuals as response of the tree model, as 
recommended in chapter 9 on the basis of a simulation study. Continuous factors were 
not categorized here. Initially, a large tree was grown,  after which it was pruned down 
to a tree with ten end nodes, using pruning parameter α = 1.85 (see chapter 5 for details 
on pruning). Figure 10.2 gives the tree diagram of the final tree – our predictive model, 
containing factors SLOPE, FREQ, NYHA, AGE, and DIGOXIN. 
In order to find responders, we consider the end nodes one by one, ordering them by the 
size of their mean response (martingale residuals), as described in section 8.3. We split 
the placebo group into ten regions, defined as the end nodes of the regression tree, 
which was constructed on the Amiodarone group. Now we are able to describe each 
region in the Amiodarone arm and compare it to its corresponding region in the placebo 
arm. 
Consider first all "negative" nodes, i.e. nodes with negative mean of the residuals 
(figure 10.2). We will be looking for responders in them. Starting with the end node 
which has the largest negative mean of the residuals in the Amiodarone group (node 14, 
region R6), we plot the mean of the residuals and its 95% confidence interval (figure 
10.3). There are only eight patients in R6 (Amiodarone arm) and the log-rank statistic 
comparing patients in R6 in the Amiodarone and the placebo groups is not significant at 
the .05 level (p(LR) = .1187). Further, we can combine the two end nodes with the 
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largest negative mean of the residuals in the Amiodarone group (node 14, region R6 and 
node 19, region R10). The mean and 95% confidence interval of the combined regions 
in the treatment group is also plotted in figure 10.3. The process is repeated until no 
more negative end nodes are left (four steps). The results are summarized in figure 10.3. 
Since initially there was no difference in survival between the Amiodarone and placebo 
groups (the entire groups), in our search for responders we should stop at the 
combination of end nodes in figure 10.3, just before the log-rank statistic becomes 
insignificant or when its p-value stops decreasing, as discussed in section 8.3. In our 
case, this happens for the combination of regions R6, R10, and R4, p(LR) = .0036.  
Then patients having the characteristics of one of these regions wold be considered to be 
positive responders: 
R4: SLOPE < 1.5697 
FREQ ≥ 83.5 
AGE < 56 
R6: SLOPE < .66004
FREQ ≥ 83.5 
62.5 ≤ AGE < 70
R10: .66004 ≤ SLOPE < 1.5697
FREQ ≥ 83.5 
AGE ≥ 70.5 
DIGOXIN = 2 (No) 
 
In order to find negative responders, the process described above needs to be repeated 
for all "positive" end nodes, starting with region R8, which has the highest mean of the 
residuals in the Amiodarone arm. Figure 10.4 illustrates the six step process.  
We can conclude that regions R2, R5, R7, R8, and R9 define negative responders: 
 
R2: SLOPE < 1.5697 
FREQ < 83.5 
NYHA = 1 
R5: SLOPE < 1.5697
FREQ ≥ 83.5 
56 ≤ AGE < 62.5
R7: SLOPE < .66004 
FREQ ≥ 83.5 
AGE ≥ 70 
     
R8: SLOPE < 1.5697 
FREQ ≥ 83.5 
AGE ≥ 62.5 
DIGOXIN = 1 (Yes)
R9: SLOPE < .66004 
FREQ ≥ 83.5 
62.5 ≤ AGE < 70.5 
DIGOXIN = 2 (No) 
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Figure 10.2: Predictive regression tree model on the Amiodarone arm of EMIAT with 
continuous input factors and martingale residuals of the prognostic 
model in section 10.4.1 as response variable. 
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Figure 10.3: Growth of the positive responder group (continuous factors tree). 
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Figure 10.4: Growth of the negative responder group (continuous factors tree). 
 
89
The scatter plot of figure 10.5 shows the martingale residuals of the identified positive 
and negative responders in the Amiodarone and placebo arm of EMIAT. 
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Figure 10.5: Scatter plot of the residuals of all patients in the responder groups for the 
placebo and Amiodarone arms of EMIAT (continuous factors tree). 
 R6+R10+R4 = positive (+) responders 
  R8+R5+R2+R9+R7 = negative (−) responders 
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10.4.3  The predictive model with categorized factors 
 
The size of the EMIAT data set and most of all its high percent censoring do not allow 
for internal validation, so in order to develop a more stable predictive model with 
CART, one can use pre-defined cut points. Pros and cons of factor categorization are 
discussed in sections 7.1 and 8.4. The resulting regression tree model with predefined 
cut points (as in table 10.1) was pruned down to a tree with 13 end nodes, using pruning 
parameter α = .925 (see chapter 5 for details on pruning). Figure 10.6 gives the tree 
diagram of the pruned tree, which contains the following predictive factors: ONSET, 
AGE, DIABETES, HRVI, BETABLO, LVEF, SLOPE, NYHA, FREQ, SEX and 
ARRYTHM. The search for end nodes containing responders is repeated as in section 
10.4.2. 
We consider first all end nodes containing Amiodarone patients with negative mean 
martingale residuals. Starting with node 19, region R6, which has the largest negative 
mean of the residuals (figure 10.6), we plot the mean and its 95% confidence interval in 
figure 10.7. Next, we plot the combined mean of the two end nodes with largest mean of 
the residuals (calculated in the Amiodarone group), namely node 19, region R6 and 
node 10, region R3. We repeat this process a total of six times until no more negative 
end nodes are available. The survival curves of the patients in each of the given end 
node combinations are compared between the placebo and Amiodarone groups. The p-
values of the resulting log-rank statistics are also given in figure 10.7. Judging the end 
node combinations by their size, mean of the residuals, and p-value of the log-rank 
statistic, we would choose the group of regions R6, R3, R10, and R13 as the positive 
responder group. That means, that the regression tree predictive model of figure 10.5 
defines patients with the following characteristics to be positive responders of 
Amiodarone (one factor combination should hold): 
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Figure 10.6: Predictive regression tree model on the Amiodarone arm of EMIAT with 
categorized input factors and martingale residuals of the prognostic 
model in 10.4.1 as response variable. 
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R6: ONSET > 1 
DIABETES = No 
LVEF ≤ 30 
AGE > 65 
ONSET > 1 
DIABETES = Yes 
BETABLO = Yes 
  
R3:
 
R10: ONSET > 1 
DIABETES = No 
LVEF ≤ 30 
AGE ≤ 65 
SEX = Male 
R9: ONSET ≤ 1 
AGE > 65 
HRVI > 20 
SLOPE ≤ 2.5 
FREQ > 75 
ARRYTHM = Yes 
 
Negative nodes
M
ea
n 
M
AR
T
0.0
-.1
-.2
-.3
-.4
-.5
-.6
N (Amiodarone) /
event 23 / 3 30 / 3 64 / 6 72 / 6 116 / 10 399 / 34
p(LR)
Amiodarone
vs. placebo
.1394 .0449 .0058 .0015 .0053 .1239
          Mean 
          95% CI 
       R6          R6+R3   R6+R3+R10   R6+R3      R6+R3+R10    R6+R3+R10 
                                                         +R10+R13    +R13+R4     +R13+R4+R1
 
Figure 10.7: Growth of the positive responder group (categorized factors tree). 
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Figure 10.8: Growth of the negative responder group (categorized factors tree). 
The same procedure is repeated on the positive end nodes in the search for non-
responders. The results are shown in figure 10.8. The p-values of the log-rank statistic 
are of the same order for all shown end node combinations except the first one (R7). We 
choose the last region combination before the mean of the martingale residuals 
dramatically drops, namely, regions R7, R9, R12, and R11. The difference in survival 
between patients with the following characteristics in the Amiodarone and the placebo 
arm is significant at the .05 level (p(LR) = .0058): 
R7: ONSET > 1 
DIABETES = Yes 
BETABLO = No 
NYHA = 1 
R9: ONSET ≤ 1 
AGE > 65 
HRVI > 20 
SLOPE ≤ 2.5 
FREQ ≤ 75 
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R12: ONSET ≤ 1 
AGE > 65 
HRVI > 20 
SLOPE ≤ 2.5 
FREQ > 75 
ARRYTHM = No 
R11: ONSET > 1 
DIABETES = No 
LVEF ≤ 30 
AGE ≤ 65 
SEX = Female 
If a patient is in one of the groups above, he/she would be considered a negative 
responder to Amiodarone. The residuals of the positive and negative responders are 
plotted against follow-up time in figure 10.9. 
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Figure 10.9: Scatter plot of the residuals of all patients in the responder groups for the 
placebo and Amiodarone arms of EMIAT (categorized factors tree).  
 R6+R3+R10+R13 = positive (+) responders 
 R7+R9+R12+R11 = negative (−) responders 
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Notice, that the p-value of the log-rank statistic for the two largest positive end nodes is 
.0082. Adding one more node increases the p-value. Instead of stopping here, as 
suggested by the algorithm, we made one more step, which did not change the mean of 
the residuals in the group, but decreased the p-value dramatically. Sometimes it is worth 
to look a step ahead in the algorithm. 
As it should be expected, the regression tree with continuous covariates finds groups of 
Amiodarone patients with more difference in survival (when compared to similar 
patients under placebo) than the model with categorized factors. For fair comparison, 
consider equal size groups:  
26 negative responders identified with continuous factors bring p(LR) = .0036.  
26 negative responders identified with categorical factors bring  
.0449 < p(LR) < .1394 (for N = 30 & 23 respectively). 
50 positive responders identified with continuous factors bring p(LR) = .0012. 
50 positive responders identified with categorical factors bring  
.0047 < p(LR) < .0058 (for N = 115 & 44 respectively). 
 
Table 10.6: Identified responders errors in the algorithm with continuous and 
categorized factors regression trees. Table cells represent number of 
patients in the Amiodarone arm. 
 
CONTINUOUS TREE  
+ responders 
(-1) 
non-responders 
(0) 
− responders 
(1) Total 
+ responders (-1) 9 52 11 72 
non-responders (0) 16 420 25 461 
C
A
T
E
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-
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− responders (1) 1 29 14 44 
 Total 26 501 50 577 
 
Table 10.6 gives a comparison in responder identification of the tree models with 
continuous and categorized factors in the Amiodarone group. The patients in the main 
nine cells of table 10.6 are also represented with their martingale residuals in figure 
10.10. The crucial mismatches in classification with respect to the other model are 
depicted in the plots of (row 1, column 3) and (row 3, column 1). The first shows the 11 
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Amiodarone patients who were considered to be positive responders by the categorized 
factors model and negative responders – by the continuous factors model. The second 
shows the patient who was considered to be a positive responder by the continuous and 
negative responder – by the categorized factors model. In both cases the continuous 
factors model shows, as expected, better fit to the data. However, the cut points in the 
continuous factors tree are hierarchically dependent on all higher level nodes, which 
makes them impossible to reproduce when the model is built on a slightly altered or 
new data set. Therefore, it is preferable to use the categorized factors tree model for 
responder identification purposes. 
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Figure 10.10: Martingale residuals of the Amiodarone patients in groups as in table 
10.6.   1= −  responders, 0 = non-responders, -1 = + responders. 
 
97
10.5 Responder identification with bump hunting 
 
As shown in the simulation study of chapter 9, the stabilized through bootstrapping 
bump hunting procedure with response martingale residuals delivers the best results in 
the responder identification algorithm. The following is an application of that algorithm 
on the EMIAT data set. 
We use the prognostic model developed in section 10.4.1 on the placebo arm of EMIAT 
with its martingale residuals in the Amiodarone as a response variable in the following 
stabilized bump hunting application. Before the search for predictive bump model can 
begin, all continuous variables need categorization (as in table 10.1). 
When the stabilized bump hunting procedure is applied on the Amiodarone arm of 
EMIAT, it finds the following predictive "bump" model: 
MAX bump MIN bump 
Box 1 Box 2 Box 1 
 
ONSET ≤ 1 
AGE ≥ 65 
NYHA > 1 
All not in Box 1 ∋: 
DIABETES = 1 
BETABLOC = 0 
THROMBOL = 0 
CALCANT = 0 
All not in MAX bump ∋: 
CALCANT = 0 
DIABETES = 0 
ONSET > 1 
SEX = male 
The maximal bump contains two boxes – one with three borders and one with four 
borders. The minimal bump consists of a single box with four borders. The evolution of 
the support-mean relationship of the bump model is shown in figure 10.11. Notice, that 
the support-mean points are denoted with circles for the three borders of the first 
positive box. Then Box 2 is added to the model border by border (denoted with 
triangles). Finally, the negative bump is added to the model (the four rhombs). The final 
support-mean of the model is denoted by the triangle with smallest support and largest 
mean for the positive bump and the rhomb with smallest support and largest in absolute 
value mean for the negative bump. The growth of the bump model is shown in detail in 
table 10.7, including the p-value of the log-rank statistic when comparing patients with 
the current model characteristics in the placebo vs. Amiodarone groups. Notice, that in 
the minimal box, adding the third border actually slightly increases the p-value of the 
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log-rank statistic, however, adding the fourth border decreases it dramatically. As 
described in chapter 7, the bootstrapped bump hunting procedure stops when the p-
value does not improve from the previous step. In our case, it was worth to consider one 
additional step. In this case, we used the advantages of doing responder analysis with a 
semi-automated software implementation to overcome the nearsightedness of the p-
value stopping criteria. 
Both the maximal and minimal bumps define groups of patients who have significantly 
different survival estimates under Amiodarone and under placebo. Therefore, we can 
consider the positive bump as a definition of negative responders and the negative bump 
as a definition of positive responders of Amiodarone under the conditions of the 
EMIAT study. Figure 10.12 contains a scatter plot of martingale residuals vs. follow-up 
time of the identified positive and negative responder groups, which shows the possibly 
misclassified by the model patients, i.e. positive responders with positive residuals and 
negative responders with large negative residuals in the Amiodarone panel. Those 
would be patients, for whom the prognostic and the predictive factors in the chosen 
models do not explain the changes in survival pattern under Amiodarone. As discussed 
in chapter 2, they either appeared by chance, or some prognostic and/or predictive 
factors were not accounted for in the EMIAT study and, therefore, the effect of 
Amiodarone on those patients cannot be explained by the current models. The "flower" 
plot of figure 10.13 represents schematically the structure of the positive and negative 
responder groups. Figure 10.14 shows the Kaplan-Meier survival curve estimates for 
those groups in the Amiodarone and placebo arms of EMIAT.    
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Figure 10.11:  Growth of the stabilized bump hunting model in the Amiodarone arm of 
EMIAT. 
 
 
 
Table 10.7:  Cumulative bump means and p-values stepwise after the addition of each 
new border to the bump model (to complement figure 10.11). 
 
PLACEBO AMIODARONE   
p(LR) Mean n events Mean n events 
1. .1537 .0298 434 44 .0341 428 57 
2. .1622 .0543 164 26 .1170 158 36 
MAX 
Box 1 
3. .1007 .0561 86 15 .1708 93 27 
1. .1181 .0457 165 33 .1220 172 48 
2. .0607 .0474 146 30 .1538 156 48 
3. .0334 .0507 117 24 .1887 125 42 
MAX 
Box 2 
4. .0147 .0453 115 23 .2096 119 42 
1. .0614 -.0197 413 53 -.0529 400 35 
2. .0979 -.0067 372 45 -.0523 359 30 
3. .1037 -.0142 105 22 -.1398 98 12 
MIN 
Box 1 
4. .0236 -.0008 89 20 -.1788 77 7 
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Figure 10.12: Scatter plot of the residuals of all patients in the responder groups for the 
placebo and Amiodarone arms of EMIAT (stabilized bump hunting 
model). 
 
 
101
 
Figure 10.13:  Flower plot of the bump model. 
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Figure 10.14: Kaplan-Meier survival curve estimates for the two responder groups of 
the bump model, compared in the Amiodarone and placebo groups of 
EMIAT. 
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10.6 Comparison and discussion 
 
 
From chapter 9 we know, that the bump hunting model performs better than the tree 
model in responder identification context when all factors are categorized. Nevertheless, 
let us compare the outcomes of the categorical factor regression tree and the stabilized 
bump hunting models. We know from section 10.4.3, that the continuous factors tree 
model fits better the data. We also know from chapter 9, that stabilized bump hunting 
performs better than ordinary bump hunting in responder identification. And since 
stabilized bump hunting requires categorized factors, in order to compare the 
procedures, we need to consider the regression tree model with categorized  factors. For 
the rest of this chapter, when not otherwise specified, "tree model" would denote the 
categorized factor tree model from section 10.4.3 and "bump model" the stabilized 
bump hunting model from section 10.5. 
Both the tree and the bump models are hierarchical, so that the first few split nodes of 
the tree contain predictive factors, which are comparable in their performance to the 
factors in the first few borders of the first box in the bump model (the main difference, 
of course, is the type of interaction between the factors). The first level of the regression 
tree model contains the predictive factor ONSET. The second level contains AGE and 
DIABETES. ONSET is the most important predictor in the bump model as well, as it 
defines the first border of the first box. AGE comes in second, DIABETES is the first 
border of the second box. So we can find the same three factors among the most 
important predictive factors in both models. Yet the models identify  different groups of 
positive and negative responders. Indeed, further comparison shows that the tree model 
is much more complicated than the bump model. Notice also that the difference between 
end nodes of the tree containing positive responders and ones containing negative 
responders is often just one or two predictors. For example, patients with high onset, 
diabetes and on beta-blockers are classified as positive responders, whereas patients 
with high onset, diabetes, off beta-blockers, and with NYHA = 1 are classified as 
negative responders. The more complicated such models are, the more difficult it is to 
judge the correctness of such differences clinically.  
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Let us now compare the groups of patients identified as positive and negative 
responders in both models. We would be interested in the Amiodarone arm only. Table 
10.8 gives a cross-tabulation of the 577 patients as classified in responder and non-
responder groups with the help of the regression tree and bump models. A complete 
mismatch in the classification scheme occurred for a total of 13 patients. Their residuals 
are plotted in figure 10.15. Only three patients who were identified as positive 
responders using the bump model were considered to be negative responders when 
using the tree model. Ten negative responders in the bump model were considered to be 
positive responders by the tree model. 
 
Table 10.8: Identified responders in the algorithm with categorized factors 
regression tree and stabilized bump hunting predictive models. Table 
cells represent number of patients in the Amiodarone arm. Please refer to 
table 10.7 and figures 10.7 & 10.8 as well. 
 
TREE  
+ responders
(-1) 
non-responders 
(0) 
− responders 
(1) Total 
+ responders 
(-1) 27 47 3 77 
non-responders 
(0) 35 326 20 381 
B
U
M
P 
− responders 
(1) 10 88 21 119 
 Total 72 461 44 577 
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Figure 10.15: Martingale residuals of patients identified to be positive responders in 
one model and negative responders in the other and vice versa: T = Tree 
model, B = Bump model, -1 = + responders, 1 = − responders.  
 
 
It is more interesting to look at patients who were identified as positive or negative 
responders by one model only. In table 10.8, the number of patients who were identified 
as positive responders in one model only are printed in bold; ones who were identified 
as negative responders in one model only are in shaded boxes. Figure 10.16 shows four 
panels, corresponding to the four possible mismatches by the models: 
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Figure 10.16:  Martingale residuals of patients identified to be positive or negative 
responders by one model only: 
Panel 1  (T-1B01) contains the 45 patients who were considered to 
be responders in the tree model only. 
Panel 2  (T01B-1) contains 50 patients classified as responders by 
the bump model only. 
Panel 3  (T-10B1) contains 98 patients who were non-responders 
in the bump model only. 
Panel 4  (T1B-10) contains 23 patients who were non-responders 
in the tree model only. 
T = Tree model, B = Bump model, -1 = + responders, 1 = − responders, 
0 = non-responders.  
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Panels 1 & 4 show differences of the bump model with respect to the tree model (notice: 
fewer patients). Panels 2 & 3 show differences of the tree model with respect to the 
bump model (notice: more patients). Chapter 9 showed that the bump model should 
deliver better results than the tree model. To see this, one should not only be looking at 
the misclassification rate with respect to the other model, but also at the size of the 
misclassified residuals (figure 10.16) as well as the survival curves for the four pannels 
of figure 10.16.  
Consider the misclassified residuals and the type of error which is likely to have 
occurred, assuming that patients with large positive residuals are likely to be negative 
responders and patients with large negative residuals are likely to be positive 
responders. Panels 3 & 4 give insight to model performance with respect to the most 
dramatic error which can be made: failing to identify negative responders, which results 
in treating patients with medication, which is harmful for them (kills them). Panel 3 
shows the martingale residuals of patients who were not identified as negative 
responders by the tree model. Concentrating on the positive residuals (patients who 
died), we notice that they all have values above .5. When comparing the entire group of 
patient in this panel to the corresponding group in the placebo arm, the survival curves 
show difference at the .1 level (p(LR) = .0986). Those patients with large positive 
residuals are likely to belong to the negative responder group, as recognized in the 
bump model. Panel 4 shows the same for the bump model. Notice, much fewer patients 
were misclassified with respect to the other model than in panel 3 and only seven had 
positive residuals, i.e. are likely negative responders and were not chosen as such by the 
bump model. Panels 1 & 2 give information on the less crucial error, which can be 
made: failing to identify positive responders, i.e. denying medication to patients, which 
would actually help them (improves survival). Very few possible errors were made here, 
which appear on the plots as large negative residuals (e.g. < -.5). The performance of 
the two models in this case is comparable. 
In general, the bump model had less (presumably) misclassified patients than the tree 
model, as it was to be expected after the simulation study in chapter 9. 
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A note on software and algorithmic implementation: 
The above analysis was done with the help of SPSS 10.0, S-PLUS 4.5 (for Windows 
and for Unix), functions from Becker's bump hunting software (1999), as well as some 
S functions, written to automate the bootstrapping part of the stabilized bump hunting 
algorithm. All self generated code is given in Appendix C.  
 
CONCLUSIONS 
 
 
 
Summary 
 
Clinical trials often judge the efficacy of a new treatment by comparing the outcome 
(survival patterns) of patients randomly assigned to undergo a new or a standard 
treatment. Usually, the entire groups are analyzed, although it is well known that certain 
subgroups of patients react differently to the new treatment than others. Some patients 
taking the new treatment might benefit from it (the positive responders) while others 
may be harmed by it (the negative responders). The topic of this thesis is extraction of 
such special subgroups of patients, based on finding the so called predictive factors, 
which describe survival differences solely due to the new treatment. 
The thesis gives an overview of the techniques used up to now for responder 
identification and proposes a new method for systematic search for responders. The 
responder identification method consists of the following three steps: 
1. Identification of "prognostic" factors (e.g. via Cox-PH model on the standard 
treatment arm). Notice, those factors are prognostic in the classical sense only if the 
study was performed with placebo, not standard treatment arm. 
2. Identification of patients in the new treatment arm, who's survival time is badly 
estimated by the prognostic model (e.g. via search for outliers in the deviance or 
martingale residuals) 
3. Identification of predictive factors, which describe common features of the patients 
with residual outliers, namely the positive and negative responders (e.g. via 
regression tree or bump hunting analysis, or via the suggested stabilized bump 
hunting procedure) 
The basic responder identification method was developed for analysis of clinical trial 
data, in which no difference in survival between the new and the classical treatment 
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groups is present. Slight changes to the method were discussed for application on data, 
which does show initial difference in survival between the two treatment groups. 
Several variations of the basic responder identification method were proposed and 
compared in a simulation study.  
In the search for predictive factors, one can apply martingale or deviance residuals to 
the prognostic model as a response variable in a regression tree, bump hunting, or the 
proposed stabilized bump hunting analysis. The simulation study showed that 
martingale residuals, combined with the stabilized bump hunting procedure are most 
suitable for responder identification. This variation of the suggested procedure has 
power of 99% (i.e. recognized the correct positive and negative responder groups 99% 
of the time).  
Some versions of the proposed responder identification method were also applied on a 
"real life" data set – the European Myocardial Infarction Amiodarone Trial (EMIAT) 
and the identified positive and negative responder groups were compared.  
All versions of the proposed responder identification algorithm, and especially the one 
employing stabilized bump hunting with martingale residuals as response, perform 
better than the method available up to now – Cox-PH model with treatment interactions. 
This was shown in the simulation study and in the analysis of the EMIAT data. The 
better performance of the new method is due to the fact that it recognizes interactions of 
higher order between covariates much easier than the Cox-PH model does. 
 
Outlook 
 
Fully automated implementation of the six different versions of the responder 
identification algorithm were done only for the simulation study, where the number and 
type of factors in the data were set. Responder analysis of the EMIAT data was done 
with semi-automated implementation, which allows more flexibility in the predictive 
model building process, but also slows down the analysis. If the best version of the 
responder identification algorithm, stabilized bump hunting with martingale residuals as 
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response, is to be used on a regular basis, a computer program is needed, which fully 
automates the procedure, allowing for different number and type of factors, different 
size of the data set, and flexibility in choosing the stopping criteria for model growth. 
The responder identification procedure was created for and tested on data sets with no 
survival difference between the new and the classical treatment groups. A future 
software product for responder analysis should allow for data with initial survival 
difference as well. The performance of the proposed responder identification method on 
such data may be tested in a simulation study. 
So far, it was also assumed that none of the prognostic and predictive factors vary with 
time. A new study can be done, which extends responder identification to data with time 
varying effects as well. 
APPENDIX A: PROOFS AND EXAMPLES 
 
 
 
1. Reduction of  to  )(ˆ tM i iM̂
 
In chapter 3.3 we defined Martingale residuals as follows (3.9): 
∫ Λ⋅−= ⋅
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For a right censored data time-constant model, such as Cox-PH: 
∫ ⋅⋅−= ⋅
i
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τβ λδ
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where: 
τi is the observation time for subject i and 
δi is the final status for subject i. 
Let us consider the integral part of the equation above and let  
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, which can be approximated by
where tc denotes censoring times and td – observed failure times. Now we can return to 
 where for the Cox-PH model we have the following: iM̂
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2. Deviance residuals examined by cases 
 
Deviance residuals, as defined in 3.16, can be combined with the definition of 
Martingale residuals (3.10) and transformed the following way: 
)ˆlnˆ(2)ˆsgn(
)]ˆln(ˆ[2)ˆsgn(
)]ˆln(ˆ[2)ˆsgn(
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impossible in this case 
 
and in general (see figure #): 
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and in general: 
1ˆ00
1ˆ0
<Λ<>
>Λ<
ii
ii
ifd
ifd
 
* solutions were found using Maple 6 and the function "solve". 
 
 
 
 
3. Pruning example to chapter 5 
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APPENDIX B:  SIMULATION STUDY PLOTS 
 
 
 
1.  Simulation study: scatter plots of the residuals 
 
 
 
 
Simulation group 1 (cmin = -2, cmax = 2, censored = 10%): 
Placebo
Treatment
 
Placebo
Treatment
-12.00
-8.00
-4.00
0.00
4.00
de
vi
AAAAAAAAA
A
AA
AAA
AA
AA
A
A
A
AAA
AAA
A
AA
AAAA
AA
AA
AAAA
A
A
A
A
A
A
A
A
A
A
A
AA
AA
A
A
A
AA
A
A
AA
A
AA
A
A
A
A
A
A
AA
AA
A
A
A
AAA
AA
A
A
A
A
A
0.00 1.00 2.00 3.00 4.00 5.00
time
-12.00
-8.00
-4.00
0.00
4.00
de
vi
AA
A
AA
A
A
A
A
A
A
A
A
A
AA
AA
A
AA
A
AA
A
A
A
A
A
A
A
A
AA
A
A
A
AA
A
A
A
A
A
A
AA
A
AA
A
A
A
A
A
AA
A
A
A
A
AAA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
AA
AA
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
 
 
 
 
 
 
 
0.00
AAAAAAAAAAAAAAAAAAAAAAAAAAAAA A A
-75.00
-50.00
-25.00
m
ar
t
AAAAA AA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.00 1.00 2.00 3.00 4.00 5.00
time
-75.00
-50.00
-25.00
0.00
m
ar
t
AAAAAAAAAAA
A
A
AA
A
A
AA
A
A
A
A
AA
A
A
A
A
AAAA
A
A
A
A
A
AAA
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
AA
A
A
 
 
 
 
 
 
   118 
Simulation group 2 (cmin = -1, cmax = 1, censored = 10%): 
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-20.00
-15.00
-10.00
-5.00
0.00
m
ar
t
AAAA
A
AAAA
A
AA
A
A
A
AAA
A
AA
A
AA
AAAAA
AA
AA
AAA
AA
A
A
A
A
AA
A
A
AAAA
AA
AA
A
A
AAA
A
A
A
A
A
A
AAA
A
A
A
AA
A
AA
AA
A
AAAA
A
AAAA
A
AA
AA
A
AA
A
A
A
A
A
AA
A
A
A
0.00 1.00 2.00
time
-20.00
-15.00
-10.00
-5.00
0.00
m
ar
t
AAAA
A
AAAAA
A
AA
A
AAAA
A
AAA
A
A
AA
A
AAA
A
AA
A
AA
A
A
A
A
AAA
A
A
A
A
A
A
A
AA
A
A
A
A
A
AA
A
A
A
AA
A
A
A
AA
A
A
A
A
A
A
A
AA
AA
A
AA
AAA
A
A
A
A
AA
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
 
Simulation group 3 (cmin = -0.5, cmax = 0.25, censored = 10%): 
 
 
 
 
 rt
 m
a
Placebo
Treatment
-8.00
-6.00
-4.00
-2.00
0.00
AAA
A
AAAA
A
A
AAA
AAAA
A
A
AA
A
A
A
AAAAA
A
A
A
AAA
AA
AA
A
A
AA
A
A
AA
A
A
A
A
AA
AA
A
A
A
AA
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
AA
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
AA
A
A
A
A
A
A
AAAA
A
A
AA
A
A
A
A
A
A
A
AA
A
A
AA
A
A
0.00 1.00 2.00
time
-8.00
-6.00
-4.00
-2.00
0.00
m
ar
t
AAA
A
AAAAAAA
A
A
AA
A
AA
AA
A
A
AA
AAAA
AAA
A
A
A
A
AA
A
A
A
A
A
A
A
AA
A
A
AA
A
AA
AA
A
A
A
A
AA
AA
A
A
A
AA
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
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A
A
A
A
A
A
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A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AAA
A
A
A
A
A
A
A
AA
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
Placebo
Treatment
-3.00
-1.00
1.00
3.00
de
vi
AAA
AA
AAA
A
A
A
A
A
A
A
A
AA
AA
A
A
A
A
AA
A
A
AA
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AAA
A
A
A
A
AA
A
AA
A
AA
A
AA
A
AA
A
A
A
A
A
A
AA
AA
AA
A
A
AA
A
A
A
A
AA
A
A
A
AA
AA
A
A
A
A
A
A
A
A
AA
A
AAA
A
A
A
A
A
A
A
A
A
A
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A
A
A
A
A
AA
AAA
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
AAA
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
0.00 1.00 2.00
time
-3.00
-1.00
1.00
3.00
de
vi
AA
AA
AA
A
AA
AA
A
AA
A
A
AA
A
A
AA
AAA
A
AA
A
AA
A
A
A
A
A
A
AAA
A
A
A
AA
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
AAA
A
A
AA
A
AA
A
A
A
A
A
A
A
A
A
A
A
AAA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
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A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
AA
A
AAAA
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
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Simulation group 4 (cmin = -2, cmax = 2, censored = 30%): 
 
Placebo
Treatment
-30.00
-20.00
-10.00
0.00
m
ar
t
AAA
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
AA
A
AA
AA
AA
A
A
AA
A
A
AAA
A
AA
A
A
AAA
A
A
A
A
A
AAAAAAAA
AA AA
0.00 1.00 2.00 3.00 4.00
time
-30.00
-20.00
-10.00
0.00
m
ar
t
A
A
A
A
AA
A
A
AA
AAA
A
A
AA
AA
A
A
A
AA
AAAA
A
A
A
A
A
A
AA
A
A
AA
AA
AA
AA
A
A
A
A
AA
A
AAAA
A
A
A
A
A
A
AAA
AA
A
A
AA
A
A
AA
A
A
A
A
AAA
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
AA
A
A
 
Placebo
Treatment
-8.00
-4.00
0.00
4.00
de
vi
AAAAAAA
A
AA
A
A
A
AA
A
A
AA
A
AA
A
A
AA
A
A
A
A
AA
A
A
A
AAA
A
A
A
AA
AA
A
A
A
AA
AA
A
A
A
AA
AAA
A
A
A
A
AA
AA
A
AA
A
AA
AAA
A
A
AAA
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
AAA
AAA
A AA
0.00 1.00 2.00 3.00 4.00
time
-8.00
-4.00
0.00
4.00
de
vi
A
A
A
A
A
AA
A
A
A
A
A
A
AA
AA
AA
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
AAA
A
AA
A
AA
A
A
A
A
A
AA
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
AA
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
AA
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
AA
A
A
A
AA
A
A
AA
A
A
AA
A
A
A
A
AAA
A
A
A
A
A
A
AA
A
A
A
A
A
A
AA AA
AA
A
A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Simulation group 5 (cmin = -1, cmax = 1, censored = 30%): 
 
Placebo
Treatment
-8.00
-6.00
-4.00
-2.00
0.00
m
ar
t
AAAAA
A
AA
A
A
A
AAA
A
A
AA
AA
A
AAA
A
AAA
A
A
A
A
AAA
A
AA
A
A
A
AAAA
AA
AA
A
A
A
A
A
A
AA
AA
AA
A
AA
A
A
A
A
AA
A
A
A
A
A
A
A
A
AAA
AA
A
AA
A
AA
A
AAA
A
A
AA
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
AA
AA
A
A
A
AA
A
A
A
AAAA
AA
A
A
A
A
A
A
A
A A
A
0.00 0.50 1.00 1.50 2.00
time
-8.00
-6.00
-4.00
-2.00
0.00
m
ar
t
AAA
A
AA
A
AAA
AA
AA
A
AA
A
AA
A
AAA
AA
AA
A
AA
AAA
AA
A
A
AAA
AA
A
A
AA
A
A
A
AA
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
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A
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A
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A
A
A
A
A
AA
A
A
A
A
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A
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A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
Placebo
Treatment
-4.00
-2.00
0.00
2.00
de
vi
AA
AA
AAAA
A
A
AA
AA
A
A
A
A
A
AA
A
A
A
A
A
A
AA
A
A
A
AA
A
A
AA
A
AAA
A
A
A
A
AAA
A
A
A
A
A
A
A
AA
AA
A
A
A
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A
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A
A
A
AA
A
A
A
A
A
A
A
AA
A
A
A
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A
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A
A
A
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A
A
A
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A
A
A
A
A
A
A
A A
A
0.00 0.50 1.00 1.50 2.00
time
-4.00
-2.00
0.00
2.00
de
vi
A
A
A
A
A
A
A
A
AA
A
AA
A
AAA
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A
A
A
A
A
AA
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
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A
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A
A
A
A
A
A
A
A
A
A
AA
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Simulation group 6 (cmin = -0.5, cmax = 0.25, censored = 30%): 
 
Placebo
Treatment
-3.00
-2.00
-1.00
0.00
1.00
m
ar
t
AAAA
A
AA
A
A
AA
A
A
AA
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
AAA
A
A
A
A
A
A
A
A
A
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A
A
A
A
A
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AA
A
A
0.00 1.00 2.00 3.00
time
-3.00
-2.00
-1.00
0.00
1.00
m
ar
t
AAAA
A
AAAA
AA
AA
A
A
A
A
AA
AA
A
A
A
A
AA
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
AA
A
A
A
A
A
A
AAA
A
A
A
A
A
A
A
A
A
A
AA
A
AA
A
A
A
A
A
A
A
A
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A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A A
Placebo
Treatment
-2.00
-1.00
0.00
1.00
2.00
3.00
de
vi
AA
AAA
AAAAAAA
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
AA
AA
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
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A
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A
A
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A
A
AA
AA
AA
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
AA
A
A
A
AA
A
A
A
A
A
AA
A
A
A
AA
A
AA
A
AA
A
AA
AA
A
A
0.00 1.00 2.00 3.00
time
-2.00
-1.00
0.00
1.00
2.00
3.00
de
vi
AAA
A
AAAA
A
A
A
AAAA
AAA
A
AA
A
A
A
AA
A
A
A
AAA
A
A
A
A
AA
A
A
A
A
A
A
AA
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
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A
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A
A
A
A
A
AA
A A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Simulation group 7 (cmin = -2, cmax = 2, censored = 70%): 
Placebo
Treatment
-2.00
0.00
2.00
4.00
de
vi
AA
AAA
AA
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
AA
A
A
A
AA
A
A
A
AA
AA
A
A
A
A
A
A
A
A
A
A
AA
AA
A
AA
AA
AA
A
AAA
A
A
AA
AAAA
AAAA
A
AA
AAAAAAAAAAAAA
0.00 1.00 2.00 3.00 4.00
time
-2.00
0.00
2.00
4.00
de
vi
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
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A
AA
A
A
A
A
A
A
AA
A
AA
A
AAA
A
A
A
AAA
A
A
A
A
A
A
A
A
A
A
A
AAAA
A
A
AA
 
Placebo
Treatment
-4.00
-3.00
-2.00
-1.00
0.00
1.00
m
ar
t
AA
A
A
A
A
AA
AA
A
A
AA
A
A
A
A
A
A
AA
AA
AA
A
A
A
A
A
AA
AA
A
AAA
A
AA
A
A
AAA
A
A
AAAA
AAA
AAA
AAAAAAAAAAAAA
0.00 1.00 2.00 3.00 4.00
time
-4.00
-3.00
-2.00
-1.00
0.00
1.00
m
ar
t
A
A
A
A
AA
A
AA
AA
AA
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
AAA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
AA
A
AA
AA
AA
A
A
AAA
A
A
A
A
A
A
A
A
A
AA
AA
A
A
A
AA
A
AA
A
AAA
A
A
A
AA
A
A
A
A
AA
A
AA
A
A
A
A
A
A
AAA
A
A
AA
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Simulation group 8 (cmin = -1, cmax = 1, censored = 70%): 
 
Placebo
Treatment
-1.00
-0.50
0.00
0.50
1.00
m
ar
t
A
A
AA
A
AA
A
A
A
A
A
A
AA
A
A
A
AA
AAA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
AA
A
A
A
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m
ar
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de
vi
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Simulation group 9(cmin = -0.5, cmax = 0.25, censored = 70%): 
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APPENDIX C:  ALGORITHMIC IMPLEMENTATION IN S 
 
 
 
1. Functions needed for simulations with bump hunting 
(on UNIX) 
".boot.sim" <- function(nboot=10, coeffmin=1, coeffmax=-2, cens.max=11, beta =.1) 
{ 
  rownames <- c("x10", "x11", "x20", "x21", "x22", "x30", "x31", "x40", "x41", "x50", "x51", 
"x60", "x61") 
  output <- rep(0,4) 
  simdata <- .data.sim(coeffmin=coeffmin, coeffmax=coeffmax, cens.max=11) 
  martdata <- .model.fit(simdata) 
  prepdata.max <- .box.prep(martdata) 
  prepdata.min <- prepdata.max 
  minbox <- .boxes(train.data = prepdata.min, type = rep(1, 6), nboxes = 1, maxi = F, beta = 
beta, pasting = F, peel.crit = 2, output = F) 
  min.rank <- .border.ranking(minbox, crit.valid = F) 
  maxbox <- .boxes(train.data = prepdata.max, type = rep(1, 6), nboxes = 1, maxi = T, beta = 
beta, pasting = F, peel.crit = 2, output = F) 
  max.rank <- .border.ranking(maxbox, crit.valid = F) 
   
  # min original bump hunting 
  onm <- dimnames(min.rank[[4]])[[1]] 
  orm <- min.rank[[4]][,3] 
  n <- length(onm) 
  if(onm[n]=="x4" && onm[n-1]=="x5" && onm[n-2]=="x6" && orm[n]=="= 0" && orm[n-1]=="= 
0" && orm[n-2]=="= 0") output[1] <- 1 
  if(onm[n]=="x4" && onm[n-1]=="x6" && onm[n-2]=="x5" && orm[n]=="= 0" && orm[n-1]=="= 
0" && orm[n-2]=="= 0") output[1] <- 1 
  if(onm[n]=="x5" && onm[n-1]=="x6" && onm[n-2]=="x4" && orm[n]=="= 0" && orm[n-1]=="= 
0" && orm[n-2]=="= 0") output[1] <- 1 
  if(onm[n]=="x5" && onm[n-1]=="x4" && onm[n-2]=="x6" && orm[n]=="= 0" && orm[n-1]=="= 
0" && orm[n-2]=="= 0") output[1] <- 1 
  if(onm[n]=="x6" && onm[n-1]=="x4" && onm[n-2]=="x5" && orm[n]=="= 0" && orm[n-1]=="= 
0" && orm[n-2]=="=0") output[1] <- 1 
  if(onm[n]=="x6" && onm[n-1]=="x5" && onm[n-2]=="x4" && orm[n]=="= 0" && orm[n-1]=="= 
0" && orm[n-2]=="= 0") output[1] <- 1 
 
  # max original BH 
  onx <- dimnames(max.rank[[4]])[[1]] 
  orx <- max.rank[[4]][,3] 
  n <- length(onx) 
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  if(onx[n]=="x5" && onx[n-1]=="x2" && onx[n-2]=="x2" && orx[n]=="= 0" && orx[n-1]=="= 0" 
&& orx[n-2]=="= 1") output[2] <- 1 
  if(onx[n]=="x5" && onx[n-1]=="x2" && onx[n-2]=="x2" && orx[n]=="= 0" && orx[n-1]=="= 1" 
&& orx[n-2]=="= 0") output[2] <- 1 
  if(onx[n]=="x2" && onx[n-1]=="x2" && onx[n-2]=="x5" && orx[n]=="= 0" && orx[n-1]=="= 1" 
&& orx[n-2]=="= 0") output[2] <- 1 
  if(onx[n]=="x2" && onx[n-1]=="x5" && onx[n-2]=="x2" && orx[n]=="= 0" && orx[n-1]=="= 0" 
&& orx[n-2]=="= 1") output[2] <- 1 
  if(onx[n]=="x2" && onx[n-1]=="x5" && onx[n-2]=="x2" && orx[n]=="= 1" && orx[n-1]=="= 0" 
&& orx[n-2]=="= 0") output[2] <- 1 
  if(onx[n]=="x2" && onx[n-1]=="x2" && onx[n-2]=="x5" && orx[n]=="= 1" && orx[n-1]=="= 0" 
&& orx[n-2]=="= 0") output[2] <- 1 
 
  # initiate resulting vectors 
  orignam.max <- rep("0", 14) 
  origrestr.max <- rep("0", 14) 
  orignam.min <- rep("0", 14) 
  origrestr.min <- rep("0", 14) 
  boxmax <- rep("0", 14) 
  boxmin <- rep("0", 14) 
  res.supp.max <- c(1,rep(0, 13))  
  res.supp.min <- c(1,rep(0, 13)) 
  res.mean.max <- rep(0, 14) 
  res.mean.max[1] <- mean(prepdata.max$mart) 
  res.mean.min <- rep(0, 14) 
  res.mean.min[1] <- res.mean.max[1] 
  res.lr.max <- rep(0, 14) 
  lrmax <-.logrank(S=Surv(martdata$time, martdata$death), group=martdata$treat) 
  res.lr.max[1] <- lrmax$pval 
  res.lr.min <- rep(0, 14) 
  res.lr.min[1] <- res.lr.max[1] 
  treat.num <- dim(prepdata.max)[1] 
   
  # constructing boxmax 
  cat("maxbox", "\n") 
  nbord <- 1 
  spri <-F 
  while(spri == F) 
    { 
      outmat.max <- matrix(0, 13, nboot+1, dimnames=list(rownames, NULL)) 
      oresult <- .evaluate(prepdata.max, maxi=T, beta=.05) 
      op <- dim(oresult[[4]])[1] 
      orignam.max[nbord] <- dimnames(oresult[[4]])[[1]][op] 
      origrestr.max[nbord] <- oresult[[4]][op,3] 
      j <- 1       # bootstrap sample number 
      while(j < nboot+1)            #bootstrap samples 
        { 
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          length <- dim(prepdata.max)[1] 
          n <- c(1:length) 
          samp <- sample(n, replace=T) 
          sampdata <- prepdata.max[samp,] 
          names(sampdata) <- names(prepdata.max) 
          result <- .evaluate(sampdata, maxi=T, beta=.05) 
          p <- dim(result[[4]])[1] 
          varnam <- dimnames(result[[4]])[[1]][p] 
          restrict <- result[[4]][p,3] 
          outmat.max <- .fals.funk(j=j, varnam=varnam, restrict=restrict, outmat=outmat.max) 
          j <- j+1 
        } 
      for(i in 1:13) 
        outmat.max[i,nboot+1] <- sum(outmat.max[i,]) 
      cat(outmat.max[,nboot+1], "\n") 
      maximal <- max(outmat.max[,nboot+1]) 
 
      # if two borders are maximal, take the one with the bigger support 
      support <- rep(0,13) 
      for(i in 1:13) 
        if(outmat.max[i,nboot+1]==maximal) 
          { 
            maxrow <- rownames[i] 
            tempo.max <- .restrict(prepdata=prepdata.max, maxrow=maxrow) 
            support[i] <- dim(tempo.max)[1] 
          } 
      maxi.supp <- max(support) 
      for(i in 1:13) 
        if(support[i] == maxi.supp) index <- i 
      maxrow <- rownames[index] 
      prepdata.max <- .restrict(prepdata=prepdata.max, maxrow=maxrow) 
      boxmax[nbord+1] <- maxrow 
       
      # update loop parameter 
      nbord <- nbord+1 
      supp.max <- dim(prepdata.max)[1] 
      res.supp.max[nbord] <- supp.max/treat.num 
      res.mean.max[nbord] <- mean(prepdata.max$mart) 
      boxdata.max <- .box.restrict(box=boxmax, martdata) 
      lrmax <- .logrank(S=Surv(boxdata.max$time, boxdata.max$death), 
group=boxdata.max$treat) 
      res.lr.max[nbord] <- lrmax$pval 
 
      # stopping criteria 
      if(res.supp.max[nbord] < beta) 
        spri <- T 
    } 
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  # constructing minbox 
  cat("minbox", "\n") 
  nbord <- 1 
  spri <- F 
  while(spri == F) 
    { 
      outmat.min <- matrix(0, 13, nboot+1, dimnames=list(rownames, NULL)) 
      oresult <- .evaluate(prepdata.min, maxi=F, beta=.05) 
      op <- dim(oresult[[4]])[1] 
      orignam.min[nbord] <- dimnames(oresult[[4]])[[1]][op] 
      origrestr.min[nbord] <- oresult[[4]][op,3] 
      j<- 1          # bootstrap sample number 
      while(j < nboot+1)         #bootstrap samples 
        { 
          length <- dim(prepdata.min)[1] 
          n <- c(1:length) 
          samp <- sample(n, replace=T) 
          sampdata <- prepdata.min[samp,] 
          names(sampdata) <- names(prepdata.min) 
          result <- .evaluate(sampdata, maxi=F, beta=.05) 
          p <- dim(result[[4]])[1] 
          varnam <- dimnames(result[[4]])[[1]][p] 
          restrict <- result[[4]][p,3] 
          outmat.min <- .fals.funk(j=j, varnam=varnam, restrict=restrict, outmat=outmat.min) 
          j <- j+1   
        } 
          
      for(i in 1:13) 
        outmat.min[i,nboot+1] <- sum(outmat.min[i,]) 
      cat(outmat.min[,nboot+1], "\n") 
      maximal <- max(outmat.min[,nboot+1]) 
 
      # if two borders are maximal, take the one with the bigger support 
      support <- rep(0,13)           
      for(i in 1:13) 
        if(outmat.min[i,nboot+1]==maximal) 
          { 
            maxrow <- rownames[i] 
            tempo.min <- .restrict(prepdata=prepdata.min, maxrow=maxrow) 
            support[i] <- dim(tempo.min)[1] 
          } 
      maxi.supp <- max(support) 
      for(i in 1:13) 
        if(support[i] == maxi.supp) index <- i 
      maxrow <- rownames[index] 
      prepdata.min <- .restrict(prepdata=prepdata.min, maxrow=maxrow) 
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      boxmin[nbord+1] <- maxrow 
       
      # update loop parameter 
      nbord <- nbord+1 
      supp.min <- dim(prepdata.min)[1] 
      res.supp.min[nbord] <- supp.min/treat.num 
      res.mean.min[nbord] <- mean(prepdata.min$mart) 
      boxdata.min <- .box.restrict(box=boxmin, martdata) 
      lrmin <- .logrank(S=Surv(boxdata.min$time, boxdata.min$death), 
group=boxdata.min$treat) 
      res.lr.min[nbord] <- lrmin$pval 
 
      # stopping criteria 
      if(res.supp.min[nbord] < beta) 
        spri <- T           
    } 
 
  # cutting all zeros 
  spri <- F 
  i.max <- 2 
  while(spri == F) 
    { 
      if(boxmax[i.max] == "0") 
        spri <- T 
      else 
        i.max <- i.max + 1 
    } 
  spri <- F 
  i.min <- 2 
  while(spri == F) 
    { 
      if(boxmin[i.min] == "0") 
        spri <- T 
      else 
        i.min <- i.min + 1 
    } 
  boxmax <- boxmax[1:i.max-1] 
  boxmin <- boxmin[1:i.min-1] 
  res.supp.max <- res.supp.max[1:i.max-1]  
  res.supp.min <- res.supp.min[1:i.min-1] 
  res.mean.max <- res.mean.max[1:i.max-1] 
  res.mean.min <- res.mean.min[1:i.min-1] 
  res.lr.max <- res.lr.max[1:i.max-1] 
  res.lr.min <- res.lr.min[1:i.min-1] 
  if(boxmin[2]=="x40" && boxmin[3]=="x50" && boxmin[4]=="x60") 
    output[3] <- 1 
  if(boxmin[2]=="x40" && boxmin[3]=="x60" && boxmin[4]=="x50") 
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    output[3] <- 1 
  if(boxmin[2]=="x50" && boxmin[3]=="x60" && boxmin[4]=="x40") 
    output[3] <- 1 
  if(boxmin[2]=="x50" && boxmin[3]=="x40" && boxmin[4]=="x60") 
    output[3] <- 1 
  if(boxmin[2]=="x60" && boxmin[3]=="x40" && boxmin[4]=="x50") 
    output[3] <- 1 
  if(boxmin[2]=="x60" && boxmin[3]=="x50" && boxmin[4]=="x40") 
    output[3] <- 1 
  if(boxmax[2]=="x50" && boxmax[3]=="x20" && boxmax[4]=="x21") 
    output[4] <- 1 
  if(boxmax[2]=="x50" && boxmax[3]=="x21" && boxmax[4]=="x20") 
    output[4] <- 1 
  if(boxmax[2]=="x20" && boxmax[3]=="x21" && boxmax[4]=="x50") 
    output[4] <- 1 
  if(boxmax[2]=="x20" && boxmax[3]=="x50" && boxmax[4]=="x21") 
    output[4] <- 1 
  if(boxmax[2]=="x21" && boxmax[3]=="x50" && boxmax[4]=="x20") 
    output[4] <- 1 
  if(boxmax[2]=="x21" && boxmax[3]=="x20" && boxmax[4]=="x50") 
    output[4] <- 1 
   
  return(output, boxmin, boxmax, min.rank[[4]][,3], max.rank[[4]][,3]) 
} 
 
".box.prep"<-function(daten) 
{ 
  # prepares data from .model.fit for use in .boxes 
  treat <- daten[, 9] 
  simtreat <- daten[treat == 1,  ] 
  names(simtreat) <- names(daten) 
  mart <- simtreat[, c(14, 2:8)] 
  mart <- mart[, -4] 
  m <- mean(mart[,4]) 
  for(i in 1:dim(mart)[1]) 
    if(mart[i,4] <= m) mart[i,4] <- 0  
    else mart[i,4] <- 1 
  return(mart) 
} 
 
".box.prep.devi"<-function(daten) 
{ 
  # prepares data from .model.fit for use in .boxes 
  treat <- daten[, 9] 
  simtreat <- daten[treat == 1,  ] 
  names(simtreat) <- names(daten) 
  devi <- simtreat[, c(17, 2:8)] 
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  devi <- devi[, -4] 
  m <- mean(devi[, 4]) 
  for(i in 1:dim(devi)[1]) 
    if(devi[i, 4] <= m) devi[i, 4] <- 0 else devi[i, 4] <- 1 
  return(devi) 
} 
 
".data.sim"<-function(coeffmin = 1, coeffmax = -2, cens.max = 10) 
{ 
  n <- c(1:1000) 
  x1 <- rbinom(1000, 1, 0.5) 
  x2 <- rep(0, 1000) 
  tempo <- runif(1000, min = 0, max = 1) 
  for(i in 1:1000) 
    if(tempo[i] > 0.3333) x2[i] <- 1 
  for(i in 1:1000) 
    if(tempo[i] > 0.6667) x2[i] <- 2 
  ind2x2 <- rep(0, 1000) 
  for(i in 1:1000) 
    if(x2[i] == 2) ind2x2[i] <- 1 
  x3 <- rnorm(1000, mean = 5, sd = 2) 
  x4 <- rbinom(1000, 1, 0.5) 
  x5 <- rbinom(1000, 1, 0.5) 
  x6 <- rbinom(1000, 1, 0.5) 
  treat <- rbinom(1000, 1, 0.5) 
  rr <-  - log(3) * x1 + (2 * log(3) * x1 * x3)/10 - (log(3) * x3)/10 + coeffmax * ind2x2 * x5 * 
treat + coeffmin * x4 * x5 * x6 * treat 
  lambda <- exp(rr) 
  simdata <- cbind(n, x1, x2, ind2x2, x3, x4, x5, x6, treat, rr, lambda) 
  simdata <- as.data.frame(simdata) 
  zeit <- rep(0, 1000) 
  for(i in 1:1000) 
    zeit[i] <- rweibull(1, shape = 2, scale = sqrt(lambda[i])) 
  censor <- runif(1000, min = 0, max = cens.max) 
  death <- rep(0, 1000) 
  l <- (zeit <= censor) 
  for(i in 1:1000) 
    if(l[i] == 1) death[i] <- 1 
  simdata <- cbind(simdata, zeit, death) 
  names(simdata)[12] <- "time" 
  names(simdata)[13] <- "death" 
  return(simdata) 
} 
 
".evaluate"<-function(boxdata, maxi=T, beta =.05) 
{ 
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  # takes data from .box.prep and runs .boxes; uses .express.boxes to see which variables 
are in the box 
  type <- rep(1, 6) 
  x2 <- boxdata[, 3] 
  x5 <- boxdata[, 6] 
  box <- .boxes.vic(train.data = boxdata, type = type, nboxes = 1, maxi = maxi, beta=beta, 
pasting = F, peel.crit = 2, output=F) 
  if(box$flag == 0) 
    { 
      rank.bord <- NA 
      cat("no more boxes can be found", "\n") 
    } 
  else 
    { 
      descr <- .express.boxes(box$result) 
      rank.bord <- .border.ranking(box$result, crit.valid = F) 
    } 
  return(rank.bord) 
} 
 
".fals.funk" <- function(j, varnam, restrict, outmat) 
{ 
   
   if((varnam == "x1") && (restrict == "= 0")) outmat[1,j] <- 1 
      
   if((varnam == "x1") && (restrict == "= 1")) outmat[2,j] <- 1 
     
   if((varnam == "x2") && (restrict == "= 0")) outmat[3,j] <- 1 
     
   if((varnam == "x2") && (restrict == "= 1")) outmat[4,j] <- 1 
     
   if((varnam == "x2") && (restrict == "= 2")) outmat[5,j] <- 1 
  
   if((varnam == "x3") && (restrict == "= 0")) outmat[6,j] <- 1 
 
   if((varnam == "x3") && (restrict == "= 1")) outmat[7,j] <- 1 
 
   if((varnam == "x4") && (restrict == "= 0")) outmat[8,j] <- 1 
 
   if((varnam == "x4") && (restrict == "= 1")) outmat[9,j] <- 1 
 
   if((varnam == "x5") && (restrict == "= 0")) outmat[10,j] <- 1 
  
   if((varnam == "x5") && (restrict == "= 1")) outmat[11,j] <- 1 
 
   if((varnam == "x6") && (restrict == "= 0")) outmat[12,j] <- 1 
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   if((varnam == "x6") && (restrict == "= 1")) outmat[13,j] <- 1 
 
   return(outmat) 
 
} 
".logrank" <- function(S, group) 
{ 
  for(j in 1:length(group)) 
    if(group[j]==0) group[j]<-2  
  y <- S[,1] 
  event <- S[,2] 
  i <- order(-y) 
  y <- y[i] 
  event <- event[i] 
  group <- group[i] 
  x <- cbind(group==1, group==2, (group==1)*event, (group==2)*event) 
  s <- rowsum(x, y, F) 
  nr1 <- cumsum(s[,1]) 
  nr2 <- cumsum(s[,2]) 
  d1 <- s[,3] 
  d2 <- s[,4] 
  rd <- d1 + d2 
  rs <- nr1 + nr2 - rd 
  n <- nr1+nr2 
  oecum <- d1 - (rd*nr1)/n 
  vcum <- (rd*rs*nr1*nr2)/n/n/(n-1) 
  chival <- sum(oecum)^2/sum(vcum, na.rm=T) 
  pval <- 1-pchisq(chival,df=1) 
  return(chival, pval) 
} 
 
".model.fit" <- function(daten, coeffmin = 1, coeffmax = -2) 
{ 
  ind <- order(daten$treat, daten$time, rev(daten$death)) 
  ordtreat <- daten[ind,  ] 
  names(ordtreat) <- names(daten) 
  # omits all (first) rows in the data set for which delta(t1)=0 
  while(ordtreat$death[1]==0) ordtreat<-ordtreat[-1,] 
  treat <- ordtreat[, 9] 
  plac <- ordtreat[treat == 0,  ] 
  coxmod <- coxph(Surv(time, death) ~ x1 + x3 + x1 * x3, data = plac, method = "breslow", x 
= T) 
  coxdetail <- coxph.detail(coxmod) 
  beta <- as.vector(coxmod$coefficients) 
  mart <- coxmod$residuals 
  hazard <- plac$death - mart 
  plac.linpred <- beta[1] * plac$x1 + beta[2] * plac$x3 + beta[3] * plac$x1 * plac$x3 
 
 
 
   
 
131
  basehaz <- hazard/exp(plac.linpred) 
  len <- length(mart) 
  m <- dim(ordtreat)[1] 
  martfull <- c(mart, rep(-999, (m - len))) 
  hazfull <- c(hazard, rep(-999, (m - len))) 
  basefull <- c(basehaz, rep(-999, (m - len))) 
  ordtreat <- cbind(ordtreat, martfull, hazfull, basefull) 
  names(ordtreat)[14:16] <- c("mart", "hazard", "basehaz") 
  ind <- order(ordtreat$time, rev(ordtreat$death), ordtreat$treat) 
  orddata <- ordtreat[ind,  ] 
  names(orddata) <- names(ordtreat) 
  p <- 1 #pionts to the index of the first basehaz != -999   
  while(orddata$basehaz[p]==-999) p <- p+1 
 
  # replaces all treatment values with the last known (placebo) estimate 
  for(i in (p+1):m) 
    { 
      if(orddata$basehaz[i] == -999)  
orddata$basehaz[i] <- orddata$basehaz[i - 1] 
      if(orddata$hazard[i] == -999)  
orddata$hazard[i] <- orddata$basehaz[i] * exp(beta[1] * orddata$x1[i] + beta[2] * 
orddata$x3[i] + beta[3] * orddata$x1[i] * orddata$x3[i] + coeffmax * 
orddata$ind2x2[i] * orddata$x5[i] * orddata$treat[i] + coeffmin * orddata$x4[i] 
* orddata$x5[i] * orddata$x6[i] * orddata$treat[i])   
      if(orddata$mart[i] == -999)  
orddata$mart[i] <- orddata$death[i] - orddata$hazard[i] 
    } 
   
  # erraces the first treatment values which cannot be estimated with placebo values 
  orddata <- orddata[-(1:(p-1)),] 
  orddata$n <- c(1:dim(orddata)[1]) 
  return(orddata) 
} 
 
".model.fit.devi"<-function(daten, coeffmin = 1, coeffmax = -2) 
{ 
  ind <- order(daten$treat, daten$time, rev(daten$death)) 
  ordtreat <- daten[ind,  ] 
  names(ordtreat) <- names(daten)  
  # omits all (first) rows in the data set for which delta(t1)=0 
  while(ordtreat$death[1] == 0) ordtreat <- ordtreat[-1,  ] 
  treat <- ordtreat[, 9] 
  plac <- ordtreat[treat == 0,  ] 
  coxmod <- coxph(Surv(time, death) ~ x1 + x3 + x1 * x3, data = plac, method = "breslow", x 
= T) 
  coxdetail <- coxph.detail(coxmod) 
  beta <- as.vector(coxmod$coefficients) 
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  mart <- coxmod$residuals 
  hazard <- plac$death - mart 
  plac.linpred <- beta[1] * plac$x1 + beta[2] * plac$x3 + beta[3] * plac$x1 * plac$x3 
  basehaz <- hazard/exp(plac.linpred) 
  len <- length(mart) 
  m <- dim(ordtreat)[1] 
  martfull <- c(mart, rep(-999, (m - len))) 
  hazfull <- c(hazard, rep(-999, (m - len))) 
  basefull <- c(basehaz, rep(-999, (m - len))) 
  ordtreat <- cbind(ordtreat, martfull, hazfull, basefull) 
  names(ordtreat)[14:16] <- c("mart", "hazard", "basehaz") 
  ind <- order(ordtreat$time, rev(ordtreat$death), ordtreat$treat) 
  orddata <- ordtreat[ind,  ] 
  names(orddata) <- names(ordtreat) 
  p <- 1 #ponts to the index of the first basehaz != -999   
  while(orddata$basehaz[p] == -999) p <- p + 1  
  # replaces all treatment values with the last known (placebo) estimate 
  for(i in (p + 1):m) { 
    if(orddata$basehaz[i] == -999) 
       orddata$basehaz[i] <- orddata$basehaz[i - 1] 
    if(orddata$hazard[i] == -999) 
orddata$hazard[i] <- orddata$basehaz[i] * exp(beta[1] * orddata$x1[i] + beta[2] * 
orddata$x3[i] + beta[3] * orddata$x1[i] * orddata$x3[i] + coeffmax * 
orddata$ind2x2[i] * orddata$x5[i] * orddata$treat[i] + coeffmin * orddata$x4[i] 
* orddata$x5[i] * orddata$x6[i] * orddata$treat[i]) 
    if(orddata$mart[i] == -999) 
       orddata$mart[i] <- orddata$death[i] - orddata$hazard[i] 
  } 
  # erraces the first treatment values which cannot be estimated with placebo values 
  orddata <- orddata[ - (1:(p - 1)),  ] 
  orddata$n <- c(1:dim(orddata)[1]) # calculates deviance residuals 
  devi <- rep(0, dim(orddata)[1]) 
  for(i in 1:dim(orddata)[1]) 
    if(orddata$mart[i] >= 0)  
devi[i] <- sqrt(-2 * (orddata$mart[i] + orddata$death[i] * log(orddata$death[i] - 
orddata$mart[i]))) else devi[i] <-  - sqrt(-2 * (orddata$mart[i] + orddata$death[i] 
* log(orddata$death[i] - orddata$mart[i]))) 
  orddata <- cbind(orddata, devi) 
  names(orddata)[17] <- "devi" 
  return(orddata) 
} 
 
".restrict" <- function(prepdata, maxrow) 
{ 
  vari <- maxrow 
  if(vari == "x10") 
    { 
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      x <- prepdata[,2] 
      prepdata <- prepdata[x != 0,] 
    } 
  if(vari == "x11") 
    { 
      x <- prepdata[,2] 
      prepdata <- prepdata[x != 1,] 
    } 
  if(vari == "x20") 
    { 
      x <- prepdata[,3] 
      prepdata <- prepdata[x != 0,] 
    } 
  if(vari == "x21") 
    { 
      x <- prepdata[,3] 
      prepdata <- prepdata[x != 1,] 
    } 
  if(vari == "x22") 
    { 
      x <- prepdata[,3] 
      prepdata <- prepdata[x != 2,] 
    } 
  if(vari == "x30") 
    { 
      x <- prepdata[,4] 
      prepdata <- prepdata[x != 0,] 
    } 
  if(vari == "x31") 
    { 
      x <- prepdata[,4] 
      prepdata <- prepdata[x != 1,] 
    } 
  if(vari == "x40") 
    { 
      x <- prepdata[,5] 
      prepdata <- prepdata[x != 0,] 
    } 
  if(vari == "x41") 
    { 
      x <- prepdata[,5] 
      prepdata <- prepdata[x != 1,] 
    } 
  if(vari == "x50") 
    { 
      x <- prepdata[,6] 
      prepdata <- prepdata[x != 0,] 
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    } 
  if(vari == "x51") 
    { 
      x <- prepdata[,6] 
      prepdata <- prepdata[x != 1,] 
    } 
  if(vari == "x60") 
    { 
      x <- prepdata[,7] 
      prepdata <- prepdata[x != 0,] 
    } 
  if(vari == "x61") 
    { 
      x <- prepdata[,7] 
      prepdata <- prepdata[x != 1,] 
    } 
  return(prepdata) 
} 
 
2. Functions needed for simulations with regression trees 
(on Windows) 
".100.trees" <- function(nsim = 1, coeffmin = 2, coeffmax = -2, cens.max = 11) 
{ 
 min.percent.correct <- rep(0, nsim) 
 max.percent.correct <- rep(0, nsim) 
 for(k in 1:nsim) { 
  result <- .sim.tree(coeffmin = coeffmin, coeffmax = coeffmax, cens.max = 
cens.max) 
  min.percent.correct[k] <- result[[1]] 
  max.percent.correct[k] <- result[[2]] 
 } 
 return(min.percent.correct, max.percent.correct) 
} 
 
".100.trees.devi" <- function(nsim = 1, coeffmin = 2, coeffmax = -2, cens.max = 11) 
{ 
 min.percent.correct <- rep(0, nsim) 
 max.percent.correct <- rep(0, nsim) 
 for(k in 1:nsim) { 
  result <- .sim.tree.devi(coeffmin = coeffmin, coeffmax = coeffmax, cens.max = 
cens.max) 
  min.percent.correct[k] <- result[[1]] 
  max.percent.correct[k] <- result[[2]] 
 } 
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 mean.min <- mean(min.percent.correct) 
 mean.max <- mean(max.percent.correct) 
 return(min.percent.correct, max.percent.correct, mean.min, mean.max) 
} 
 
".plac.prep" <- function(daten) 
{ 
 treat <- daten[, 9] 
 tempdata <- daten[treat == 0,  ] 
 names(tempdata) <- names(daten) 
 placdata <- tempdata[, c(14, 2, 3, 5:9, 12, 13)] 
 m <- mean(placdata[, 4]) 
 for(i in 1:dim(placdata)[1]) 
  if(placdata[i, 4] <= m) placdata[i, 4] <- 0 else placdata[i, 4] <- 1 
 return(placdata) 
} 
 
".plac.prep.devi" <- function(daten) 
{ 
 treat <- daten[, 9] 
 tempdata <- daten[treat == 0,  ] 
 names(tempdata) <- names(daten) 
 placdata <- tempdata[, c(17, 2, 3, 5:9, 12, 13)] 
 m <- mean(placdata[, 4]) 
 for(i in 1:dim(placdata)[1]) 
  if(placdata[i, 4] <= m) placdata[i, 4] <- 0 else placdata[i, 4] <- 1 
 return(placdata) 
} 
 
".sim.tree" <- function(coeffmin = 2, coeffmax = -2, cens.max = 11) 
{ 
 simdata <- .data.sim(coeffmin, coeffmax, cens.max) 
 martdata <- .model.fit(simdata, coeffmin, coeffmax) 
 placdata <- .plac.prep(martdata) 
 treatdata <- .treat.prep(martdata) 
 boxtree <- tree(mart ~ x1 + x2 + x3 + x4 + x5 + x6, data = treatdata) 
 treattree <- prune.tree(boxtree, best = 5) 
 endnodes <- treattree$frame 
 ind <- order(endnodes$var, endnodes$yval) 
 ordnodes <- endnodes[ind,  ] 
 var <- ordnodes[, 1] 
 ordnodes <- ordnodes[var == "<leaf>",  ] 
 ordnodes <- ordnodes[, -3] 
 ordnodes <- ordnodes[, -4] 
 ordnodes <- ordnodes[, -4] 
 ordnodes <- ordnodes[, -1] 
 pos.ind <- rep(0, dim(ordnodes)[1]) 
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 for(i in 1:dim(ordnodes)[1]) 
  if(ordnodes$yval[i] >= 0) pos.ind[i] <- 1 
 ordnodes <- cbind(ordnodes, pos.ind) 
 names(ordnodes)[3] <- "pos.ind" 
 ind.treat <- identify.tree(treattree, nodes = row.names(ordnodes)) 
 plactree <- predict.tree(treattree, newdata = placdata, type = "tree") 
 ind.plac <- identify.tree(plactree, nodes = row.names(ordnodes)) 
 n <- dim(ordnodes)[1] 
 lr <- rep(-1, n) 
 p <- 0 
 if(ordnodes[p + 1, 3] != 1) { 
  plactemp <- placdata[ind.plac[[1]],  ] 
  treattemp <- treatdata[ind.treat[[1]],  ] 
  mincurrent <- rbind(plactemp, treattemp) 
  lr[1] <- .logrank(S = Surv(mincurrent$time, mincurrent$death), group = 
mincurrent$treat) 
  minregion <- mincurrent 
  p <- 1 
  while(ordnodes[p + 1, 3] != 1 && p + 1 <= n) { 
   p <- p + 1 
   plactemp <- placdata[ind.plac[[p]],  ] 
   treattemp <- treatdata[ind.treat[[p]],  ] 
   mincurrent <- rbind(plactemp, treattemp) 
   minregion <- rbind(minregion, mincurrent) 
   lr[p] <- .logrank(S = Surv(minregion$time, minregion$death), group = 
minregion$treat) 
  } 
 } 
 if(ordnodes[n, 3] == 1) { 
  plactemp <- placdata[ind.plac[[n]],  ] 
  treattemp <- treatdata[ind.treat[[n]],  ] 
  maxcurrent <- rbind(plactemp, treattemp) 
  lr[n] <- .logrank(S = Surv(maxcurrent$time, maxcurrent$death), group = 
maxcurrent$treat) 
  maxregion <- maxcurrent 
  q <- 1 
  while(ordnodes[n - q, 3] == 1 && n - q > p) { 
   plactemp <- placdata[ind.plac[[n - q]],  ] 
   treattemp <- treatdata[ind.treat[[n - q]],  ] 
   maxcurrent <- rbind(plactemp, treattemp) 
   maxregion <- rbind(maxregion, maxcurrent) 
   lr[n - q] <- .logrank(S = Surv(maxregion$time, maxregion$death), group = 
maxregion$treat) 
   q <- q + 1 
  } 
 } 
 ind <- 1 
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 while(ind + 1 <= p && lr[ind] > lr[ind + 1]) ind <- ind + 1 
 indm <- n 
 while(indm - 1 > p && lr[indm] > lr[indm - 1]) indm <- indm - 1 
 tree <- rep(0, dim(treatdata)[1]) 
 treatdata <- cbind(treatdata, tree, tree) 
 names(treatdata)[11] <- "tree" 
 names(treatdata)[12] <- "actual" 
 treatdata[ind.treat[[ind]], 11] <- -1 
 treatdata[ind.treat[[indm]], 11] <- 1 
 for(i in 1:dim(treatdata)[1]) { 
  if(treatdata[i, 3] == 2 && treatdata[i, 6] == 1) 
   treatdata[i, 12] <- 1 
  if(treatdata[i, 5] == 1 && treatdata[i, 6] == 1 && treatdata[i,7] == 1 && treatdata[i, 
12] == 0) 
   treatdata[i, 12] <- -1 
 } 
 tabelle <- table(treatdata$tree, treatdata$actual) 
 sums <- colSums(tabelle) 
 min.percent.correct <- (100 * tabelle[1, 1])/sums[1] 
 max.percent.correct <- (100 * tabelle[3, 3])/sums[3] 
 return(min.percent.correct, max.percent.correct) 
} 
 
".sim.tree.devi" <- function(coeffmin = 2, coeffmax = -2, cens.max = 11) 
{ 
 simdata <- .data.sim(coeffmin, coeffmax, cens.max) 
 martdata <- .model.fit.devi(simdata, coeffmin, coeffmax) 
 placdata <- .plac.prep.devi(martdata) 
 treatdata <- .treat.prep.devi(martdata) 
 boxtree <- tree(devi ~ x1 + x2 + x3 + x4 + x5 + x6, data = treatdata) 
 treattree <- prune.tree(boxtree, best = 5) 
 endnodes <- treattree$frame 
 ind <- order(endnodes$var, endnodes$yval) 
 ordnodes <- endnodes[ind,  ] 
 var <- ordnodes[, 1] 
 ordnodes <- ordnodes[var == "<leaf>",  ] 
 ordnodes <- ordnodes[, -3] 
 ordnodes <- ordnodes[, -4] 
 ordnodes <- ordnodes[, -4] 
 ordnodes <- ordnodes[, -1] 
 pos.ind <- rep(0, dim(ordnodes)[1]) 
 for(i in 1:dim(ordnodes)[1]) 
  if(ordnodes$yval[i] >= 0) pos.ind[i] <- 1 
 ordnodes <- cbind(ordnodes, pos.ind) 
 names(ordnodes)[3] <- "pos.ind" 
 ind.treat <- identify.tree(treattree, nodes = row.names(ordnodes)) 
 plactree <- predict.tree(treattree, newdata = placdata, type = "tree") 
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 ind.plac <- identify.tree(plactree, nodes = row.names(ordnodes)) 
 n <- dim(ordnodes)[1] 
 lr <- rep(-1, n) 
 p <- 0 
 if(ordnodes[p + 1, 3] != 1) { 
  plactemp <- placdata[ind.plac[[1]],  ] 
  treattemp <- treatdata[ind.treat[[1]],  ] 
  mincurrent <- rbind(plactemp, treattemp) 
  lr[1] <- .logrank(S = Surv(mincurrent$time, mincurrent$death), group = 
mincurrent$treat) 
  minregion <- mincurrent 
  p <- 1 
  while(ordnodes[p + 1, 3] != 1 && p + 1 <= n) { 
   p <- p + 1 
   plactemp <- placdata[ind.plac[[p]],  ] 
   treattemp <- treatdata[ind.treat[[p]],  ] 
   mincurrent <- rbind(plactemp, treattemp) 
   minregion <- rbind(minregion, mincurrent) 
   lr[p] <- .logrank(S = Surv(minregion$time, minregion$death), group = 
minregion$treat) 
  } 
 } 
 if(ordnodes[n, 3] == 1) { 
  plactemp <- placdata[ind.plac[[n]],  ] 
  treattemp <- treatdata[ind.treat[[n]],  ] 
  maxcurrent <- rbind(plactemp, treattemp) 
  lr[n] <- .logrank(S = Surv(maxcurrent$time, maxcurrent$death), group = 
maxcurrent$treat) 
  maxregion <- maxcurrent 
  q <- 1 
  while(ordnodes[n - q, 3] == 1 && n - q > p) { 
   plactemp <- placdata[ind.plac[[n - q]],  ] 
   treattemp <- treatdata[ind.treat[[n - q]],  ] 
   maxcurrent <- rbind(plactemp, treattemp) 
   maxregion <- rbind(maxregion, maxcurrent) 
   lr[n - q] <- .logrank(S = Surv(maxregion$time, maxregion$death), group = 
maxregion$treat) 
   q <- q + 1 
  } 
 } 
 ind <- 1 
 while(ind + 1 <= p && lr[ind] > lr[ind + 1]) ind <- ind + 1 
 indm <- n 
 while(indm - 1 > p && lr[indm] > lr[indm - 1]) indm <- indm - 1 
 tree <- rep(0, dim(treatdata)[1]) 
 treatdata <- cbind(treatdata, tree, tree) 
 names(treatdata)[11] <- "tree" 
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 names(treatdata)[12] <- "actual" 
 treatdata[ind.treat[[ind]], 11] <- -1 
 treatdata[ind.treat[[indm]], 11] <- 1 
 for(i in 1:dim(treatdata)[1]) { 
  if(treatdata[i, 3] == 2 && treatdata[i, 6] == 1) 
   treatdata[i, 12] <- 1 
  if(treatdata[i, 5] == 1 && treatdata[i, 6] == 1 && treatdata[i,7] == 1 && treatdata[i, 
12] == 0) 
   treatdata[i, 12] <- -1 
 } 
 tabelle <- table(treatdata$tree, treatdata$actual) 
 sums <- colSums(tabelle) 
 min.percent.correct <- (100 * tabelle[1, 1])/sums[1] 
 max.percent.correct <- (100 * tabelle[3, 3])/sums[3] 
 return(min.percent.correct, max.percent.correct) 
} 
 
".treat.prep" <- function(daten) 
{ 
 treat <- daten[, 9] 
 tempdata <- daten[treat == 1,  ] 
 names(tempdata) <- names(daten) 
 treatdata <- tempdata[, c(14, 2, 3, 5:9, 12, 13)] 
 m <- mean(treatdata[, 4]) 
 for(i in 1:dim(treatdata)[1]) 
  if(treatdata[i, 4] <= m) treatdata[i, 4] <- 0 else treatdata[i,4] <- 1 
 return(treatdata) 
} 
 
".treat.prep.devi" <- function(daten) 
{ 
 treat <- daten[, 9] 
 tempdata <- daten[treat == 1,  ] 
 names(tempdata) <- names(daten) 
 treatdata <- tempdata[, c(17, 2, 3, 5:9, 12, 13)] 
 m <- mean(treatdata[, 4]) 
 for(i in 1:dim(treatdata)[1]) 
  if(treatdata[i, 4] <= m) treatdata[i, 4] <- 0 else treatdata[i,4] <- 1 
 return(treatdata) 
} 
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3. Functions needed for analysis of EMIAT with stabilized 
bump hunting (on UNIX) 
 
".bumping.borders"<-function(method = 3, train.data, valid.data = 0, varno = 1, type =  
rep(0,dim(train.data)[2] - 1), maxi = T, pasting = T, missing = -9999, 
beta = 1/dim(train.data)[1], alpha = seq(from = 0.05, to = 0.1, by = 
0.005), thinning = T, peel.crit = 2, globalmean = T, legende = T, 
interactive = F, n.samples = 10, train = F, xl = 0, xu = 1, yl = 
min(train.data[train.data[, varno] != missing, varno]), yu = 
max(train.data[train.data[, varno] != missing, varno]), denom = 10, 
lineplot = T, both = T, language = 1) 
{ 
  traj <- .multiple.traj(method = method, train.data = train.data, valid.data = train.data,  
type = type, maxi = maxi, alpha = alpha, beta = beta, peel.crit = peel.crit, 
interactive = interactive, n.samples = n.samples) 
  m <- order(traj[[1]][, 6], traj[[1]][, 3])  
   
# gives a vector of coefficients ordered first by sample no., then by train.ymean as in traj 
  traj.sorted <- cbind(traj[[1]][, 1][m], traj[[1]][, 3][m], traj[[1]][, 6][m])  
# contains the columns: beta before pasting, ymean, and sample no. 
  traj.sorted <- data.frame(traj.sorted) 
  end <- dim(traj[[2]])[2] 
  cat("Original Data", "\n")  
  for(i in 1:(n.samples + 1)) { 
    index.samples <- traj[[2]][, 2:end]  
# extracts the indexes of all bootstrap samples 
    data <- train.data[index.samples[i,  ],  ]  
# takes only the current boot sample data 
    beta <- traj.sorted[2, 1]  
# takes the beta before pasting for the current sample 
    if(beta > 0 && beta < 1) { 
      box <- .boxes(train.data = data, alpha = alpha, beta = beta, nboxes = 1, output = F, maxi  
= maxi, type= type, peel.crit = peel.crit) 
      outbox <- .express.boxes(box) 
      cat(outbox[[2]], "\n", outbox[[5]], "\n") 
    } 
    cat("bootstrap sample = ", (i + 1), "\n") 
    Sample <- traj.sorted[, 3] 
    traj.sorted <- traj.sorted[Sample != i,  ] 
  } 
  return(0) 
} 
 
 
 
 
 
 
   
 
141
".bumping.borders.min"<-function(method = 3, train.data, valid.data = 0, varno = 1, type =  
rep(0, dim(train.data)[2] - 1), maxi = F, pasting = T, missing = 
-9999, beta = 1/dim(train.data)[1], alpha = seq(from = 0.05, 
to = 0.1, by = 0.005), thinning = T, peel.crit = 2, globalmean = 
T, legende = T, interactive = F, n.samples = 10, train = F, xl = 
0, xu = 1, yl = min(train.data[train.data[, varno] != missing, 
varno]), yu = max(train.data[train.data[, varno] != missing, 
varno]), denom = 10, lineplot = T, both = T, language = 1) 
{ 
  traj <- .multiple.traj(method = method, train.data = train.data, valid.data = train.data,  
type = type, maxi = maxi, alpha = alpha, beta = beta, peel.crit = peel.crit, ^
 interactive = interactive, n.samples = n.samples) 
  m <- order(traj[[1]][, 6],  - traj[[1]][, 3])  
# gives a vector of coefficients ordered first by sample no., then by train.ymean as in traj 
  traj.sorted <- cbind(traj[[1]][, 1][m], traj[[1]][, 3][m], traj[[1]][, 6][m])  
# contains the columns: beta before pasting, ymean, and sample no. 
  traj.sorted <- data.frame(traj.sorted) 
  resultat <- traj.sorted 
  end <- dim(traj[[2]])[2] 
  cat("Original Data", "\n")  
  for(i in 1:(n.samples + 1)) { 
    index.samples <- traj[[2]][, 2:end]  
# extracts the indexes of all bootstrap samples 
    data <- train.data[index.samples[i,  ],  ]  
# takes only the current boot sample data 
    beta <- traj.sorted[2, 1]  
# takes the beta before pasting for the current sample 
    if(beta > 0 && beta < 1) { 
      box <- .boxes(train.data = data, alpha = alpha, beta = beta, nboxes = 1, output = F, maxi  
= F, type = type, peel.crit = peel.crit) 
      outbox <- .express.boxes(box) 
      cat(outbox[[2]], "\n", outbox[[5]], "\n") 
    } 
    cat("bootstrap sample = ", (i + 1), "\n") 
    Sample <- traj.sorted[, 3] 
    traj.sorted <- traj.sorted[Sample != i,  ] 
  } 
  return(resultat) 
} 
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ZUSAMMENFASSUNG 
Klinische Untersuchungen beurteilen die Wirksamkeit einer neuen Behandlungs-
methode oftmals dadurch, dass sie Patienten zufällig der neuen oder einer etablierten 
Behandlungsmethode zuweisen und danach die Ergebnisse (Überlebensrate) 
vergleichen. Gewöhnlicherweise wird dabei die komplette Patientengruppe analysiert 
obwohl bekannt ist, dass bestimmte Untergruppen unterschiedlich auf die neue 
Behandlungsmethode reagieren. Einige der Patienten profitieren von der neuen 
Behandlung (positive Respondern), während andere dadurch zu Schaden kommen 
(negative Respondern). Das Ziel dieser Dissertation ist es, solche Untergruppen von 
Patienten zu identifizieren. Erreicht wird es dadurch dass man sogenannte prädiktive 
Faktoren findet, die unterschiedliche Überlebenswahrscheinlichkeiten nur anhand von 
Unterschieden in der Behandlungsmethode beschreiben. 
Diese Dissertation beginnt mit einer Übersicht über Techniken, die bisher zur 
Responderidentifikation benutzt wurden und schlägt gleichzeitig eine neue Methode zur 
systematischen Suche nach Respondern vor. Diese neue Methode besteht aus den 
folgenden drei Schritten: 
1. Identifikation von prognostischen Faktoren hinsichtlich der neuen Behandlung 
(Zum Beispiel durch das Cox-PH Model angewandt auf die Teilgruppe der 
Patienten die man der Standardbehandlung unterzieht). Diese Faktoren sind 
'prognostisch' im klassischen Sinne für den Fall, dass in der Studie gegen Placebo 
und nicht eine Standardmethode getestet wurde. 
2. Identifizierung der Patientengruppe(n) aus der Neubehandlungsgruppe, deren 
Überlebenswahrscheinlichkeiten nur schlecht durch das Prognosemodel 
vorhergesagt wurden. (Zum Beispiel durch eine Suche nach Ausreissern in der 
Devianz- oder Martingaleresiduen.) 
3. Identifikation der prädiktive Faktoren, welche die gemeinsamen Eigenschaften von 
Patienten mit Residuenausreissern beschreiben (positive und negative Respondern). 
Dies führt man mit Regressionsbäumen, bump hunting oder mit dem 
vorgeschlagenen stabilisierten  bump hunting durch. 
Die Methode zur Identifizierung von Respondern wurde zur Analyse von Daten 
klinischer Studien entwickelt, in denen kein Unterschied in den Überlebens-
wahrscheinlichkeiten von Patienten, die nach der alten oder der neuen Behandlungs-
methode versorgt wurden, festzustellen ist. Änderungen an der Methode für den Fall, 
dass bei den Daten der beiden Patientengruppen doch Unterschiede in den Überlebens-
kurven bestehen, wurden diskutiert. Darüber hinaus wurden Variationen der Responder-
identifikation vorgeschlagen und in einer Simulationsstudie verglichen. 
Bei der Suche nach prädiktive Faktoren kann man Martingale- oder Devianzresiduen 
auf das Prognosemodel als Responsevariable im Regressionsbaum, bump hunting oder 
stabilisierten bump hunting Prozess anwenden. Die Simulationsstudie hat gezeigt, dass 
Martingaleresiduen kombiniert mit dem stabilisierten bump hunting Prozess am 
geeignetsten für die Identifizierung von Respondern ist. Diese Variante des 
vorgeschlagenen Prozesses identifizierte positive und negative Respondern in 99% aller 
Fälle. 
Einige Variationen der vorgeschlagenen Methode zur Identifikation von Respondern 
wurden auch auf einen ‚echten’ Datensatz (dem European Myocardial Infarction 
Amiodarone Trial EMIAT) angewandt. Die dabei identifizierten Gruppen von positiven 
und negativen Respondern wurden verglichen. 
Alle Variationen des beschriebenen Algorithmus zur Identifikation von Respondern und 
speziell der Prozess mit stabilisiertem bump hunting mit martingale Residuen als 
Response zeigen eine bessere Leistung als die momentan verwendete Cox-PH Methode 
mit Behandlungsinteraktionen. Dies wurde anhand der Simulationsstudie und anhand 
der Daten von EMIAT gezeigt. Die besseren Ergebnisse der neuen Methode erklären 
sich aus der Tatsache, dass es im Vergleich zu dem Cox-PH Model viel leichter 
Interaktionen höherer Ordnung zwischen Kovariablen erkennt. 
Ausblick 
Eine vollständige Implementierung der sechs verschiedenen Variationen des 
Algorithmus zur Responderidentifizierung mit festgelegter Art und Anzahl von 
Faktoren wurde für die Simulationsstudie durchgeführt. Die Responderanalyse der 
EMIAT-Daten wurde teilautomatisch durchgeführt. Dadurch erhält man einerseits mehr 
Flexibilität bei der Bestimmung eines prädiktiven Models, verlangsamt andererseits 
aber die Analyse der Daten. Für eine zukünftige Verwendung des nachweislich besten 
Algorithmus, stabilisiertes bump hunting mit Martingaleresiduen, macht es Sinn, eine 
vollständige Implementierung mit frei wählbaren Einstellungen für die Anzahl und Art 
der Faktoren, verschiedenen Größen von Datensätzen, und der Stopkriterien für den Bau 
des Models zu verwirklichen. 
Die Methode zur Identifizierung von Respondern wurde für Datensätze entwickelt, bei 
denen die beiden Patientengruppen (klassische und neue Behandlungsmethode) keine 
Unterschiede in den Überlebenskurven zeigen, und auch an diesen getestet. Ein 
zukünftiges Softwareprodukt zur Responderanalyse sollte dieser Beschränkung nicht 
mehr unterliegen und auch Datensätze sinnvoll analysieren können, bei denen bei den 
beiden Patientengruppen Unterschiede in der Überlebenscharakteristik bestehen. Die 
Leistung eines solchen Programms könnte man dann auch wieder anhand simulierte 
Daten testen. 
Bisher wurde angenommen, dass weder prognostische noch prädiktive Faktoren sich 
mit der Zeit ändern. Eine neue Studie könnte durchgeführt, werden die Zeit-
abhängigkeiten bei der Identifikation von Respondern berücksichtigt. 
 
 
 
 
Lebenslauf 
 
Victoria Ivanova Kehl 
 
 
Gymnasium:  Gymnasium der Wissenschaft und Mathematik „Acad. N. Obreshkov“ 
Burgas, Bulgarien 
 
 
Universitäten: 
 
1993-97  Southern Oregon University, Ashland, Oregon, U. S. A.  
Studium der Mathematik mit Nebenfach Informatik 
Juni 1997  Abschluß: Bachelor’s Degree in Mathematics, mit Auszeichnung 
 
1997-99  Clemson University, South Carolina, U. S. A. 
Studium der Mathematik mit Schwerpunkt Statistik 
August 1999  Abschluß: Master in Mathematical Sciences 
 
1998-99  Universität Kaiserslautern 
Teilnahme am Programm „Mathematics International“ 
September 1999  Abschluß: Master bei Mathematics International 
 
2000-2002  Ludwig-Maximilians-Universität, München 
Promotionsstudium in Statistik 
November 2002 
(erwartet) 
 
 Abschluß: Promotion, Dr. rer. nat. 
 
Abschluß Arbeiten: 
 
Bachelor’s Arbeit  „Mathematisches modellieren des HIV-Virus in Interaktion mit dem 
menschlichen Immunsystem.“ 
 
Master Arbeit  „Beeinflussung des Gewichtszuwachses während der Schwangerschaft von 
Minderjährigen durch psycho-soziale Faktoren, und deren beider Einfluß auf 
Geburtsgewicht von Babies.“ 
 
Dissertation  „Responder identification in Clinical Trials“ 
 
 
 
Lehrerfahrung und Wissenschaftliche Arbeit: 
 
1997  Assistentenstelle an der Southern Oregon University 
• Übungsgruppenleiter in Analysis 
 
1997-98  Lehrassistentenstelle an der Clemson University 
• Statistik  
• Analysis 
 
1998-99  Wissenschaftliche Assistentin an dem Institut für Techno-und-Wirtschafts-
mathematik, Kaiserslautern 
• Statistische Analyse von Daten des Öffentlichen Verkehrs 
 
Seit November 1999  Wissenschaftliche Mitarbeiterin an dem Institut für Medizinische Statistik und 
Epidemiologie, TU – München   
• Überlebensanalyse 
• Responderanalyse  
 
 
 
Gesellschaftliches Engagement:  
 
 Während meiner Zeit an der Southern Oregon University, war ich „International Cultural Service 
Program Coordinator“.  Des weiteren war ich im Studentenparlament („Inter-club Council Member“) und 
der Studentenverwaltung als Abgeordnete tätig. 
 
 
 
Auszeichnungen und Ehrungen: 
 
 Lithia Springs Rotary Club Scholarship 
 1994-95 
 International Student Fee Remission – Studiengebühren Übernahme vom  Staat Oregon  
 1993-95 
 International Cultural Service Program – Studiengebühren Übernahme vom  Staat Oregon für 
ausländische Studenten im Austausch für kulturelle gemeinnützige Arbeit. 
 1993-95 – Teilnehmer am Programm 
 1995-97 – Hilfs-Organisator des Programmes 
 Churchill Scholars Honors Program – Oregon Laurels Scholarship – wird an Studenten des „Ethics 
Studies Program“ vergeben. 
 1994-95 
 Ida and Eugene Bowman Scholarship – wird an herausragende Studenten der Mathematik vergeben. 
 1995-96 
 Harry S. Keival Auszeichnungen – wird an herausragende Studenten der Mathematik vergeben. 
 1995-96 
 Internationaler Mathematik Wettbewerb in Modellieren - Auszeichnung: „Honorable Mention“ 
1997 
Universitad de Guanajuato’s International Student Achievement Award at Southern Oregon 
University – Auszeichnung für exzellente akademische Arbeit, Universitäts politisches Engagement, und 
Beitrag zum internationalen Verständnis. 
1997 
Vorgeschlagen für „Associate Member of ΣΧ – Scientific research Society“ 
1997 
American Association of University Women’s Outstanding Senior Woman Award 
1997 
Vorgeschlagen für „Who’s Who Among Students in American Universities and Colleges“ 
1996-97 
Bachelor’s Abschluß in Mathematik mit Auszeichnung 
1997   
 
 
 
Sprachen:  Bulgarisch – Muttersprache 
  Englisch – fließend 
  Deutsch  – fließend  
  Russisch – gut 
 
 
Referenzen: 
 
• Prof. Dr. K. Ulm, Institut für Medizinische Statistik und Epidemiologie 
TU – München, Ismaningerstr. 22, D-80675 München 
 
• Dr. H. Senter, Department of Mathematical Sciences, 
Clemson University, Martin Hall, Box 341907, Clemson, SC 29634-1907, U. S. A. 
 
• Dr. K Yates, Department of Mathematics, 
Southern Oregon University, Ashland, OR 97520-5026, U. S. A. 
